{"items": "735", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers", "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/", "time_published": "20240118T194930", "authors": ["Arianna Johnson"], "summary": "Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.061908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.113329", "ticker_sentiment_score": "0.068214", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.056808", "ticker_sentiment_score": "0.046999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.113329", "ticker_sentiment_score": "0.052573", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.113329", "ticker_sentiment_score": "0.052573", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update", "url": "https://www.zacks.com/stock/news/2212227/biotech-stock-roundup-vrtxcrsp-gene-therapy-label-expansion-allk-falls-on-update", "time_published": "20240118T152100", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.168993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALLK", "relevance_score": "0.359014", "ticker_sentiment_score": "-0.066483", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.123526", "ticker_sentiment_score": "0.137767", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.302429", "ticker_sentiment_score": "0.235638", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Charles River's  ( CRL )  New Launch to Boost Gene Therapy Programs", "url": "https://www.zacks.com/stock/news/2212039/charles-rivers-crl-new-launch-to-boost-gene-therapy-programs", "time_published": "20240118T141000", "authors": ["Zacks Equity Research"], "summary": "Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.189454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.060694", "ticker_sentiment_score": "0.040071", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.121037", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.121037", "ticker_sentiment_score": "-0.094236", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.239305", "ticker_sentiment_score": "0.149442", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.180685", "ticker_sentiment_score": "0.133374", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Declines More Than Market: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2211744/vertex-pharmaceuticals-vrtx-declines-more-than-market-some-information-for-investors", "time_published": "20240117T225017", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.197661, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.55992", "ticker_sentiment_score": "0.204315", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics", "url": "https://www.prnewswire.com/news-releases/beta-thalassemia-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-evaluates-delveinsight--leading-companies---vertex-pharmaceuticals-crispr-therapeutics-agios-pharmaceuticals-celgene-forma-therapeutics-302034997.html", "time_published": "20240117T220100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period ( 2019-2032 ) , Evaluates DelveInsight ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178567, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.027257", "ticker_sentiment_score": "0.038951", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.054483", "ticker_sentiment_score": "0.093789", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMDA", "relevance_score": "0.027257", "ticker_sentiment_score": "0.043538", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLN", "relevance_score": "0.054483", "ticker_sentiment_score": "0.044844", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.027257", "ticker_sentiment_score": "0.096627", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.027257", "ticker_sentiment_score": "0.038951", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.027257", "ticker_sentiment_score": "0.096627", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.027257", "ticker_sentiment_score": "0.043538", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.081645", "ticker_sentiment_score": "0.095821", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.027257", "ticker_sentiment_score": "0.038951", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Whales and Their Recent Bets on VRTX Options - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/24/01/36666930/market-whales-and-their-recent-bets-on-vrtx-options", "time_published": "20240117T200041", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.111783, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.623976", "ticker_sentiment_score": "0.156892", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX ) , CRSP's Casgevy Gets FDA Nod for Thalassemia", "url": "https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsps-casgevy-gets-fda-nod-for-thalassemia", "time_published": "20240117T170400", "authors": ["Zacks Equity Research"], "summary": "This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.241684", "ticker_sentiment_score": "0.091496", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.182506", "ticker_sentiment_score": "0.073526", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.182506", "ticker_sentiment_score": "0.148808", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.122269", "ticker_sentiment_score": "0.055742", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stock to Invest $1,000 in Right Now", "url": "https://www.fool.com/investing/2024/01/17/the-best-stock-to-invest-1000-in-right-now/", "time_published": "20240117T105000", "authors": ["Keith Speights"], "summary": "This stock has what it takes to be a big winner.", "banner_image": "https://g.foolcdn.com/editorial/images/761362/happy-stock-investor-holding-smartphone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.060694", "ticker_sentiment_score": "0.103004", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.060694", "ticker_sentiment_score": "0.15826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.238791", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves New CRISPR Gene-Editing Treatment", "url": "https://www.forbes.com/sites/jamesfarrell/2024/01/16/fda-approves-new-crispr-gene-editing-treatment/", "time_published": "20240116T225905", "authors": ["James Farrell"], "summary": "The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia-marking the second major U.S. regulatory approval for the emerging ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a70a106171deb3993b76ee/0x0.jpg?format=jpg&crop=2614,1469,x0,y135,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.202184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.102013", "ticker_sentiment_score": "0.109846", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Announces U.S. Food and Drug Administration  ( FDA )  Approval of CASGEVY\u2122  ( exagamglogene autotemcel )  for the Treatment of Transfusion-Dependent Beta Thalassemia - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36649789/crispr-therapeutics-announces-u-s-food-and-drug-administration-fda-approval-of-casgevy-exagamgloge", "time_published": "20240116T210100", "authors": ["Globe Newswire"], "summary": "- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.118577, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.11894", "ticker_sentiment_score": "0.096945", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.089351", "ticker_sentiment_score": "0.105743", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex's Warpath Continues With A Second Crispr Gene-Editing OK", "url": "https://www.investors.com/news/technology/crsp-stock-dips-despite-snagging-a-second-gene-editing-ok-vrtx-stock-continues-on-its-warpath/", "time_published": "20240116T202100", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "CRSP Stock Dips Despite Snagging A Second Gene-Editing OK. VRTX Stock Continues On Its Warpath Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-crispr-dna-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.293283, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.47147", "ticker_sentiment_score": "-0.076163", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.100308", "ticker_sentiment_score": "0.125644", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge", "url": "https://www.fool.com/investing/2024/01/16/these-2-stocks-carry-lot-of-risk-but-their-upside/", "time_published": "20240116T131500", "authors": ["Ryan Downie"], "summary": "These risky stocks can deliver big returns for investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761175%2Fgettyimages-1214328228.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.126185, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.045569", "ticker_sentiment_score": "0.030929", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.045569", "ticker_sentiment_score": "-0.012901", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.045569", "ticker_sentiment_score": "0.030929", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why CRISPR Therapeutics Stock Rose 54% Last Year", "url": "https://www.fool.com/investing/2024/01/15/heres-why-crispr-therapeutics-stock-rose-54-last-y/", "time_published": "20240115T215600", "authors": ["Ryan Downie"], "summary": "Key regulatory developments sent this biotech stock higher.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761374%2Fdna-genetic-sequencing-biotech.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.134919, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.139669", "ticker_sentiment_score": "0.117333", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.070105", "ticker_sentiment_score": "0.079486", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down 88%, Could Editas Medicine Be a Good Investment Now?", "url": "https://www.fool.com/investing/2024/01/15/down-88-could-editas-medicine-be-a-good-investment/", "time_published": "20240115T101900", "authors": ["Cory Renauer"], "summary": "The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761086%2Fsmart-investor-looking-for-stocks-to-buy-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.142489, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.24289", "ticker_sentiment_score": "0.207009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.463792", "ticker_sentiment_score": "0.176254", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?", "url": "https://www.fool.com/investing/2024/01/14/what-does-it-mean-if-crispr-gets-bought-out/", "time_published": "20240114T183000", "authors": ["David Jagielski"], "summary": "An acquisition could be both a blessing and a curse for long-term investors.", "banner_image": "https://g.foolcdn.com/editorial/images/760422/people-agreeing-on-a-deal.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.26526, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053035", "ticker_sentiment_score": "0.170688", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "My 3 Highest-Conviction Growth Stocks to Buy in 2024", "url": "https://www.fool.com/investing/2024/01/14/my-3-highest-conviction-growth-stocks-to-buy-in-20/", "time_published": "20240114T151300", "authors": ["Keith Speights"], "summary": "Simply put, these stocks inspire confidence.", "banner_image": "https://g.foolcdn.com/editorial/images/760970/solar-panels-and-workers.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.296196, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.096866", "ticker_sentiment_score": "0.071053", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.048523", "ticker_sentiment_score": "0.069022", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEP", "relevance_score": "0.23907", "ticker_sentiment_score": "0.217306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.048523", "ticker_sentiment_score": "0.085103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.19231", "ticker_sentiment_score": "0.192281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Growth Stocks to Buy That Could Be Massive Long-Term Winners", "url": "https://www.fool.com/investing/2024/01/14/3-growth-stocks-to-buy-that-could-be-massive-long/", "time_published": "20240114T140000", "authors": ["Keith Speights"], "summary": "These stocks appear to have what it takes to keep up their winning ways.", "banner_image": "https://g.foolcdn.com/editorial/images/760683/artificial-intelligence-investing-algorithms.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.248026, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116067", "ticker_sentiment_score": "0.159005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.173333", "ticker_sentiment_score": "-0.022476", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.284861", "ticker_sentiment_score": "0.129709", "ticker_sentiment_label": "Neutral"}]}, {"title": "My 5 Top Growth Stocks to Buy Hand Over Fist for 2024", "url": "https://www.fool.com/investing/2024/01/14/my-5-top-growth-stocks-to-buy-for-2024/", "time_published": "20240114T101000", "authors": ["Adria Cimino"], "summary": "2024 could be a year of growth.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760878%2Fgettyimages-three-business-people-use-tablets.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999994"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.429002, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.252987", "ticker_sentiment_score": "0.243893", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.036756", "ticker_sentiment_score": "0.277177", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.073434", "ticker_sentiment_score": "0.255571", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETSY", "relevance_score": "0.18223", "ticker_sentiment_score": "0.091942", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.217834", "ticker_sentiment_score": "0.4119", "ticker_sentiment_label": "Bullish"}]}, {"title": "Want to Get Richer? 2 Stocks to Buy and Hold for 10 Years", "url": "https://www.fool.com/investing/2024/01/13/want-to-get-richer-2-stocks-to-buy-and-hold-for-10/", "time_published": "20240113T130000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are leaders in their respective fields.", "banner_image": "https://g.foolcdn.com/editorial/images/760535/physicians-in-an-operating-room.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.226875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.53784", "ticker_sentiment_score": "0.344138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.116914", "ticker_sentiment_score": "0.081648", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.058615", "ticker_sentiment_score": "0.069982", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Unstoppable Stocks to Buy in 2024", "url": "https://www.fool.com/investing/2024/01/13/3-unstoppable-stocks-to-buy-in-2024/", "time_published": "20240113T124800", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "These stocks appear to be on a clear path to continued growth.", "banner_image": "https://g.foolcdn.com/editorial/images/761021/scientists-in-a-lab-smiling.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.25543, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.266343", "ticker_sentiment_score": "0.049266", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.349945", "ticker_sentiment_score": "0.133208", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.045224", "ticker_sentiment_score": "0.143626", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.308614", "ticker_sentiment_score": "0.308668", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:DKK", "relevance_score": "0.045224", "ticker_sentiment_score": "0.270178", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:NOK", "relevance_score": "0.045224", "ticker_sentiment_score": "0.270178", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week", "url": "https://www.fool.com/investing/2024/01/13/cathie-wood-bargain-hunts-3-stocks-she-bought/", "time_published": "20240113T102000", "authors": ["Adria Cimino"], "summary": "These companies could stand out thanks to game-changing technology.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761087%2Fgettyimages-904880170.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.298602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04583", "ticker_sentiment_score": "0.174802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RXRX", "relevance_score": "0.136888", "ticker_sentiment_score": "0.071337", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOST", "relevance_score": "0.472733", "ticker_sentiment_score": "0.352021", "ticker_sentiment_label": "Bullish"}]}, {"title": "Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Abbott Laboratories  ( NYSE:ABT ) , Uber Technologies  ( NYSE:UBER ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36606668/uber-abbott-laboratories-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades", "time_published": "20240112T135103", "authors": ["Avi Kapoor"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. UBER shares hit an all-time high on Thursday above the Feb. 2021 high. He remains long on the stock and still loves it.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/12/uber_-logo.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.29394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.436009", "ticker_sentiment_score": "0.618511", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.558244", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.152499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.558244", "ticker_sentiment_score": "0.571354", "ticker_sentiment_label": "Bullish"}]}, {"title": "Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from Insight to Therapeutics", "url": "https://www.prnewswire.com/news-releases/arena-bioworks-launches-as-a-privately-funded-fully-independent-biomedical-institute-to-shorten-the-path-from-insight-to-therapeutics-302033563.html", "time_published": "20240112T113000", "authors": ["Arena BioWorks"], "summary": "Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2279495/Arena_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.268175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.019026", "ticker_sentiment_score": "0.046462", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORZQ", "relevance_score": "0.03804", "ticker_sentiment_score": "0.049775", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.019026", "ticker_sentiment_score": "0.055053", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.019026", "ticker_sentiment_score": "0.055053", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRI", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.019026", "ticker_sentiment_score": "0.090388", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.019026", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.019026", "ticker_sentiment_score": "0.073128", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.019026", "ticker_sentiment_score": "0.046462", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/24/01/36598743/unpacking-the-latest-options-trading-trends-in-vertex-pharmaceuticals", "time_published": "20240111T174648", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.066955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.592095", "ticker_sentiment_score": "0.028215", "ticker_sentiment_label": "Neutral"}]}, {"title": "State Economics - Spotlight on New England: The Kiplinger Letter", "url": "https://www.kiplinger.com/personal-finance/job-search/state-economics-new-england-the-kiplinger-letter", "time_published": "20240111T124728", "authors": ["David Payne"], "summary": "After the 2023 boom, New England states see modest employment growth Kiplinger's Personal Finance ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/TtbbcgnxqkMad2zGHHTYXa-1200-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.252829, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.047465", "ticker_sentiment_score": "0.209683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.047465", "ticker_sentiment_score": "0.209683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics", "url": "https://www.prnewswire.com/news-releases/focal-segmental-glomerulosclerosis-market-to-observe-impressive-growth-by-2032-predicts-delveinsight--leading-companies---acelyrin-genentech-chemocentryx-travere-therapeutics-boehringer-ingelheim-chinook-therapeutics-302030785.html", "time_published": "20240110T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZVSA", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALDX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.086235", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.084821", "ticker_sentiment_score": "0.088295", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.056607", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.056607", "ticker_sentiment_score": "0.085954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMAC", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028321", "ticker_sentiment_score": "0.038274", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.028321", "ticker_sentiment_score": "0.086235", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}, {"ticker": "PROK", "relevance_score": "0.056607", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028321", "ticker_sentiment_score": "0.002769", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Red Flags for Bluebird Bio Stock", "url": "https://www.fool.com/investing/2024/01/10/2-red-flags-for-bluebird-bio-stock/", "time_published": "20240110T115500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech's struggles may continue.", "banner_image": "https://g.foolcdn.com/editorial/images/760285/patient-sitting-on-hospital-bed.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.043943, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.123526", "ticker_sentiment_score": "-0.029978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.359014", "ticker_sentiment_score": "0.173967", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend", "url": "https://www.fool.com/investing/2024/01/10/these-3-stocks-have-beaten-the-sp-average-return-f/", "time_published": "20240110T105100", "authors": ["Keith Speights"], "summary": "These winners seem likely to keep up their winning ways.", "banner_image": "https://g.foolcdn.com/editorial/images/760612/smiling-person-looking-at-a-monitor-with-stock-chart.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.345138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AXON", "relevance_score": "0.110462", "ticker_sentiment_score": "0.152537", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.110462", "ticker_sentiment_score": "-0.147233", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.055364", "ticker_sentiment_score": "0.247979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TTD", "relevance_score": "0.218817", "ticker_sentiment_score": "0.253948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ESG Is Under Fire. How These 5 Funds Still Beat the Market.", "url": "https://www.barrons.com/amp/articles/top-esg-funds-nvidia-active-f851057c", "time_published": "20240110T073000", "authors": ["Lauren Foster"], "summary": "The Top ESG Funds Held Nvidia and Other ...", "banner_image": "https://images.barrons.com/im-37596237/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.372991, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.167322", "ticker_sentiment_score": "0.275832", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMDUF", "relevance_score": "0.042122", "ticker_sentiment_score": "0.036696", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.042122", "ticker_sentiment_score": "0.027664", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.208285", "ticker_sentiment_score": "0.312065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GWRE", "relevance_score": "0.042122", "ticker_sentiment_score": "0.027664", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.042122", "ticker_sentiment_score": "0.186886", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.042122", "ticker_sentiment_score": "0.195868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MORN", "relevance_score": "0.042122", "ticker_sentiment_score": "0.249905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPLK", "relevance_score": "0.042122", "ticker_sentiment_score": "0.027664", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.042122", "ticker_sentiment_score": "0.156017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MLM", "relevance_score": "0.042122", "ticker_sentiment_score": "0.102216", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You'd Have If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago", "url": "https://www.zacks.com/stock/news/2207791/heres-how-much-youd-have-if-you-invested-1000-in-vertex-pharmaceuticals-a-decade-ago", "time_published": "20240109T225434", "authors": ["Zacks Equity Research"], "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.155139, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.422493", "ticker_sentiment_score": "0.202301", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Ascends While Market Falls: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2207797/vertex-pharmaceuticals-vrtx-ascends-while-market-falls-some-facts-to-note", "time_published": "20240109T225020", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $421.01, indicating a +0.45% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.201034, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.561606", "ticker_sentiment_score": "0.216119", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What Makes Vertex Pharmaceuticals  ( VRTX )  a Strong Momentum Stock: Buy Now?", "url": "https://www.zacks.com/stock/news/2207704/what-makes-vertex-pharmaceuticals-vrtx-a-strong-momentum-stock-buy-now", "time_published": "20240109T215602", "authors": ["Zacks Equity Research"], "summary": "Does Vertex Pharmaceuticals (VRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.274814, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.596651", "ticker_sentiment_score": "0.351022", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2207718/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe", "time_published": "20240109T215449", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default27.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.202758, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.128135", "ticker_sentiment_score": "0.069783", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.19117", "ticker_sentiment_score": "0.112309", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.128135", "ticker_sentiment_score": "0.069783", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.128135", "ticker_sentiment_score": "0.069783", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech ETFs Stage Solid Comeback at the Start of 2024", "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024", "time_published": "20240109T160500", "authors": ["Sweta Killa"], "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.147642, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.133346", "ticker_sentiment_score": "0.06769", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.089129", "ticker_sentiment_score": "0.058856", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084886", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.133346", "ticker_sentiment_score": "0.162037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.133346", "ticker_sentiment_score": "0.071668", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.089129", "ticker_sentiment_score": "0.140918", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/24/01/36557818/a-look-into-vertex-pharmaceuticals-incs-price-over-earnings", "time_published": "20240109T144515", "authors": ["Benzinga Insights"], "summary": "In the current session, the stock is trading at $419.65, after a 0.13% increase. Over the past month, Vertex Pharmaceuticals Inc. VRTX stock increased by 17.04%, and in the past year, by 43.26%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.130669, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.412298", "ticker_sentiment_score": "0.116901", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors", "url": "https://investingnews.com/nuvation-bio-announces-appointment-of-dr-robert-mashal-to-its-board-of-directors/", "time_published": "20240108T221451", "authors": ["Investing News Network"], "summary": "Nuvation Bio Inc. ( NYSE: NUVB ) , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.", "banner_image": "https://investingnews.com/media-library/image.jpg?id=30128384&width=1200&height=600", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.167531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.008432", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUVB", "relevance_score": "0.60098", "ticker_sentiment_score": "0.388595", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.008432", "ticker_sentiment_label": "Neutral"}]}, {"title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2024/01/08/2805839/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html", "time_published": "20240108T210500", "authors": ["Inc.", "MaxCyte"], "summary": "ROCKVILLE, MD, January 8, 2024 - MaxCyte, Inc., ( NASDAQ: MXCT.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/ca8c6b64-4f99-4a88-86a6-5c0b5f3d49fe", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999982"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.185878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MXCT", "relevance_score": "0.270202", "ticker_sentiment_score": "0.358072", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.039353", "ticker_sentiment_score": "0.252586", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2024/01/08/2805846/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html", "time_published": "20240108T210500", "authors": ["Inc", "MaxCyte"], "summary": "ROCKVILLE, Md., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999982"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.185876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MXCT", "relevance_score": "0.269351", "ticker_sentiment_score": "0.355437", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.039224", "ticker_sentiment_score": "0.252519", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results - MaxCyte  ( NASDAQ:MXCT ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36544610/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-results", "time_published": "20240108T210500", "authors": ["Globe Newswire"], "summary": "ROCKVILLE, Md., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999982"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.183564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MXCT", "relevance_score": "0.192387", "ticker_sentiment_score": "0.27462", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.038843", "ticker_sentiment_score": "0.252315", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/24/01/36539655/1000-invested-in-this-stock-15-years-ago-would-be-worth-14-000-today", "time_published": "20240108T173015", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual return of 18.8%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.68 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Will Vertex  ( VRTX )  Beat Estimates Again in Its Next Earnings Report?", "url": "https://www.zacks.com/stock/news/2207133/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report", "time_published": "20240108T171011", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.312447, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.210994", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PBYI vs. VRTX: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/2207091/pbyi-vs-vrtx-which-stock-is-the-better-value-option", "time_published": "20240108T164012", "authors": ["Zacks Equity Research"], "summary": "Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech ( PBYI Quick QuotePBYI - ) and Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks offers value investors a better bang for their buck right now?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default112.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.455342, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.68471", "ticker_sentiment_score": "0.522443", "ticker_sentiment_label": "Bullish"}]}, {"title": "Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference - Editas Medicine  ( NASDAQ:EDIT ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36532383/editas-medicine-highlights-2024-anticipated-milestones-and-strategic-priorities-at-the-j-p-morgan-", "time_published": "20240108T131500", "authors": ["Globe Newswire"], "summary": "Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.152988, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04531", "ticker_sentiment_score": "0.102362", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.350564", "ticker_sentiment_score": "0.127243", "ticker_sentiment_label": "Neutral"}]}, {"title": "Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html", "time_published": "20240108T131500", "authors": ["Editas Medicine", "Inc."], "summary": "Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.132441, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.031079", "ticker_sentiment_score": "0.051041", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.214937", "ticker_sentiment_score": "0.089716", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics", "url": "https://www.fool.com/investing/2024/01/08/better-gene-editing-stock-editas-medicine-vs-intel/", "time_published": "20240108T124500", "authors": ["Alex Carchidi"], "summary": "These two are at very different stages of the clinical trials process.", "banner_image": "https://g.foolcdn.com/editorial/images/759688/scientist-configures-tilting-machine.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.244538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.056674", "ticker_sentiment_score": "0.075978", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.113062", "ticker_sentiment_score": "0.155062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.029015", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.113062", "ticker_sentiment_score": "0.155062", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Ultimate Growth Stock to Buy With $1,000 Right Now", "url": "https://www.fool.com/investing/2024/01/08/the-ultimate-growth-stock-to-buy-with-1000-now/", "time_published": "20240108T100000", "authors": ["Adria Cimino"], "summary": "The stock, trading for about $60, has plenty of room to run.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760286%2Fgettyimages-519517489-1.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.312875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.055751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.055751", "ticker_sentiment_score": "0.138", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Top Stocks to Buy in January", "url": "https://www.fool.com/investing/2024/01/07/5-top-stocks-to-buy-in-january/", "time_published": "20240107T104500", "authors": ["Keith Speights", "Anders Bylund", "Demitri Kalogeropoulos", "and Neha Chamaria", "Daniel Foelber"], "summary": "Start the year off right by investing in these quality businesses.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760264%2Fgettyimages-618335432-1201x801-d21b45d.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.302481, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.1294", "ticker_sentiment_score": "0.205403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.086478", "ticker_sentiment_score": "0.156576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.021659", "ticker_sentiment_score": "0.039331", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.374937", "ticker_sentiment_score": "0.435517", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIPC", "relevance_score": "0.234787", "ticker_sentiment_score": "0.15869", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBM", "relevance_score": "0.171943", "ticker_sentiment_score": "0.146872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Vertex Pharmaceuticals Stock a Buy Now?", "url": "https://www.fool.com/investing/2024/01/06/is-vertex-pharmaceuticals-stock-a-buy-now/", "time_published": "20240106T134500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech's prospects keep improving.", "banner_image": "https://g.foolcdn.com/editorial/images/759939/physician-talking-to-patient.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.217359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.475618", "ticker_sentiment_score": "0.430073", "ticker_sentiment_label": "Bullish"}, {"ticker": "BLUE", "relevance_score": "0.063425", "ticker_sentiment_score": "0.097054", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks With Huge Catalysts in 2024", "url": "https://www.fool.com/investing/2024/01/05/2-biotech-stocks-with-huge-catalysts-in-2024/", "time_published": "20240105T103400", "authors": ["Cory Renauer"], "summary": "Important clinical-trial readouts on the way could send these stocks soaring in early 2024.", "banner_image": "https://g.foolcdn.com/editorial/images/760000/two-people-use-devices-at-home-getty.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.075292, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.160633", "ticker_sentiment_score": "0.150694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMLX", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.051537", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stran & Company Appoints Ian Thomas Wall as Chief Information Officer", "url": "https://www.globenewswire.com/news-release/2024/01/04/2804023/0/en/Stran-Company-Appoints-Ian-Thomas-Wall-as-Chief-Information-Officer.html", "time_published": "20240104T140000", "authors": ["Inc.", "Stran & Company"], "summary": "Quincy, MA, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Stran & Company, Inc. ( \"Stran\" or the \"Company\" ) ( NASDAQ: SWAG. SWAGW ) , a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, announces that it has appointed Ian Thomas Wall ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/b48087c7-1d09-44f4-b051-176a3ab4efaf", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.285414, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04794", "ticker_sentiment_score": "0.073616", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAG", "relevance_score": "0.369456", "ticker_sentiment_score": "0.569935", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.04794", "ticker_sentiment_score": "0.073616", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $1,000 in Right Now", "url": "https://www.fool.com/investing/2024/01/04/the-best-stocks-to-invest-1000-in-right-now/", "time_published": "20240104T140000", "authors": ["Prosper Junior Bakiny"], "summary": "It's not too late to get in on these market beaters.", "banner_image": "https://g.foolcdn.com/editorial/images/759414/pharmacist-talking-to-patient.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.270989, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.276491", "ticker_sentiment_score": "0.36389", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.168099", "ticker_sentiment_score": "0.264564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.3796", "ticker_sentiment_score": "0.27009", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics", "url": "https://www.fool.com/investing/2024/01/04/heres-why-2024-could-be-a-big-year-for-crispr-ther/", "time_published": "20240104T100000", "authors": ["Adria Cimino"], "summary": "CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759122%2Fscientists-high-five-smile.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.33254, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.062005", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Downgrades Vertex Pharmaceuticals  ( NASDAQ:VRTX )  to Buy", "url": "https://www.defenseworld.net/2024/01/04/stocknews-com-downgrades-vertex-pharmaceuticals-nasdaqvrtx-to-buy.html", "time_published": "20240104T062445", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued to investors on Thursday.", "banner_image": "https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo.png?v=20231228113929", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.297567, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.042346", "ticker_sentiment_score": "0.058743", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.042346", "ticker_sentiment_score": "0.058743", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.042346", "ticker_sentiment_score": "0.058743", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.735169", "ticker_sentiment_score": "0.465748", "ticker_sentiment_label": "Bullish"}, {"ticker": "SEIC", "relevance_score": "0.084572", "ticker_sentiment_score": "0.219221", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNV", "relevance_score": "0.084572", "ticker_sentiment_score": "0.219221", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.042346", "ticker_sentiment_score": "0.058743", "ticker_sentiment_label": "Neutral"}]}, {"title": "InnovationRx: TikTok's Parent Company Is Moving Into Pharma", "url": "https://www.forbes.com/sites/katiejennings/2024/01/03/innovationrx-tiktoks-parent-company-is-moving-into-pharma/", "time_published": "20240103T225426", "authors": ["Alex Knapp"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6595e262535a2a6b7e7d0520/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121447, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.062597", "ticker_sentiment_score": "0.059009", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.062597", "ticker_sentiment_score": "0.072015", "ticker_sentiment_label": "Neutral"}, {"ticker": "RADCQ", "relevance_score": "0.062597", "ticker_sentiment_score": "-0.092344", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Moves -0.05%: What You Should Know", "url": "https://www.zacks.com/stock/news/2205305/vertex-pharmaceuticals-vrtx-stock-moves--005-what-you-should-know", "time_published": "20240103T225017", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $410.71, signifying a -0.05% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.214612, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.571903", "ticker_sentiment_score": "0.262764", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Voyager  ( VYGR )  Gains on Gene Therapy Deal With Novartis", "url": "https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis", "time_published": "20240103T161500", "authors": ["Zacks Equity Research"], "summary": "Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2e/972.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.154057, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.059785", "ticker_sentiment_score": "0.073998", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.235823", "ticker_sentiment_score": "0.083852", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.178021", "ticker_sentiment_score": "0.073644", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.178021", "ticker_sentiment_score": "0.020082", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20240103T112007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.279971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.230782", "ticker_sentiment_score": "0.218856", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}]}, {"title": "January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.", "url": "https://www.fool.com/investing/2024/01/03/january-worst-month-sp-500-stocks-buy/", "time_published": "20240103T105000", "authors": ["Keith Speights"], "summary": "These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly.", "banner_image": "https://g.foolcdn.com/editorial/images/759884/young-woman-looking-at-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.193821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEP", "relevance_score": "0.31006", "ticker_sentiment_score": "0.325769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.139505", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.31006", "ticker_sentiment_score": "0.266519", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A Closer Look at CRISPR Therapeutics's Options Market Dynamics - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/options/24/01/36456642/a-closer-look-at-crispr-therapeuticss-options-market-dynamics", "time_published": "20240102T180116", "authors": ["Benzinga Insights"], "summary": "High-rolling investors have positioned themselves bearish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.184336, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.073546", "ticker_sentiment_score": "0.154411", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Editas  ( EDIT )  Stock Gains 23% in the Past 6 Months: Here's Why", "url": "https://www.zacks.com/stock/news/2204495/editas-edit-stock-gains-23-in-the-past-6-months-heres-why", "time_published": "20240102T151500", "authors": ["Zacks Equity Research"], "summary": "Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.19702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089629", "ticker_sentiment_score": "0.121267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.17813", "ticker_sentiment_score": "-0.007337", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.306416", "ticker_sentiment_score": "0.110989", "ticker_sentiment_label": "Neutral"}]}, {"title": "\"Murder In Boston\" Reopens The City's Troubled History Of Race Relations: One Path Forward", "url": "https://www.forbes.com/sites/sachinjain/2024/01/01/murder-in-boston-reopens-the-citys-troubled-history-of-race-relations-one-path-forward/", "time_published": "20240101T174137", "authors": ["Sachin H. Jain"], "summary": "Charles Stuart shot his pregnant wife Carol and himself on the way out of a birthing class at the Brigham and Women's Hospital. When Stuart, a white man, called 911 for assistance, he implicated a fictitious \"black man\" who fled into Boston's Mission Hill neighborhood.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65923b81ddab975226978df2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.173835, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.027667", "ticker_sentiment_score": "0.155307", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBD", "relevance_score": "0.027667", "ticker_sentiment_score": "-0.08895", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Growth Stocks to Buy for Less Than $100", "url": "https://www.fool.com/investing/2024/01/01/3-no-brainer-growth-stocks-to-buy-for-less-than-10/", "time_published": "20240101T140500", "authors": ["David Jagielski"], "summary": "These businesses have promising futures and make for great investment options today.", "banner_image": "https://g.foolcdn.com/editorial/images/759494/an-excited-investor-looking-at-a-chart.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.313856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.244109", "ticker_sentiment_score": "0.230309", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.117349", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.123526", "ticker_sentiment_score": "0.245392", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Prediction: These 3 Stocks Will Soar in 2024", "url": "https://www.fool.com/investing/2024/01/01/prediction-these-3-stocks-will-soar-in-2024/", "time_published": "20240101T115000", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "Investors could enjoy an especially happy new year with these great stocks.", "banner_image": "https://g.foolcdn.com/editorial/images/759462/cheering-person-with-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.196612, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.121241", "ticker_sentiment_score": "0.009226", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.040553", "ticker_sentiment_score": "0.035663", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.278109", "ticker_sentiment_score": "0.148716", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.200688", "ticker_sentiment_score": "0.14049", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024", "url": "https://www.fool.com/investing/2023/12/31/1-cathie-wood-stock-worth-buying-hand-over-fist-in/", "time_published": "20231231T153000", "authors": ["George Budwell"], "summary": "Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759712%2Ftime-to-buy.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.120457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.147818", "ticker_sentiment_score": "0.057218", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/12/31/gene-editing-stocks-that-might-be-the-next-crispr/", "time_published": "20231231T134500", "authors": ["Alex Carchidi"], "summary": "Curing rare inherited illnesses could be a lucrative business model.", "banner_image": "https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.236539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.056275", "ticker_sentiment_score": "0.214987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.157128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERV", "relevance_score": "0.112269", "ticker_sentiment_score": "0.071337", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.056275", "ticker_sentiment_score": "0.161027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.112269", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2023 in Review: Nvidia, Interest Rates, Taylor Swift", "url": "https://www.fool.com/investing/2023/12/30/2023-in-review-nvidia-interest-rates-taylor-swift/", "time_published": "20231230T130000", "authors": ["Motley Fool Staff"], "summary": "And a little bit of real estate insight.", "banner_image": "https://g.foolcdn.com/editorial/images/759028/mfm_15.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "IPO", "relevance_score": "0.928139"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.169813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.006353", "ticker_sentiment_score": "0.100645", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.025406", "ticker_sentiment_score": "0.044326", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEN", "relevance_score": "0.012705", "ticker_sentiment_score": "0.038429", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.044445", "ticker_sentiment_score": "0.027924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.012705", "ticker_sentiment_score": "0.105946", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.006353", "ticker_sentiment_score": "-0.002475", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.006353", "ticker_sentiment_score": "0.099553", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.006353", "ticker_sentiment_score": "0.10031", "ticker_sentiment_label": "Neutral"}, {"ticker": "Z", "relevance_score": "0.006353", "ticker_sentiment_score": "-0.012089", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.006353", "ticker_sentiment_score": "0.055043", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stocks That Could Be Monster Winners in 2024", "url": "https://www.fool.com/investing/2023/12/30/3-stocks-that-could-be-monster-winners-in-2024/", "time_published": "20231230T115000", "authors": ["and Prosper Junior Bakiny", "Keith Speights", "David Jagielski"], "summary": "Don't be surprised if these three stocks take off in the new year.", "banner_image": "https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.275292, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDGL", "relevance_score": "0.176502", "ticker_sentiment_score": "0.067451", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.088799", "ticker_sentiment_score": "0.2227", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.044469", "ticker_sentiment_score": "0.043979", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.044469", "ticker_sentiment_score": "0.245827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRNA", "relevance_score": "0.176502", "ticker_sentiment_score": "-0.26264", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.", "url": "https://www.fool.com/investing/2023/12/30/1-million-retirement-invest-stocks-wait-decade/", "time_published": "20231230T105000", "authors": ["Keith Speights"], "summary": "These stocks offer attractive risk-reward profiles.", "banner_image": "https://g.foolcdn.com/editorial/images/759443/middle-aged-couple-with-calculator.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256419, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEP", "relevance_score": "0.288893", "ticker_sentiment_score": "0.133278", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.462953", "ticker_sentiment_score": "0.295504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.098255", "ticker_sentiment_score": "0.082414", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now", "url": "https://www.fool.com/investing/2023/12/29/2-exceptional-growth-stocks-up-42-and-66-to-buy/", "time_published": "20231229T120000", "authors": ["Rachel Warren"], "summary": "It's been a crazy year across sectors, but winners remain.", "banner_image": "https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.244549, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.113062", "ticker_sentiment_score": "0.059546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.330286", "ticker_sentiment_score": "0.217938", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gene Editing, Obesity Drugs And Long-Living Dogs: The Year In Biotech", "url": "https://www.forbes.com/sites/alexknapp/2023/12/29/gene-editing-obesity-drugs-and-long-living-dogs-the-year-in-biotech/", "time_published": "20231229T113000", "authors": ["Alex Knapp"], "summary": "ike a lot of sectors, the biopharma industry kicked off a tumultuous year with a number of shakeups. Big and small biotech companies alike saw thousands of layoffs, not to mention significant leadership changes. In the startup landscape, one big change has been a strategic shift among investors.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/658320c5ef3e4dd3ec4375c2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.249292, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.029184", "ticker_sentiment_score": "0.06454", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.029184", "ticker_sentiment_score": "0.104223", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.029184", "ticker_sentiment_score": "0.072285", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.05833", "ticker_sentiment_score": "0.094036", "ticker_sentiment_label": "Neutral"}]}, {"title": "Casgevy approval unlikely to be followed up by another CRISPR drug in near future, says GlobalData", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/casgevy-approval-unlikely-to-be-followed-up-by-another-crispr-drug-in-near-future-says-globaldata/3349959/", "time_published": "20231229T013000", "authors": ["Health Desk"], "summary": "Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, exagamglogene autotemcel ( Casgevy ) .", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/thermometer-gb80a1464a_1920-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.273546, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.158519", "ticker_sentiment_score": "0.15281", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.150224", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Beats Stock Market Upswing: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2203367/vertex-pharmaceuticals-vrtx-beats-stock-market-upswing-what-investors-need-to-know", "time_published": "20231228T225019", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $409.27, indicating a +0.3% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.20928, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.468029", "ticker_sentiment_score": "0.264644", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/23/12/36402803/decoding-vertex-pharmaceuticalss-options-activity-whats-the-big-picture", "time_published": "20231227T191608", "authors": ["Benzinga Insights"], "summary": "High-rolling investors have positioned themselves bearish on Vertex Pharmaceuticals VRTX, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.031132, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.777061", "ticker_sentiment_score": "0.12708", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.074692", "ticker_sentiment_score": "-0.117125", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow", "url": "https://www.fool.com/investing/2023/12/27/3-reasons-to-buy-vertex-pharmaceuticals-stock-like/", "time_published": "20231227T114500", "authors": ["Alex Carchidi"], "summary": "With a new medicine on the market and plenty of money, Vertex is in great shape.", "banner_image": "https://g.foolcdn.com/editorial/images/757049/vertex-sign.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.317035, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13347", "ticker_sentiment_score": "0.299724", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/12/27/3-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20231227T105000", "authors": ["Keith Speights"], "summary": "These are easy choices for investors seeking market-beating long-term gains.", "banner_image": "https://g.foolcdn.com/editorial/images/759343/hands-behind-head-young-man.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.268385, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.054857", "ticker_sentiment_score": "0.164172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.109455", "ticker_sentiment_score": "0.08296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.269181", "ticker_sentiment_score": "0.337638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.054857", "ticker_sentiment_score": "0.134994", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.508593", "ticker_sentiment_score": "0.345767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.054857", "ticker_sentiment_score": "-0.012001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/12/27/vertex-pharmaceuticals-nasdaqvrtx-upgraded-at-stocknews-com.html", "time_published": "20231227T061843", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued on Wednesday. Several other research analysts also recently weighed in on the stock.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.294047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.791081", "ticker_sentiment_score": "0.472297", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.041755", "ticker_sentiment_score": "0.096077", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.041755", "ticker_sentiment_score": "0.096077", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.041755", "ticker_sentiment_score": "0.075972", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.041755", "ticker_sentiment_score": "0.096077", "ticker_sentiment_label": "Neutral"}]}, {"title": "Unpacking the Latest Options Trading Trends in CRISPR Therapeutics - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/options/23/12/36389306/unpacking-the-latest-options-trading-trends-in-crispr-therapeutics", "time_published": "20231226T190042", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics CRSP we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.199269, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.154823", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in Bluebird Bio Right Now?", "url": "https://www.fool.com/investing/2023/12/26/should-you-invest-in-bluebird-bio-right-now/", "time_published": "20231226T130000", "authors": ["David Moadel"], "summary": "After two December share price crashes, there's no evident cure for Bluebird Bio's ills.", "banner_image": "https://g.foolcdn.com/editorial/images/757293/bluebird_bio_blue_biotechnology_biotech_stocks_stock.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": -0.014857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.176287", "ticker_sentiment_score": "-0.143111", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.734661", "ticker_sentiment_score": "-0.083381", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Nine Breakthroughs of the Year", "url": "https://www.theatlantic.com/ideas/archive/2023/12/scientific-breakthroughs-2023-list/676952/", "time_published": "20231225T110000", "authors": ["Derek Thompson"], "summary": "This is Work in Progress, a newsletter about work, technology, and how to solve some of America's biggest problems. Sign up here. The theme of my second-annual Breakthroughs of the Year is the long road of progress. My top breakthrough is Casgevy, a gene-editing treatment for sickle-cell anemia.", "banner_image": "https://cdn.theatlantic.com/thumbor/_nv7L0KkiZ0RIF6apGC39d1BCIw=/0x43:2000x1085/1200x625/media/img/mt/2023/12/breakthroughs/original.gif", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.120445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.013379", "ticker_sentiment_score": "0.126719", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.013379", "ticker_sentiment_score": "-0.030885", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.013379", "ticker_sentiment_score": "0.093169", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.013379", "ticker_sentiment_score": "0.071524", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.026755", "ticker_sentiment_score": "0.068026", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.013379", "ticker_sentiment_score": "0.087075", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Stocks to Buy Hand Over Fist Before the End of 2023", "url": "https://www.fool.com/investing/2023/12/25/3-top-stocks-to-buy-hand-over-fist-before-the-end/", "time_published": "20231225T105400", "authors": ["Keith Speights"], "summary": "These are ideal stocks to buy sooner rather than later.", "banner_image": "https://g.foolcdn.com/editorial/images/759066/couple-smiling-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.251371, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.11983", "ticker_sentiment_score": "0.274234", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.11983", "ticker_sentiment_score": "0.115291", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today", "url": "https://www.fool.com/investing/2023/12/24/if-you-invested-10000-in-bluebird-bio-in-2018-this/", "time_published": "20231224T123900", "authors": ["David Jagielski"], "summary": "Can things get better for this struggling stock?", "banner_image": "https://g.foolcdn.com/editorial/images/758514/businessman-checking-his-phone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": -0.046778, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.112057", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.276648", "ticker_sentiment_score": "0.176878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSVT", "relevance_score": "0.070517", "ticker_sentiment_score": "0.038533", "ticker_sentiment_label": "Neutral"}]}, {"title": "Editas Just Caught a Break Thanks to Vertex Pharmaceuticals", "url": "https://www.fool.com/investing/2023/12/23/editas-just-caught-a-break-thanks-to-vertex-pharma/", "time_published": "20231223T130200", "authors": ["Alex Carchidi"], "summary": "Editas isn't out of the woods yet, but it's better off than before.", "banner_image": "https://g.foolcdn.com/editorial/images/758926/scientists-lab-testing-blood-draw.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.185888, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VOR", "relevance_score": "0.052112", "ticker_sentiment_score": "0.157552", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.155451", "ticker_sentiment_score": "0.1941", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.104002", "ticker_sentiment_score": "-0.187641", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BLUE", "relevance_score": "0.052112", "ticker_sentiment_score": "0.016966", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Green Flag and 1 Red Flag for Bluebird Bio Stock", "url": "https://www.fool.com/investing/2023/12/23/1-green-flag-and-1-red-flag-for-bluebird-bio-stock/", "time_published": "20231223T123000", "authors": ["Prosper Junior Bakiny"], "summary": "The stock has been in the news lately.", "banner_image": "https://media.ycharts.com/charts/d77724504b74e6e076b5cc679e2bb2f8.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.151209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.060541", "ticker_sentiment_score": "0.058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.505737", "ticker_sentiment_score": "0.137544", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Top Stocks to Buy With Your End-of-the-Year Bonus", "url": "https://www.fool.com/investing/2023/12/23/5-top-stocks-to-buy-with-your-bonus/", "time_published": "20231223T100000", "authors": ["Adria Cimino"], "summary": "Your bonus could become the gift that keeps on giving.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758889%2Fgettyimages-1178121483.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.41286, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.147103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.229872", "ticker_sentiment_score": "0.418924", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.077593", "ticker_sentiment_score": "0.045518", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.116161", "ticker_sentiment_score": "0.275375", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.077593", "ticker_sentiment_score": "0.150159", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Could CRISPR Therapeutics Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/12/22/could-crispr-therapeutics-stock-help-you-become-a/", "time_published": "20231222T220200", "authors": ["David Jagielski"], "summary": "There are plenty of reasons to be optimistic about CRISPR's future.", "banner_image": "https://g.foolcdn.com/editorial/images/758864/rich-couple-on-a-boat.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.346562, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.071145", "ticker_sentiment_score": "0.198471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHPEF", "relevance_score": "0.071145", "ticker_sentiment_score": "0.141886", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At CRISPR Therapeutics's Recent Unusual Options Activity - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/options/23/12/36369249/looking-at-crispr-therapeuticss-recent-unusual-options-activity", "time_published": "20231222T201700", "authors": ["Benzinga Insights"], "summary": "Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics CRSP, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15903, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.069294", "ticker_sentiment_score": "0.15373", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.069294", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Whales and Their Recent Bets on VRTX Options - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/23/12/36368906/market-whales-and-their-recent-bets-on-vrtx-options", "time_published": "20231222T194546", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 11 trades.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.026262, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.679474", "ticker_sentiment_score": "-0.052565", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.022795", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks set for a rebound in 2024, analysts say", "url": "https://www.marketwatch.com/story/biotech-stocks-set-for-a-rebound-in-2024-analysts-say-24df6236", "time_published": "20231222T160600", "authors": ["Eleanor Laise"], "summary": "A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.", "banner_image": "https://images.mktw.net/im-15783720/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.133016, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.089129", "ticker_sentiment_score": "0.156557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRUS", "relevance_score": "0.089129", "ticker_sentiment_score": "0.080617", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IRON", "relevance_score": "0.089129", "ticker_sentiment_score": "0.033685", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17715", "ticker_sentiment_score": "0.070894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.009465", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.203569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.085373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LLY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.111772", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.008934", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?", "url": "https://www.fool.com/investing/2023/12/22/could-sarepta-therapeutics-be-the-next-vertex/", "time_published": "20231222T151500", "authors": ["Alex Carchidi"], "summary": "Both develop medicines for rare diseases, and each aims to conquer a niche market.", "banner_image": "https://g.foolcdn.com/editorial/images/758683/vertex.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.119923, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.172713", "ticker_sentiment_score": "0.105122", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.08687", "ticker_sentiment_score": "0.220264", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Money-Saving Tricks for Investing in Biotech Stocks in 2024", "url": "https://www.fool.com/investing/2023/12/22/3-money-saving-tricks-for-investing-in-biotech/", "time_published": "20231222T134500", "authors": ["Alex Carchidi"], "summary": "Doing a little math and doing a little extra research can make a big difference.", "banner_image": "https://g.foolcdn.com/editorial/images/758692/scientist-examines-samples-with-microscope-while-in-laboratory.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.089119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.041466", "ticker_sentiment_score": "0.074833", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.123951", "ticker_sentiment_score": "0.035543", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Alphabet, Comcast, NextEra, Vertex and Eni", "url": "https://www.zacks.com/stock/news/2201362/the-zacks-analyst-blog-highlights-alphabet-comcast-nextera-vertex-and-eni", "time_published": "20231222T110000", "authors": ["Zacks Investment Research"], "summary": "Alphabet, Comcast, NextEra, Vertex and Eni are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/444.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.278536, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.135347", "ticker_sentiment_score": "0.039353", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.135347", "ticker_sentiment_score": "0.039353", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.135347", "ticker_sentiment_score": "0.039353", "ticker_sentiment_label": "Neutral"}, {"ticker": "E", "relevance_score": "0.135347", "ticker_sentiment_score": "0.039353", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.390904", "ticker_sentiment_score": "0.088555", "ticker_sentiment_label": "Neutral"}]}, {"title": "Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?", "url": "https://www.fool.com/investing/2023/12/22/up-more-than-60-in-2023-is-it-too-late-to-buy-this/", "time_published": "20231222T102700", "authors": ["Cory Renauer"], "summary": "The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758888%2Fa-person-delivering-a-presentation-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.002427, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.191549", "ticker_sentiment_score": "0.062591", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.096477", "ticker_sentiment_score": "0.181709", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks To Watch: Roivant Sciences Sees Relative Strength Rating Jump To 83", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-roivant-sciences-sees-relative-strength-rating-jump-to-83/", "time_published": "20231222T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Roivant Sciences ( ROIV ) had its Relative Strength ( RS ) Rating upgraded from 77 to 83 Friday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.416054, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ROIV", "relevance_score": "0.395012", "ticker_sentiment_score": "0.757", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.395012", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.395012", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Immunocore Holdings ADR Sees RS Rating Rise To 75", "url": "https://www.investors.com/ibd-data-stories/immunocore-holdings-adr-sees-rs-rating-rise-to-75/", "time_published": "20231222T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, Immunocore Holdings ADR ( IMCR ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 69 to 75. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.451746, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMCR", "relevance_score": "0.779232", "ticker_sentiment_score": "0.685347", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Vertex Pharmaceuticals? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36342428/how-is-the-market-feeling-about-vertex-pharmaceuticals", "time_published": "20231221T133020", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 7.22% since its last report. The company recently reported that it has 2.69 million shares sold short, which is 1.04% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy", "url": "https://www.fool.com/investing/2023/12/21/6-words-that-explain-why-crispr-stock-isnt-soaring/", "time_published": "20231221T133000", "authors": ["David Jagielski"], "summary": "Should you buy CRISPR's stock on the dip?", "banner_image": "https://media.ycharts.com/charts/453f752f127b883cae71a2a2123b90e9.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.341901, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.25769", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Vertex Pharmaceuticals Sitting on a Gold Mine?", "url": "https://www.fool.com/investing/2023/12/21/is-vertex-pharmaceuticals-sitting-on-a-gold-mine/", "time_published": "20231221T100000", "authors": ["Adria Cimino"], "summary": "Vertex shares have climbed about 40% this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758783%2Fgettyimages-two-researchers-work-in-a-lab.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.101367", "ticker_sentiment_score": "0.26303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Moves -0.72%: What You Should Know", "url": "https://www.zacks.com/stock/news/2200748/vertex-pharmaceuticals-vrtx-stock-moves--072-what-you-should-know", "time_published": "20231220T224521", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $400.25, marking a -0.72% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.177091, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.523451", "ticker_sentiment_score": "0.221771", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "bluebird  ( BLUE )  Stock Down on Raising Additional Capital", "url": "https://www.zacks.com/stock/news/2200724/bluebird-blue-stock-down-on-raising-additional-capital", "time_published": "20231220T181800", "authors": ["Zacks Equity Research"], "summary": "bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.118249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRDA", "relevance_score": "0.140485", "ticker_sentiment_score": "0.071925", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.140485", "ticker_sentiment_score": "0.0756", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.209365", "ticker_sentiment_score": "0.129659", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow", "url": "https://www.fool.com/investing/2023/12/20/3-reasons-to-buy-crispr-therapeutics-stock/", "time_published": "20231220T100000", "authors": ["Adria Cimino"], "summary": "CRISPR Therapeutics stock has increased in the double digits this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758605%2Finvestors-look-at-tablet-outside.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.362342, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.140056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Downgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/12/20/vertex-pharmaceuticals-nasdaqvrtx-downgraded-by-stocknews-com-to-buy.html", "time_published": "20231220T082042", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Vertex Pharmaceuticals ( NASDAQ:VRTX - Free Report ) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.269895, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.042723", "ticker_sentiment_score": "0.022431", "ticker_sentiment_label": "Neutral"}, {"ticker": "WING", "relevance_score": "0.042723", "ticker_sentiment_score": "0.09678", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.042723", "ticker_sentiment_score": "0.09678", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.716023", "ticker_sentiment_score": "0.421723", "ticker_sentiment_label": "Bullish"}, {"ticker": "SEIC", "relevance_score": "0.085324", "ticker_sentiment_score": "0.194561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNV", "relevance_score": "0.085324", "ticker_sentiment_score": "0.194561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.042723", "ticker_sentiment_score": "0.022431", "ticker_sentiment_label": "Neutral"}]}, {"title": "Xenon Pharmaceuticals Getting Closer To Key Technical Measure", "url": "https://www.investors.com/ibd-data-stories/xenon-pharmaceuticals-getting-closer-to-key-technical-measure/", "time_published": "20231220T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Xenon Pharmaceuticals ( XENE ) had its Relative Strength ( RS ) Rating upgraded from 69 to 74 Wednesday -- a welcome improvement, but still below the 80 or higher score you prefer to see. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.379617, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.380012", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.380012", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XENE", "relevance_score": "0.678673", "ticker_sentiment_score": "0.573117", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks To Watch: Kura Oncology Sees RS Rating Jump To 85", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-kura-oncology-sees-rs-rating-jump-to-85/", "time_published": "20231220T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, Kura Oncology ( KURA ) reached a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 85, up from 79 the day before. X When looking for the best stocks to buy and watch, one factor to watch closely is ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.360189, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.366061", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.366061", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.524949", "ticker_sentiment_score": "0.473741", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Upgrades: Editas Medicine Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-editas-medicine-shows-rising-relative-strength-6/", "time_published": "20231220T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, Editas Medicine ( EDIT ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 88 to 91. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's unique rating identifies price performance with a 1 ( worst ) ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.427028, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.629492", "ticker_sentiment_score": "0.665262", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.17715", "ticker_sentiment_score": "0.257069", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arvinas Shows Rising Price Performance With Jump To 92 RS Rating", "url": "https://www.investors.com/ibd-data-stories/arvinas-shows-rising-price-performance-with-jump-to-92-rs-rating/", "time_published": "20231220T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Arvinas ( ARVN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 89 to 92. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.34524, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.130676", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.343279", "ticker_sentiment_score": "0.130676", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.343279", "ticker_sentiment_score": "0.755936", "ticker_sentiment_label": "Bullish"}]}, {"title": "Structure Therap ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/structure-therap-adr-scores-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20231220T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Structure Therap ADR Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.293245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.340915", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.340915", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Recursion Pharm Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-recursion-pharm-shows-rising-relative-strength/", "time_published": "20231220T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Recursion Pharm ( RXRX ) is one stock that just reached the mark, now earning a score of 85. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.251405, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Mirum Pharmaceuticals Sees RS Rating Rise To 87", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-mirum-pharmaceuticals-sees-rs-rating-rise-to-87/", "time_published": "20231220T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Mirum Pharmaceuticals ( MIRM ) climbed into a new percentile Wednesday, with an increase from 80 to 87. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.221791, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIRM", "relevance_score": "0.448842", "ticker_sentiment_score": "0.093143", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/12/36306828/1000-invested-in-vertex-pharmaceuticals-20-years-ago-would-be-worth-this-much-today", "time_published": "20231219T153232", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 12.73% on an annualized basis producing an average annual return of 20.32%. Currently, Vertex Pharmaceuticals has a market capitalization of $103.67 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Better Growth Stock: Archer Aviation or Prime Medicine?", "url": "https://www.fool.com/investing/2023/12/19/better-growth-stock-archer-aviation-or-prime-medic/", "time_published": "20231219T153000", "authors": ["George Budwell"], "summary": "Which of these innovation-themed growth stocks is the better buy?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758708%2Fgrowth-trend.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.304279, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.059049", "ticker_sentiment_score": "0.125", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHR", "relevance_score": "0.232996", "ticker_sentiment_score": "0.295881", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRME", "relevance_score": "0.175859", "ticker_sentiment_score": "0.211305", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Charles River's  ( CRL )  Memphis Site Achieves Crucial Approval", "url": "https://www.zacks.com/stock/news/2199833/charles-rivers-crl-memphis-site-achieves-crucial-approval", "time_published": "20231219T130100", "authors": ["Zacks Equity Research"], "summary": "Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.203174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.143415", "ticker_sentiment_score": "0.072807", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.095899", "ticker_sentiment_score": "0.037313", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAE", "relevance_score": "0.236742", "ticker_sentiment_score": "0.08821", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.143415", "ticker_sentiment_score": "0.054195", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Healthcare Stocks That Could Help Make You a Millionaire", "url": "https://www.fool.com/investing/2023/12/19/3-healthcare-stocks-could-help-make-you-rich/", "time_published": "20231219T100000", "authors": ["Adria Cimino"], "summary": "These stocks each have reached an important turning point that could signal growth ahead.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758604%2Fgettyimages-474008420.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.295687, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05339", "ticker_sentiment_score": "0.294926", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.159218", "ticker_sentiment_score": "0.23199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.159218", "ticker_sentiment_score": "0.106569", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK", "url": "https://www.zacks.com/stock/news/2199740/the-zacks-analyst-blog-highlights-novo-nordisk-eli-lilly-vertex-pharmaceuticals-regeneron-and-gsk", "time_published": "20231219T093400", "authors": ["Zacks Investment Research"], "summary": "Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.198286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.200134", "ticker_sentiment_score": "0.176485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.067347", "ticker_sentiment_score": "0.08218", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.156316", "ticker_sentiment_score": "0.133696", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.200134", "ticker_sentiment_score": "0.143776", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.022473", "ticker_sentiment_score": "0.021801", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vivos Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/vivos-therapeutics-clears-key-benchmark-hitting-90-plus-rs-rating/", "time_published": "20231219T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Tuesday, Vivos Therapeutics ( VVOS ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 81 to 93. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.364901, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.129183", "ticker_sentiment_label": "Neutral"}, {"ticker": "VVOS", "relevance_score": "0.595343", "ticker_sentiment_score": "0.510548", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.323078", "ticker_sentiment_score": "0.129183", "ticker_sentiment_label": "Neutral"}]}, {"title": "Celldex Therapeutics Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/celldex-therapeutics-earns-relative-strength-rating-upgrade-2/", "time_published": "20231219T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Celldex Therapeutics ( CLDX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an increase from 67 to 72. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.381836, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.585687", "ticker_sentiment_score": "0.729785", "ticker_sentiment_label": "Bullish"}]}, {"title": "Vertex  ( VRTX ) , CRISPR Get Positive CHMP Opinion for Gene-Therapy", "url": "https://www.zacks.com/stock/news/2199442/vertex-vrtx-crispr-get-positive-chmp-opinion-for-gene-therapy", "time_published": "20231218T145800", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.119848, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.182162", "ticker_sentiment_score": "0.149685", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.137148", "ticker_sentiment_score": "0.029745", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.182162", "ticker_sentiment_score": "0.243495", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Biotech Stocks Most Wall Street Analysts Are Bullish About", "url": "https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about", "time_published": "20231218T140100", "authors": ["Ekta Bagri"], "summary": "Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.26846, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRSP", "relevance_score": "0.149424", "ticker_sentiment_score": "0.159067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITCI", "relevance_score": "0.112357", "ticker_sentiment_score": "0.110298", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.037563", "ticker_sentiment_score": "0.202684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CERE", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.075043", "ticker_sentiment_score": "0.061531", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.037563", "ticker_sentiment_score": "0.058359", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Big Drug Stocks That May Continue to Outperform in 2024", "url": "https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024", "time_published": "20231218T135400", "authors": ["Kinjel Shah"], "summary": "Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.200783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.184775", "ticker_sentiment_score": "0.189145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.046588", "ticker_sentiment_score": "0.141465", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.139131", "ticker_sentiment_score": "0.152648", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.184775", "ticker_sentiment_score": "0.155351", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.023304", "ticker_sentiment_score": "0.021882", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Stocks Profiting From Unstoppable Trends That Could Make You Rich", "url": "https://www.fool.com/investing/2023/12/18/2-stocks-that-could-make-you-rich/", "time_published": "20231218T103000", "authors": ["Adria Cimino"], "summary": "It's important to choose companies involved in trends that have long-term potential.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758556%2Fgettyimages-1139299116.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.305506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.223686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMNF", "relevance_score": "0.063594", "ticker_sentiment_score": "0.140131", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.367865", "ticker_sentiment_score": "0.119342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Price Strength: Arcturus Therapeutics", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-arcturus-therapeutics-2/", "time_published": "20231218T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Arcturus Therapeutics ( ARCT ) had its Relative Strength ( RS ) Rating upgraded from 88 to 91 Monday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.349059, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.521465", "ticker_sentiment_score": "0.794721", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.363388", "ticker_sentiment_score": "0.136437", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.363388", "ticker_sentiment_score": "0.136437", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years", "url": "https://www.fool.com/investing/2023/12/17/2-stocks-that-could-turn-1000-into-3500-in-10-year/", "time_published": "20231217T134500", "authors": ["Prosper Junior Bakiny"], "summary": "These businesses are exciting and can also lead to outsized long-term returns.", "banner_image": "https://g.foolcdn.com/editorial/images/757594/person-sitting-and-working-at-a-desk.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.368027, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.098054", "ticker_sentiment_score": "0.157483", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SQ", "relevance_score": "0.333685", "ticker_sentiment_score": "0.380139", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.098054", "ticker_sentiment_score": "0.084491", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?", "url": "https://www.fool.com/investing/2023/12/16/crispr-therapeutics-just-made-history-so-why-did/", "time_published": "20231216T144500", "authors": ["Alex Carchidi"], "summary": "The benefits from its first drug launch will trickle in slowly, at least at first.", "banner_image": "https://g.foolcdn.com/editorial/images/758106/concerned-investor-with-two-people-in-background.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.210772, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.110717", "ticker_sentiment_score": "0.044829", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.055492", "ticker_sentiment_score": "0.046199", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally", "url": "https://www.fool.com/investing/2023/12/16/3-fantastic-stocks-that-could-enjoy-a-santa-claus/", "time_published": "20231216T115500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "These stocks could bring investors more than just a lump of coal for Christmas.", "banner_image": "https://g.foolcdn.com/editorial/images/758336/santa-claus-buggy-chart.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.198521, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.081001", "ticker_sentiment_score": "0.084485", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.040553", "ticker_sentiment_score": "0.136672", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.278109", "ticker_sentiment_score": "0.196332", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.239698", "ticker_sentiment_score": "0.073491", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip", "url": "https://www.fool.com/investing/2023/12/16/key-reason-buy-crispr-therapeutics-stock/", "time_published": "20231216T105300", "authors": ["Keith Speights"], "summary": "This biotech could have more winners on the way.", "banner_image": "https://g.foolcdn.com/editorial/images/758246/dna-scientist-test-tube.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.137878, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.059785", "ticker_sentiment_score": "0.037994", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.119235", "ticker_sentiment_score": "0.200668", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?", "url": "https://www.fool.com/investing/2023/12/15/down-30-in-a-week-what-in-the-world-is-going-on-wi/", "time_published": "20231215T161400", "authors": ["Alex Carchidi"], "summary": "An expected big win is rapidly turning into a defeat.", "banner_image": "https://g.foolcdn.com/editorial/images/758103/a-young-scientist-recording-her-findings-on-a-tablet.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.017298, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.033876", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.152821", "ticker_sentiment_score": "-0.0774", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-surges-to-2023-highs-as-fed-pivots-toward-rate-cuts-weekly-review/", "time_published": "20231215T155400", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally raced higher in a powerful, broad advance as the Federal Reserve signaled it could cut rates three times in 2024. The Dow Jones hit a record high while the S&P 500, Nasdaq composite, S&P MidCap 400 and small-cap Russell 2023 all set 2023 bests. Treasury yields plunged.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/LSSECRETS-peak-040221.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.972193"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.065812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.059935", "ticker_sentiment_score": "0.086", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.029989", "ticker_sentiment_score": "-0.028872", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.108167", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.178459", "ticker_sentiment_score": "-0.007668", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.441897", "ticker_sentiment_label": "Bearish"}, {"ticker": "OXY", "relevance_score": "0.089797", "ticker_sentiment_score": "-0.031906", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.119532", "ticker_sentiment_score": "0.106769", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.029989", "ticker_sentiment_score": "0.217562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEN", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.003011", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.1491", "ticker_sentiment_score": "0.10867", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.178459", "ticker_sentiment_score": "0.058147", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.141007", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.2386", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Where Will CRISPR Therapeutics Be in 5 Years?", "url": "https://www.fool.com/investing/2023/12/15/where-will-crispr-therapeutics-be-in-5-years/", "time_published": "20231215T143000", "authors": ["David Jagielski"], "summary": "Does the recent approval make the stock a no-brainer buy?", "banner_image": "https://g.foolcdn.com/editorial/images/757823/people-discussing-a-sales-report.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20083, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.119609", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.105141", "ticker_sentiment_score": "0.14288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.105141", "ticker_sentiment_score": "-0.119275", "ticker_sentiment_label": "Neutral"}]}, {"title": "Twist Bioscience  ( TWST )  Soars 12.5%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2198479/twist-bioscience-twst-soars-125-is-further-upside-left-in-the-stock", "time_published": "20231215T131100", "authors": ["Zacks Equity Research"], "summary": "Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default179.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.284572, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.360752", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.565345", "ticker_sentiment_score": "0.472677", "ticker_sentiment_label": "Bullish"}]}, {"title": "After This Landmark Win, Is CRISPR Therapeutics a Buy?", "url": "https://www.fool.com/investing/2023/12/15/after-this-landmark-win-is-crispr-a-buy/", "time_published": "20231215T103000", "authors": ["Adria Cimino"], "summary": "CRISPR Therapeutics stock already has advanced in the double digits this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758279%2Fcrsp.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.33067, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.06211", "ticker_sentiment_score": "0.192152", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ironwood Pharm Cl A Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/ironwood-pharm-cl-a-clears-technical-benchmark-hitting-80-plus-rs-rating-2/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Ironwood Pharm Cl A ( IRWD ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, rising from 66 to 80. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.374028, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.353059", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.353059", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Xenon Pharmaceuticals Trying To Close In On Key Technical Measure", "url": "https://www.investors.com/ibd-data-stories/xenon-pharmaceuticals-trying-to-close-in-on-key-technical-measure/", "time_published": "20231215T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "In a welcome move, Xenon Pharmaceuticals ( XENE ) saw its Relative Strength Rating improve from 63 to 71 on Friday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating identifies market leadership with a 1 ( worst ) ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.40205, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XENE", "relevance_score": "0.625937", "ticker_sentiment_score": "0.576564", "ticker_sentiment_label": "Bullish"}, {"ticker": "NBIX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Rising Market Leadership: Editas Medicine Earns 87 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-rising-market-leadership-editas-medicine-earns-87-rs-rating-2/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When putting together your watch list, look for stocks with an 80 or higher RS Rating. Editas Medicine ( EDIT ) just met that criteria with a new score of 87. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.351908, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.338582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.618922", "ticker_sentiment_score": "0.194741", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.173333", "ticker_sentiment_score": "0.083624", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.338582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Vericel Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-vericel-shows-rising-relative-strength-4/", "time_published": "20231215T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vericel ( VCEL ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an upgrade from 76 to 83. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.326729, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.155451", "ticker_sentiment_score": "0.177909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCEL", "relevance_score": "0.567144", "ticker_sentiment_score": "0.141251", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2198296/vertex-pharmaceuticals-vrtx-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231214T224517", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $406.60, representing a +0.38% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default358.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.208545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.543535", "ticker_sentiment_score": "0.318843", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html", "time_published": "20231214T221500", "authors": [], "summary": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177123, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDPQ", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTGN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.22385", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AZN", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Promising new gene therapies for sickle cell are out of reach in countries where they're needed most", "url": "https://apnews.com/article/sickle-cell-gene-therapy-crispr-global-0a76d10be53462d57e9d3cc07d15fc02", "time_published": "20231214T155506", "authors": ["LAURA UNGAR"], "summary": "Gautam Dongre's two children in India and Pascazia Mazeze's son in Tanzania live with an inherited blood disorder that turns blood cells into instruments of pain. Now that new gene therapies promise a cure for their sickle cell disease, Dongre says he's \"praying the treatment should come to us.\"", "banner_image": "https://dims.apnews.com/dims4/default/dd5f9a9/2147483647/strip/true/crop/4902x3265+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F9d%2F91%2F81d5cc92f3fc2a885f8414ab501f%2F57f4cd1601c24a309396eb7cd7223fa8", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.012064, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.026328", "ticker_sentiment_score": "0.006495", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.026328", "ticker_sentiment_score": "0.135019", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.052627", "ticker_sentiment_score": "0.140608", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.026328", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics", "url": "https://www.zacks.com/stock/news/2198066/the-zacks-analyst-blog-highlights-bluebird-editas-medicine-beam-therapeutics-and-intellia-therapeutics", "time_published": "20231214T153600", "authors": ["Zacks Equity Research"], "summary": "bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.162286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.365085", "ticker_sentiment_score": "0.035532", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.03443", "ticker_sentiment_score": "0.071953", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.204359", "ticker_sentiment_score": "0.090058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.103035", "ticker_sentiment_score": "0.050229", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.395532", "ticker_sentiment_score": "0.132488", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News", "url": "https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news", "time_published": "20231214T145500", "authors": ["Zacks Equity Research"], "summary": "bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.255199, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.142989", "ticker_sentiment_score": "0.144851", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.178196", "ticker_sentiment_score": "0.174354", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.107495", "ticker_sentiment_score": "0.067248", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.035929", "ticker_sentiment_score": "0.10456", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.071784", "ticker_sentiment_score": "0.091535", "ticker_sentiment_label": "Neutral"}]}, {"title": "Editas  ( EDIT )  Licenses Cas9 Tool to Vertex, Stock Up 6%", "url": "https://www.zacks.com/stock/news/2197854/editas-edit-licenses-cas9-tool-to-vertex-stock-up-6", "time_published": "20231214T133200", "authors": ["Zacks Equity Research"], "summary": "Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/1887.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.263609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.112008", "ticker_sentiment_score": "0.094706", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.221819", "ticker_sentiment_score": "-0.008676", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.275246", "ticker_sentiment_score": "0.317606", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Hits Record High on Non-Opioid Pain Drug Data", "url": "https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data", "time_published": "20231214T131700", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.051034, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.214462", "ticker_sentiment_score": "-0.122114", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.214462", "ticker_sentiment_score": "0.163211", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.108222", "ticker_sentiment_score": "-0.050746", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: What To Do As Rally Runs", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-market-rally-runs-on-fed-rate-cut-shift/", "time_published": "20231214T114200", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures Rise As Market Rally Runs On Fed Rate-Cut Shift. What To Do Now Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.014438, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.146202", "ticker_sentiment_score": "0.025365", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.203582", "ticker_sentiment_score": "-0.006401", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.231884", "ticker_sentiment_score": "0.014447", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.259881", "ticker_sentiment_score": "-0.00583", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.203582", "ticker_sentiment_score": "-0.105018", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.088039", "ticker_sentiment_score": "0.122924", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.058759", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.1172", "ticker_sentiment_score": "0.029224", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.029399", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.088039", "ticker_sentiment_score": "0.089746", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.058759", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Soars 13.2%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2197712/vertex-vrtx-soars-132-is-further-upside-left-in-the-stock", "time_published": "20231214T111200", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.238921, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.286913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "InnovationRx: Tough Road Ahead For Bluebird's Gene Therapy", "url": "https://www.forbes.com/sites/alexknapp/2023/12/13/innovationrx-tough-road-ahead-for-bluebirds-gene-therapy/", "time_published": "20231213T233329", "authors": ["Katie Jennings"], "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. Last Friday marked a biotech milestone as the Food and Drug Administration approved two Cripsr-based gene therapies for the treatment of sickle cell disease.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657a3ef34c311e5c46af2b43/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.026364, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.034933", "ticker_sentiment_score": "0.055813", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.034933", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDCCQ", "relevance_score": "0.034933", "ticker_sentiment_score": "0.016338", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.034933", "ticker_sentiment_score": "0.08559", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.034933", "ticker_sentiment_score": "0.055813", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.069798", "ticker_sentiment_score": "0.067246", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.034933", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUGX", "relevance_score": "0.034933", "ticker_sentiment_score": "0.055813", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034933", "ticker_sentiment_score": "-0.125168", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Hits New High In Fed-Led Rally; Adobe Falls Late", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-hits-record-high-as-fed-sees-three-rate-cuts-markets-bet-on-six-adobe-falls-late/", "time_published": "20231213T215300", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Hits Record High As Fed Sees Three Rate Cuts. Markets Bet On Six. Adobe Falls Late Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Federal-Reserve-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.016808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.148915", "ticker_sentiment_score": "0.025646", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.207317", "ticker_sentiment_score": "-0.006493", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.236109", "ticker_sentiment_score": "0.014658", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.264578", "ticker_sentiment_score": "-0.005916", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.207317", "ticker_sentiment_score": "-0.08465", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.089685", "ticker_sentiment_score": "0.123366", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.05986", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.119383", "ticker_sentiment_score": "0.029449", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.029951", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.05986", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Vertex Stock Is Soaring Today", "url": "https://www.fool.com/investing/2023/12/13/why-vertex-stock-is-soaring-today/", "time_published": "20231213T190823", "authors": ["James Brumley"], "summary": "The drugmaker's non-opioid painkiller is showing promise in a select set of patients.", "banner_image": "https://g.foolcdn.com/editorial/images/758217/break-through-ceiling.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.039435, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.386477", "ticker_sentiment_score": "-0.011075", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Vertex Pharmaceuticals  ( VRTX )  Stock Surging Today? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36216498/vertexs-non-opioid-diabetes-associated-nerve-pain-treatment-candidate-aces-mid-stage-trial", "time_published": "20231213T173011", "authors": ["Vandana Singh"], "summary": "Vertex Pharmaceuticals Incorporated VRTX released results from its Phase 2 dose-ranging study of VX-548 ( non-opioid pain medicine ) for diabetic peripheral neuropathy, a type of nerve damage caused by high blood sugar. VX-548 was generally well tolerated at all doses tested in the study.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/vrtx_co.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.161565, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.222795", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Vertex's stock heads for all-time high as non-opioid painkiller shows promise", "url": "https://www.marketwatch.com/story/vertexs-stock-heads-for-all-time-high-as-non-opioid-painkiller-shows-promise-3a42c530", "time_published": "20231213T170300", "authors": ["Eleanor Laise"], "summary": "Vertex Pharmaceuticals' stock was on track for an all-time high Wednesday after the company released new data on its experimental non-opioid pain medicine.", "banner_image": "https://images.mktw.net/im-69857938/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.019354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.252987", "ticker_sentiment_score": "-0.072374", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Flat Ahead Of Fed; Magnificent Seven Mixed As Tesla Falls", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-flat-ahead-of-fed-magnificent-seven-mixed-as-tesla-falls/", "time_published": "20231213T160900", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Flat Ahead Of Fed. Magnificent Seven Mixed As Tesla Falls Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/04/Stock-Tesla-chargeStation-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.99737"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.102537, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.058759", "ticker_sentiment_score": "-0.115734", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.1172", "ticker_sentiment_score": "0.20947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.058759", "ticker_sentiment_score": "-0.064984", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.1172", "ticker_sentiment_score": "0.20947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.1172", "ticker_sentiment_score": "0.20947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.1172", "ticker_sentiment_score": "0.014299", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.175009", "ticker_sentiment_score": "0.099463", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.175009", "ticker_sentiment_score": "0.099463", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.1172", "ticker_sentiment_score": "0.20947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITCI", "relevance_score": "0.1172", "ticker_sentiment_score": "0.079478", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.059628", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.175009", "ticker_sentiment_score": "-0.091027", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLAB", "relevance_score": "0.1172", "ticker_sentiment_score": "0.073855", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex's non-opioid drug reduces nerve pain in trial, shares hit record high", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/vertexs-neuropathic-pain-treatment-succeeds-mid-stage-trial-2023-12-13/", "time_published": "20231213T153700", "authors": ["Sriparna Roy"], "summary": "A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4QXBW6RP45FBRHDZQXLNRGX5UY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.147221, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.247035", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "1 Biotech Stock That Could Be the Next Amgen", "url": "https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/", "time_published": "20231213T151500", "authors": ["George Budwell"], "summary": "The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758114%2Finnovation.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.282248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.147818", "ticker_sentiment_score": "0.199185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.358669", "ticker_sentiment_score": "0.261825", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9", "url": "https://www.globenewswire.com/news-release/2023/12/13/2795602/0/en/Editas-Medicine-and-Vertex-Pharmaceuticals-Enter-into-Non-exclusive-License-Agreement-for-Cas9.html", "time_published": "20231213T140000", "authors": ["Editas Medicine", "Inc."], "summary": "Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/03686b66-5cbc-40b5-9dfa-be0e7858ac97", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.141852, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.128822", "ticker_sentiment_score": "0.128686", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.373378", "ticker_sentiment_score": "0.273044", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Rallies, Flashes Bullish Signal On Phase 2 Results For Opioid Alternative", "url": "https://www.investors.com/news/technology/vertex-stock-flashes-bullish-signal-on-phase-2-results-for-opioid-alternative/", "time_published": "20231213T134600", "authors": ["Investor's Business Daily", "HARRISON MILLER"], "summary": "Vertex Pharmaceuticals ( VRTX ) reported positive Phase 2 study results for a pain drug to treat diabetic peripheral neuropathy ( DPN ) early Wednesday. Vertex stock rallied more than 7% premarket and flashed a bullish signal to clear a downtrend.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-vertex-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": -0.022199, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.41427", "ticker_sentiment_label": "Bullish"}]}, {"title": "Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?", "url": "https://www.fool.com/investing/2023/12/13/better-growth-stock-vertex-pharmaceuticals-or-exac/", "time_published": "20231213T134500", "authors": ["George Budwell"], "summary": "Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758050%2Fbiotech.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.1701, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.099066", "ticker_sentiment_score": "0.145429", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.099066", "ticker_sentiment_score": "0.145429", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotechs With Promising Gene Therapies in the Spotlight", "url": "https://www.zacks.com/stock/news/2197203/3-biotechs-with-promising-gene-therapies-in-the-spotlight", "time_published": "20231213T130600", "authors": ["Ekta Bagri"], "summary": "The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.171518, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.352057", "ticker_sentiment_score": "0.039665", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.03642", "ticker_sentiment_score": "0.086097", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.180595", "ticker_sentiment_score": "0.108333", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.072765", "ticker_sentiment_score": "0.090617", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.384532", "ticker_sentiment_score": "0.153057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Thalassaemia International Federation applauds FDA approval of SCD gene therapies", "url": "https://www.financialexpress.com/healthcare/news-healthcare/thalassaemia-international-federation-applauds-fda-approval-of-scd-gene-therapies/3337598/", "time_published": "20231213T093715", "authors": ["Health Desk"], "summary": "The US Food and Drug Administration ( FDA ) simultaneously approved two innovative gene therapies for individuals with sickle cell anaemia last week, offering substantial hope for a radical treatment of this severe haematological disorder.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/blood-new.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.195833, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.010457", "ticker_sentiment_label": "Neutral"}]}, {"title": "What FDA Approval Means For CRSP Stock", "url": "https://www.investors.com/news/technology/crsp-stock-what-fda-approval-means-for-future-of-medicine/", "time_published": "20231212T210300", "authors": ["Investor's Business Daily", "ALEXIS GARCIA"], "summary": "CRSP Stock: What FDA's Historic Gene Editing Approval Means For The Future Of Medicine Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/q8qy2w7S.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.091212, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.133692", "ticker_sentiment_score": "0.176462", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.02686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors", "url": "https://www.fool.com/investing/2023/12/12/abbvie-just-followed-pfizers-big-move-heres-what/", "time_published": "20231212T151500", "authors": ["Alex Carchidi"], "summary": "It's making a major acquisition to beef up a key area of its pipeline.", "banner_image": "https://g.foolcdn.com/editorial/images/757505/investor-thinks-while-looking-out-a-window.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.180242, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051551", "ticker_sentiment_score": "0.103893", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.349153", "ticker_sentiment_score": "0.191583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.051551", "ticker_sentiment_score": "0.002992", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.051551", "ticker_sentiment_score": "0.002992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Intellia Therapeutics Become the Next CRISPR Therapeutics?", "url": "https://www.fool.com/investing/2023/12/12/could-intellia-become-the-next-crispr-therapeutics/", "time_published": "20231212T110000", "authors": ["Adria Cimino"], "summary": "Intellia is approaching the finish line.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757864%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.209856, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.051663", "ticker_sentiment_score": "0.094949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.051663", "ticker_sentiment_score": "0.094949", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.254042", "ticker_sentiment_score": "0.130543", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Closer Look at CRISPR Therapeutics's Options Market Dynamics - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/options/23/12/36182007/a-closer-look-at-crispr-therapeuticss-options-market-dynamics", "time_published": "20231211T181604", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics CRSP revealed 19 unusual trades. Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.169151, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.077845", "ticker_sentiment_score": "0.155314", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.077845", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CRISPR Stock Keeps Falling", "url": "https://www.fool.com/investing/2023/12/11/why-crispr-stock-keeps-falling/", "time_published": "20231211T174131", "authors": ["Rich Smith"], "summary": "CRISPR just scored its first FDA victory -- but profits remain years away.", "banner_image": "https://g.foolcdn.com/editorial/images/757908/scientists-study-strands-of-dna.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.080126, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.159569", "ticker_sentiment_score": "0.10866", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.080188", "ticker_sentiment_score": "0.100658", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.080188", "ticker_sentiment_score": "0.033076", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.080188", "ticker_sentiment_score": "0.033076", "ticker_sentiment_label": "Neutral"}]}, {"title": "BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies", "url": "https://www.zacks.com/stock/news/2196355/blue-crsp-vrtx-down-despite-fda-nod-to-scd-therapies", "time_published": "20231211T172400", "authors": ["Zacks Equity Research"], "summary": "The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.050467, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.123209", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.123209", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "bluebird  ( BLUE )  Down Despite FDA Nod to Gene Therapy for SCD", "url": "https://www.zacks.com/stock/news/2196255/bluebird-blue-down-despite-fda-nod-to-gene-therapy-for-scd", "time_published": "20231211T160800", "authors": ["Zacks Equity Research"], "summary": "bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.131142, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRDA", "relevance_score": "0.107736", "ticker_sentiment_score": "0.066167", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.107736", "ticker_sentiment_score": "0.072703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.107736", "ticker_sentiment_score": "0.069434", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP ) , Vertex Fall Despite FDA Nod to SCD Drug Casgevy", "url": "https://www.zacks.com/stock/news/2196180/crispr-crsp-vertex-fall-despite-fda-nod-to-scd-drug-casgevy", "time_published": "20231211T145100", "authors": ["Zacks Equity Research"], "summary": "CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.107726, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.173022", "ticker_sentiment_score": "0.161686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.29792", "ticker_sentiment_score": "0.19598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.087027", "ticker_sentiment_score": "0.035471", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.130217", "ticker_sentiment_score": "0.137127", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics and Dollar General have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2196025/crispr-therapeutics-and-dollar-general-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20231211T133700", "authors": ["Zacks Equity Research"], "summary": "CRISPR Therapeutics and Dollar General are part of the Zacks Bull and Bear of the Day article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/35/1287.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Earnings", "relevance_score": "0.986413"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.098548, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MPC", "relevance_score": "0.075675", "ticker_sentiment_score": "0.128462", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.088239", "ticker_sentiment_score": "0.015602", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.088239", "ticker_sentiment_score": "0.113025", "ticker_sentiment_label": "Neutral"}, {"ticker": "FXNC", "relevance_score": "0.012631", "ticker_sentiment_score": "0.083489", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.012631", "ticker_sentiment_score": "0.011913", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.025259", "ticker_sentiment_score": "0.153504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.012631", "ticker_sentiment_score": "0.000887", "ticker_sentiment_label": "Neutral"}, {"ticker": "EOG", "relevance_score": "0.100782", "ticker_sentiment_score": "0.062743", "ticker_sentiment_label": "Neutral"}]}, {"title": "Daily: Ohtani Scores Biggest Deal In U.S. Team Sports History", "url": "https://www.forbes.com/sites/daniellechemtob/2023/12/11/forbes-daily-ohtani-scores-biggest-deal-in-us-team-sports-history/", "time_published": "20231211T132049", "authors": ["Danielle Chemtob"], "summary": "This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. While WeWork may have collapsed, the demand for coworking space hasn't gone away.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6576ff8615ee7605fd1dad2a/0x0.jpg?format=jpg&crop=3581,2013,x0,y75,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.165009, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.061263", "ticker_sentiment_score": "0.109013", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.020439", "ticker_sentiment_score": "0.159704", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.020439", "ticker_sentiment_score": "0.034098", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.020439", "ticker_sentiment_score": "0.040754", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.020439", "ticker_sentiment_score": "-0.013694", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.020439", "ticker_sentiment_score": "0.200226", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.020439", "ticker_sentiment_score": "-0.022198", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?", "url": "https://www.fool.com/investing/2023/12/11/is-crispr-therapeutics-a-good-stock-to-buy-followi/", "time_published": "20231211T104300", "authors": ["Cory Renauer"], "summary": "A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757756%2Finvestor-stock-charts-screens-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.038502, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.080881", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.090989", "ticker_sentiment_score": "0.180775", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bull of the Day: CRISPR Therapeutics  ( CRSP ) ", "url": "https://www.zacks.com/commentary/2195863/bull-of-the-day-crispr-therapeutics-crsp", "time_published": "20231211T102000", "authors": ["Kevin Cook"], "summary": "FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.110249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.083833", "ticker_sentiment_score": "0.081281", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.062926", "ticker_sentiment_score": "0.15093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FXNC", "relevance_score": "0.020995", "ticker_sentiment_score": "0.088609", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Unstoppable Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/12/10/3-unstoppable-stocks-to-buy-right-now/", "time_published": "20231210T115600", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "These stocks could be just the ticket for investors seeking strong growth.", "banner_image": "https://g.foolcdn.com/editorial/images/757538/two-people-with-ipad-and-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.99393"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.265592, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.411176", "ticker_sentiment_score": "0.233842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.171181", "ticker_sentiment_score": "0.189008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MORN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.134502", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.043108", "ticker_sentiment_score": "-0.011888", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.171181", "ticker_sentiment_score": "0.154166", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?", "url": "https://www.fool.com/investing/2023/12/10/vertex-pharmaceuticals-just-proved-something-big/", "time_published": "20231210T104500", "authors": ["Adria Cimino"], "summary": "The big biotech's shares have been on the rise this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757762%2Fscientists-high-five-smile.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.287526, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.049424", "ticker_sentiment_score": "0.056408", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049424", "ticker_sentiment_score": "0.163801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.181705", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person", "url": "https://www.businessinsider.com/gene-therapy-for-sickle-cell-anemia-costs-millions-fda-2023-12", "time_published": "20231209T201200", "authors": ["Kenneth Niemeyer"], "summary": "First FDA approved gene therapies for sickle cell anemia cost millions - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177131, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.095138", "ticker_sentiment_score": "0.209731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.095138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Forget the \"Magnificent Seven\": Buy This Stock Instead", "url": "https://www.fool.com/investing/2023/12/09/forget-magnificent-seven-buy-this-stock-instead/", "time_published": "20231209T150700", "authors": ["Prosper Junior Bakiny"], "summary": "It's hard to go wrong with this high-flying drugmaker.", "banner_image": "https://media.ycharts.com/charts/b0eb575531babb121888da1d4d347d5f.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.217855, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.040212", "ticker_sentiment_score": "0.178115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.237745", "ticker_sentiment_score": "0.246479", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.040212", "ticker_sentiment_score": "0.178115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.040212", "ticker_sentiment_score": "0.178115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.040212", "ticker_sentiment_score": "0.178115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.080323", "ticker_sentiment_score": "-0.068103", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years", "url": "https://www.fool.com/investing/2023/12/09/2-superior-growth-stocks-up-23-and-105-this-year/", "time_published": "20231209T143600", "authors": ["Rachel Warren"], "summary": "These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.", "banner_image": "https://g.foolcdn.com/editorial/images/757244/businesswoman-celebrating-1.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.235654, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.30211", "ticker_sentiment_score": "0.206635", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.088309", "ticker_sentiment_score": "0.040798", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rally Ready To Run? 5 Stocks In Buy Zones As Tesla Sets Up", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-looks-ready-to-run-again-5-stocks-in-buy-zones-as-tesla-sets-up/", "time_published": "20231208T215800", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The Federal Reserve meeting looms as investors look for an shift toward rate cuts. The stock market rally enjoyed modest weekly gains, with the major indexes reversing higher after Wednesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/12/YRend_runners_123016_adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.085875, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.078611", "ticker_sentiment_score": "0.038482", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.052455", "ticker_sentiment_score": "0.046722", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.28253", "ticker_sentiment_score": "0.066787", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.052455", "ticker_sentiment_score": "0.083922", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.182113", "ticker_sentiment_score": "0.089499", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.207571", "ticker_sentiment_score": "0.162266", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.207571", "ticker_sentiment_score": "0.071478", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.078611", "ticker_sentiment_score": "-0.00311", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.052455", "ticker_sentiment_score": "0.046722", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.104683", "ticker_sentiment_score": "0.059643", "ticker_sentiment_label": "Neutral"}]}, {"title": "La FDA aprueba las primeras terapias g\u00e9nicas para tratar a pacientes con anemia de c\u00e9lulas falciformes", "url": "https://www.prnewswire.com/news-releases/la-fda-aprueba-las-primeras-terapias-genicas-para-tratar-a-pacientes-con-anemia-de-celulas-falciformes-805174011.html", "time_published": "20231208T203500", "authors": ["U.S. Food and Drug Administration"], "summary": "SILVER SPRING, Md., 8 de diciembre de 2023 /PRNewswire-HISPANIC PR WIRE/ -- Hoy, la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos ( FDA, por sus siglas en ingl\u00e9s ) aprob\u00f3 dos tratamientos importantes, Casgevy y Lyfgenia, que representan las primeras terapias g\u00e9nicas basadas en ...", "banner_image": "https://mma.prnewswire.com/media/317925/FDA_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.078441, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.021446", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.021446", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "First CRISPR Sickle Cell Patient 'Reborn': FDA Approves Treatment", "url": "https://www.forbes.com/sites/ellenmatloff/2023/12/08/first-crispr-sickle-cell-patient-reborn-fda-approves-treatment/", "time_published": "20231208T185900", "authors": ["Ellen Matloff"], "summary": "Updated, Dec. 8: The Food and Drug Administration on Friday approved the first drug to treat patients with sickle cell disease using the Nobel Prize-winning CRISPR gene-editing therapy. Casgevy ( also known as Exa-cel ) is manufactured by Vertex Pharmaceuticals in Boston and CRISPR Therapeutics ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656f30ffa0d2ec8cdabd1600/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.055461, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.03178", "ticker_sentiment_score": "0.093983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.03178", "ticker_sentiment_score": "0.093983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/vertexcrispr-price-sickle-cell-disease-gene-therapy-22-mln-2023-12-08/", "time_published": "20231208T185856", "authors": ["Reuters"], "summary": "Vertex/CRISPR price sickle cell disease gene therapy at ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.246204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.514619", "ticker_sentiment_score": "0.384461", "ticker_sentiment_label": "Bullish"}, {"ticker": "BLUE", "relevance_score": "0.514619", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease", "url": "https://www.prnewswire.com/news-releases/boston-medical-center-to-offer-first-fda-approved-gene-therapy-treatment-program-for-sickle-cell-disease-302010397.html", "time_published": "20231208T185000", "authors": ["Boston Medical Center"], "summary": "Renowned, Expert Care Team to Deliver Transformative New Therapy to Eligible Adult Patients Suffering from Sickle Cell Disease", "banner_image": "https://mma.prnewswire.com/media/2296676/Boston_Medical_Center_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.265108, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.16849", "ticker_sentiment_score": "0.250014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.05654", "ticker_sentiment_score": "0.145949", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder - CRISPR Therapeutics  ( NASDAQ:CRSP ) , bluebird bio  ( NASDAQ:BLUE ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36156713/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder", "time_published": "20231208T183529", "authors": ["Vandana Singh"], "summary": "The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 years and older. Both products are made from the patient's blood stem cells, which are modified and given back as a one-time, single-dose infusion as part of a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/08/gene_therapy_30281390100_418857d210_o.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.065363, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.369685", "ticker_sentiment_score": "0.163069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.369685", "ticker_sentiment_score": "0.25353", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA approves 2 gene therapies for sickle cell. One is the first to use the editing tool CRISPR", "url": "https://apnews.com/article/sickle-cell-fda-approval-vertex-crispr-8d85279d7de0c60888d37afbfa06d39e", "time_published": "20231208T183345", "authors": ["LAURA UNGAR"], "summary": "Two gene therapies for sickle cell disease approved in US The Associated Press ...", "banner_image": "https://dims.apnews.com/dims4/default/e06e540/2147483647/strip/true/crop/3008x2004+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F5d%2F0b%2Fb65bfb2cae68deca56776e767e79%2F4b63ce272a154bf68e66661f2499aa7d", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.012089, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.039096", "ticker_sentiment_score": "0.100142", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.078099", "ticker_sentiment_score": "0.045012", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.039096", "ticker_sentiment_score": "0.162726", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Indexes Near 2023 Highs; AMD, Google Jump On AI: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-nears-2023-highs-amd-google-jump-on-ai-push-weekly-review/", "time_published": "20231208T181600", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Indexes Near 2023 Highs. AMD, Google Jump On AI: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-highprices-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.077412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.020021", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.039679", "ticker_sentiment_score": "0.111125", "ticker_sentiment_label": "Neutral"}, {"ticker": "XPEV", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.107364", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.001005", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.019846", "ticker_sentiment_score": "0.041457", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLB", "relevance_score": "0.098984", "ticker_sentiment_score": "0.068239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GWRE", "relevance_score": "0.039679", "ticker_sentiment_score": "-0.241737", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AVGO", "relevance_score": "0.039679", "ticker_sentiment_score": "0.046205", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.079261", "ticker_sentiment_score": "0.014638", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.019846", "ticker_sentiment_score": "0.057556", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.059488", "ticker_sentiment_score": "0.114012", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.039679", "ticker_sentiment_score": "0.096535", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.039679", "ticker_sentiment_score": "-0.004886", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.118647", "ticker_sentiment_score": "0.054652", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.196451", "ticker_sentiment_score": "0.101926", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0853", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.039679", "ticker_sentiment_score": "0.096535", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRZE", "relevance_score": "0.079261", "ticker_sentiment_score": "-0.064056", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.059488", "ticker_sentiment_score": "0.144348", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.039679", "ticker_sentiment_score": "0.096535", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.001005", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOL", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.126914", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.059488", "ticker_sentiment_score": "0.121", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.019846", "ticker_sentiment_score": "0.088186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAV", "relevance_score": "0.079261", "ticker_sentiment_score": "-0.168953", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NIO", "relevance_score": "0.098984", "ticker_sentiment_score": "-0.116845", "ticker_sentiment_label": "Neutral"}, {"ticker": "HA", "relevance_score": "0.059488", "ticker_sentiment_score": "-0.020021", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOD", "relevance_score": "0.039679", "ticker_sentiment_score": "0.111125", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.059488", "ticker_sentiment_score": "0.150422", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.059488", "ticker_sentiment_score": "0.114012", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:ETH", "relevance_score": "0.019846", "ticker_sentiment_score": "0.101626", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.039679", "ticker_sentiment_score": "0.118672", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment", "url": "https://www.marketwatch.com/story/crispr-therapeutics-vertex-get-fda-approval-for-breakthrough-gene-editing-treatment-30ae7842", "time_published": "20231208T170300", "authors": ["Eleanor Laise"], "summary": "Crispr Therapeutics and Vertex Pharmaceuticals got U.S. regulatory approval for a sickle-cell disease treatment based on the gene-editing technology Crispr.", "banner_image": "https://images.mktw.net/im-879446/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.132739, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.17715", "ticker_sentiment_score": "0.168366", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.262994", "ticker_sentiment_score": "0.125622", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.17715", "ticker_sentiment_score": "0.168366", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.262994", "ticker_sentiment_score": "0.337493", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US approves two gene therapies for sickle cell disease", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/", "time_published": "20231208T162100", "authors": ["Reuters"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly Acquire Licensing Rights Dec 8 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/UU3OG5Z3BFLXHE2T7HGD6QRYFQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.056445, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.179788", "ticker_sentiment_score": "0.207222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.179788", "ticker_sentiment_score": "0.207222", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease", "url": "https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html", "time_published": "20231208T161927", "authors": ["Angelica Peebles"], "summary": "Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107344708-1701972953198-AP23320388297314.jpg?v=1701973039&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.071145", "ticker_sentiment_score": "0.170161", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.071145", "ticker_sentiment_score": "0.03155", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crispr Near Buy Point With FDA Gene-Editing Approval Seen", "url": "https://www.investors.com/news/technology/crispr-stock-rises-ahead-of-expected-fda-approval-of-gene-editing-treatment/", "time_published": "20231208T143500", "authors": ["BENJAMIN PIMENTEL", "Investor's Business Daily"], "summary": "Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/06/Stock-crispr-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.307318, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.447528", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA expected to approve first CRISPR gene-editing treatment, bringing hope to thousands with sickle cell disease", "url": "https://www.cnn.com/2023/12/08/health/first-crispr-gene-editing-treatment-sickle-cell-disease-scn/index.html", "time_published": "20231208T141500", "authors": ["Meg Tirrell"], "summary": "Before Johnny Lubin got a potentially life-changing experimental treatment at the age of 13, he recalls, he had one main concern. \"I was worrying that I might get, like, superpowers,\" said Johnny, now 15, who lives in Trumbull, Connecticut, about 60 miles north of New York City.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231207153645-02-johnny-lubin-crispr-ttreatment.jpg?q=w_1110,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.028693, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.021897", "ticker_sentiment_score": "0.092794", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.021897", "ticker_sentiment_score": "0.046473", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?", "url": "https://www.fool.com/investing/2023/12/08/crispr-therapeutics-just-slashed-its-staff-by-10/", "time_published": "20231208T131500", "authors": ["Alex Carchidi"], "summary": "The timing of the cuts is setting off alarm bells, but the situation is under control.", "banner_image": "https://g.foolcdn.com/editorial/images/757216/chart-reflected-on-investor-glasses.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.135256, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055109", "ticker_sentiment_score": "0.034005", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.055109", "ticker_sentiment_score": "0.116841", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Approves First Crispr Treatment That Might Cure Sickle Cell", "url": "https://www.forbes.com/sites/roberthart/2023/12/08/fda-approves-first-crispr-treatment-that-might-cure-sickle-cell/", "time_published": "20231208T122427", "authors": ["Robert Hart"], "summary": "FDA Could Approve First Crispr Treatment Today That Might Cure Sickle Cell Forbes ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65730a856df0cff62d395fca/0x0.jpg?format=jpg&crop=3540,1991,x0,y179,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.167483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.049629", "ticker_sentiment_score": "-0.011", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Could Approve First Crispr Treatment Today That Might Cure Sickle Cell", "url": "https://www.forbes.com/sites/roberthart/2023/12/08/fda-could-approve-first-crispr-treatment-today-that-might-cure-sickle-cell/", "time_published": "20231208T122427", "authors": ["Robert Hart"], "summary": "The Food and Drug Administration on Friday is poised to approve a new therapy based on Crispr gene editing to treat sickle cell disease, which would mark the first time a treatment using the technology has secured a regulatory green light in the U.S. amid hopes the revolutionary tool will emerge ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65730a856df0cff62d395fca/0x0.jpg?format=jpg&crop=3540,1991,x0,y179,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.167434, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.049221", "ticker_sentiment_score": "-0.01", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics's Options: A Look at What the Big Money is Thinking - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/options/23/12/36140245/crispr-therapeuticss-options-a-look-at-what-the-big-money-is-thinking", "time_published": "20231207T183344", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.198744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.080728", "ticker_sentiment_score": "0.156035", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients", "url": "https://www.cnbc.com/2023/12/07/crispr-gene-editing-treatment-us-approval.html", "time_published": "20231207T141012", "authors": ["Angelica Peebles"], "summary": "The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107344477-P-5ED2-REQ-120723-SickleCellPKG.jpg?v=1701954252&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098035, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.03448", "ticker_sentiment_score": "-0.040476", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.03448", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.03448", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.03448", "ticker_sentiment_score": "-0.002937", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Stocks Could Be About to Soar: Are They Buys?", "url": "https://www.fool.com/investing/2023/12/07/these-2-stocks-could-be-about-to-soar-are-they-buy/", "time_published": "20231207T134500", "authors": ["Prosper Junior Bakiny"], "summary": "One thing is for certain -- both of these companies are innovators.", "banner_image": "https://g.foolcdn.com/editorial/images/757072/patient-taking-medicine.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.163674, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDGL", "relevance_score": "0.225321", "ticker_sentiment_score": "0.009286", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.045655", "ticker_sentiment_score": "0.184139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.43303", "ticker_sentiment_score": "0.255898", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/12/07/new-risk-headache-vertex-pharma-crispr-stock/", "time_published": "20231207T103000", "authors": ["Alex Carchidi"], "summary": "Shareholders will do well to prepare themselves for how regulators might react.", "banner_image": "https://g.foolcdn.com/editorial/images/757061/doctor-explains-paper-to-patient.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.060765, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.080188", "ticker_sentiment_score": "0.135427", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Unstoppable Trends to Invest $1,000 in for 2024", "url": "https://www.fool.com/investing/2023/12/07/5-unstoppable-trends-to-invest-1000-in-for-2024/", "time_published": "20231207T102100", "authors": ["Sean Williams"], "summary": "These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757307%2Fone-hundred-dollar-bill-cash-money-invest-2024-calculator-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.237272, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.108835", "ticker_sentiment_score": "0.140397", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.054545", "ticker_sentiment_score": "0.024089", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.108835", "ticker_sentiment_score": "0.141371", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.054545", "ticker_sentiment_score": "0.043", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.054545", "ticker_sentiment_score": "0.14982", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.081737", "ticker_sentiment_score": "0.153229", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.054545", "ticker_sentiment_score": "0.193873", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.081737", "ticker_sentiment_score": "0.025336", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Vertex  ( VRTX )  Down 6.4% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2194322/why-is-vertex-vrtx-down-64-since-last-earnings-report", "time_published": "20231206T163037", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default92.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.999816"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.121808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.046273", "ticker_sentiment_score": "-0.003989", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/vertex-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231206T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vertex Pharmaceuticals ( VRTX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 77 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.374272, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.511256", "ticker_sentiment_score": "0.78108", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.355588", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.355588", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP )  to Focus on Next-Generation CAR T Pipeline", "url": "https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline", "time_published": "20231205T181500", "authors": ["Zacks Equity Research"], "summary": "Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.165226, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.094576", "ticker_sentiment_score": "0.035504", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.233556", "ticker_sentiment_score": "0.085501", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.065273", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.141448", "ticker_sentiment_score": "0.126402", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/12/36096228/heres-how-much-100-invested-in-vertex-pharmaceuticals-15-years-ago-would-be-worth-today", "time_published": "20231205T163022", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 19.33%. Currently, Vertex Pharmaceuticals has a market capitalization of $90.07 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "1 Promising Stock Down 66% That Could Skyrocket in 2024", "url": "https://www.fool.com/investing/2023/12/05/1-promising-stock-down-66-that-could-skyrocket-in/", "time_published": "20231205T120000", "authors": ["Prosper Junior Bakiny"], "summary": "Financial results aren't what matters most right now for this company.", "banner_image": "https://media.ycharts.com/charts/642baf261ae1dae38f74f59a72ce7e80.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.142089, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051003", "ticker_sentiment_score": "0.13707", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.051003", "ticker_sentiment_score": "0.082458", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.662687", "ticker_sentiment_score": "0.190779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Growth Stock: CRISPR Therapeutics vs. Invitae", "url": "https://www.fool.com/investing/2023/12/05/better-growth-stock-crispr-therapeutics-vs-invitae/", "time_published": "20231205T100000", "authors": ["Adria Cimino"], "summary": "One of these stocks may be riskier than the other...", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757018%2Fgettyimages-investor-uses-tablet-and-phone.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.459462"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.316947, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.056143", "ticker_sentiment_score": "0.129021", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVTA", "relevance_score": "0.47379", "ticker_sentiment_score": "0.361673", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "0.056143", "ticker_sentiment_score": "0.301007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.056143", "ticker_sentiment_score": "0.301007", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Crispr gene editing technology could transform medicine | FT Tech", "url": "https://www.ft.com/video/5053951c-1c3f-41fc-a0d3-bdf1a35aa9b6", "time_published": "20231205T040144", "authors": [], "summary": "You can enable subtitles ( captions ) in the video player It's been barely a decade since two researchers came up with a plan to edit DNA in order to disrupt genetic disorders.", "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fnext-video-editor-images.s3.ap-northeast-1.amazonaws.com%2F2cb8bfec-8592-4122-a244-75e9e2269682?source=next-opengraph&fit=scale-down&width=900", "source": "Financial Times", "category_within_source": "GoogleRSS", "source_domain": "www.ft.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.108373, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.102013", "ticker_sentiment_score": "0.101518", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease", "url": "https://www.globenewswire.com/news-release/2023/12/04/2790468/0/en/CRISPR-Therapeutics-Announces-Updates-to-Immuno-Oncology-Pipeline-and-Expansion-into-Autoimmune-Disease.html", "time_published": "20231204T211500", "authors": ["CRISPR Therapeutics AG"], "summary": "-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112\u2122 targeting CD19 and CTX131\u2122 targeting ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.150621, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.022579", "ticker_sentiment_score": "0.115488", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.067664", "ticker_sentiment_score": "0.103494", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36076383/looking-into-vertex-pharmaceuticalss-recent-short-interest", "time_published": "20231204T190024", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 3.96% since its last report. The company recently reported that it has 2.51 million shares sold short, which is 0.97% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK vs. VRTX: Which Stock Should Value Investors Buy Now?", "url": "https://www.zacks.com/stock/news/2193083/gsk-vs-vrtx-which-stock-should-value-investors-buy-now", "time_published": "20231204T164011", "authors": ["Zacks Equity Research"], "summary": "GSK vs. VRTX: Which Stock Is the Better Value Option?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default21.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.481955, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.699089", "ticker_sentiment_score": "0.529246", "ticker_sentiment_label": "Bullish"}]}, {"title": "You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.", "url": "https://www.fool.com/investing/2023/12/04/you-dont-have-to-pick-a-winner-in-gene-editing-do/", "time_published": "20231204T133000", "authors": ["George Budwell"], "summary": "The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756902%2Fgrowth-trend.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.250693, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.068698", "ticker_sentiment_score": "0.27273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.136888", "ticker_sentiment_score": "0.32749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.204072", "ticker_sentiment_score": "0.239476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRBU", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.068698", "ticker_sentiment_score": "0.140565", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRME", "relevance_score": "0.068698", "ticker_sentiment_score": "-0.025609", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own.", "url": "https://www.fool.com/investing/2023/12/04/a-bull-market-is-coming-here-are-3-stocks-youll-ab/", "time_published": "20231204T105100", "authors": ["Keith Speights"], "summary": "These stocks are already big winners in 2023 and should keep their momentum going in a new bull market.", "banner_image": "https://g.foolcdn.com/editorial/images/756801/woman-in-it-data-center.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.380764, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.29234", "ticker_sentiment_score": "0.372735", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.119235", "ticker_sentiment_score": "0.21208", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.29234", "ticker_sentiment_score": "0.411029", "ticker_sentiment_label": "Bullish"}]}, {"title": "Where Will Vertex Pharmaceuticals Be in 10 Years?", "url": "https://www.fool.com/investing/2023/12/04/where-will-vertex-pharmaceuticals-be-in-10-years/", "time_published": "20231204T103000", "authors": ["Adria Cimino"], "summary": "Vertex shares have soared 400% over the past decade.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756785%2Fgettyimages-1197547531.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.218885, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.050679", "ticker_sentiment_score": "0.104675", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.101154", "ticker_sentiment_score": "0.176507", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today", "url": "https://www.fool.com/investing/2023/12/04/if-you-invested-5000-in-crispr-therapeutics-in-jan/", "time_published": "20231204T100000", "authors": ["Adria Cimino"], "summary": "CRISPR Therapeutics' shares advanced in the double-digits this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756780%2Fgettyimages-474008420.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.955357"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.239311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Growth Stocks to Buy in December", "url": "https://www.fool.com/investing/2023/12/03/3-no-brainer-growth-stocks-to-buy-in-december/", "time_published": "20231203T115400", "authors": ["Keith Speights", "and Prosper Junior Bakiny", "David Jagielski"], "summary": "No analysis paralysis is required with these great stocks.", "banner_image": "https://g.foolcdn.com/editorial/images/756702/dna-scientist-test-tube.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.226255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.34675", "ticker_sentiment_score": "0.318621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.158259", "ticker_sentiment_score": "-0.054183", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.273224", "ticker_sentiment_score": "0.220697", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/12/03/got-5000-best-growth-stocks-buy-right-now/", "time_published": "20231203T105300", "authors": ["Keith Speights"], "summary": "The one thing these two stocks have in common is tremendous growth prospects.", "banner_image": "https://g.foolcdn.com/editorial/images/756706/smiling-man-holding-fist-up.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.284527, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.369163", "ticker_sentiment_score": "0.39076", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.109206", "ticker_sentiment_score": "0.302414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.054732", "ticker_sentiment_score": "-0.063233", "ticker_sentiment_label": "Neutral"}]}, {"title": "CASGEVY Gets Bahrain approval for treatment, marking it second country in the world", "url": "https://www.benzinga.com/pressreleases/23/12/g36058548/casgevy-gets-bahrain-approval-for-treatment-marking-it-second-country-in-the-world", "time_published": "20231202T175921", "authors": ["Globe Newswire"], "summary": "MANAMA, Bahrain, Dec. 02, 2023 ( GLOBE NEWSWIRE ) -- Bahrain has become the second country in the world and the first in the Middle East to approve the use of CASGEVY ( exagamglogene autotemcel ) for the treatment of patients with sickle cell disease and transfusion-dependent beta-thalassemia.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.356232, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.091162", "ticker_sentiment_score": "0.076813", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Important History Lesson for Gene-Editing Investors", "url": "https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/", "time_published": "20231202T133000", "authors": ["George Budwell"], "summary": "Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756820%2Fbiotech-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.127419, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.040691", "ticker_sentiment_score": "-0.095989", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.081276", "ticker_sentiment_score": "0.096784", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.12165", "ticker_sentiment_score": "0.115922", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.040691", "ticker_sentiment_score": "0.050122", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040691", "ticker_sentiment_score": "0.094399", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.040691", "ticker_sentiment_score": "0.050122", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.003598", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Top Stocks to Buy Before 2024", "url": "https://www.fool.com/investing/2023/12/02/5-top-stocks-to-buy-before-2024/", "time_published": "20231202T100000", "authors": ["Adria Cimino"], "summary": "These stocks have room to run -- next year and over the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756622%2Fgettyimages-1323758599.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.309374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.223522", "ticker_sentiment_score": "0.23701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.075397", "ticker_sentiment_score": "0.147665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.075397", "ticker_sentiment_score": "0.285192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.259529", "ticker_sentiment_score": "0.252343", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Lululemon, Toll Brothers, Broadcom And November Jobs: Investing Action Plan", "url": "https://www.investors.com/research/investing-action-plan/lululemon-stock-toll-brothers-broadcom-and-november-jobs-investing-action-plan/", "time_published": "20231201T225300", "authors": ["Investor's Business Daily", "ALAN R. ELLIOTT"], "summary": "Lululemon, Toll Brothers, Broadcom And November Jobs: Investing ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/stock-alan-NYSE1-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.08882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.076765", "ticker_sentiment_score": "0.06301", "ticker_sentiment_label": "Neutral"}, {"ticker": "GWRE", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.055963", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.102231", "ticker_sentiment_score": "0.052253", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.102231", "ticker_sentiment_score": "0.050079", "ticker_sentiment_label": "Neutral"}, {"ticker": "ULTA", "relevance_score": "0.051221", "ticker_sentiment_score": "0.102004", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRZE", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.051951", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.076765", "ticker_sentiment_score": "0.06301", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.076765", "ticker_sentiment_score": "0.119475", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.076765", "ticker_sentiment_score": "0.081926", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.076765", "ticker_sentiment_score": "0.06301", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIG", "relevance_score": "0.076765", "ticker_sentiment_score": "-0.12913", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOL", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.031517", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.102231", "ticker_sentiment_score": "0.08722", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAV", "relevance_score": "0.076765", "ticker_sentiment_score": "0.081926", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.051221", "ticker_sentiment_score": "0.090163", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZO", "relevance_score": "0.051221", "ticker_sentiment_score": "0.202995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CME", "relevance_score": "0.076765", "ticker_sentiment_score": "0.06301", "ticker_sentiment_label": "Neutral"}, {"ticker": "THO", "relevance_score": "0.102231", "ticker_sentiment_score": "0.019922", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.161815", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2191965/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20231201T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.284941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061315", "ticker_sentiment_score": "0.071003", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?", "url": "https://www.fool.com/investing/2023/12/01/could-crispr-therapeutics-become-the-next-vertex/", "time_published": "20231201T111500", "authors": ["Prosper Junior Bakiny"], "summary": "It's not as long a shot as some might think.", "banner_image": "https://g.foolcdn.com/editorial/images/756214/patient-sitting-on-hospital-bed.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.284159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.330286", "ticker_sentiment_score": "0.240925", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.168884", "ticker_sentiment_score": "0.018183", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking for Growth? 2 Top Stocks to Buy Hand Over Fist", "url": "https://www.fool.com/investing/2023/12/01/looking-for-growth-2-top-stocks-to-buy/", "time_published": "20231201T101500", "authors": ["Adria Cimino"], "summary": "These stocks offer enormous long-term growth potential.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756452%2Fgettyimages-1272759382.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.411005, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055236", "ticker_sentiment_score": "0.054864", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.164656", "ticker_sentiment_score": "0.294287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.055236", "ticker_sentiment_score": "0.074848", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie", "url": "https://www.zacks.com/stock/news/2191938/the-zacks-analyst-blog-highlights-avidity-bristol-myers-squibb-vertex-arcturus-and-biovie", "time_published": "20231201T100900", "authors": ["Zacks Investment Research"], "summary": "Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.164184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.160099", "ticker_sentiment_score": "0.102954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCT", "relevance_score": "0.238133", "ticker_sentiment_score": "0.220312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.04028", "ticker_sentiment_score": "0.029739", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNA", "relevance_score": "0.160099", "ticker_sentiment_score": "0.027595", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.313817", "ticker_sentiment_score": "0.036968", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.238133", "ticker_sentiment_score": "0.102868", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More", "url": "https://www.zacks.com/stock/news/2191567/biotech-stock-roundup-rna-up-on-bmy-deal-expansion-bivi-down-on-setback-more", "time_published": "20231130T153300", "authors": ["Zacks Equity Research"], "summary": "Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.173654, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129284", "ticker_sentiment_score": "0.150144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.2138", "ticker_sentiment_score": "0.296321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.043264", "ticker_sentiment_score": "0.029874", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNA", "relevance_score": "0.129284", "ticker_sentiment_score": "0.072436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.295867", "ticker_sentiment_score": "0.046906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.2138", "ticker_sentiment_score": "0.123296", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Flashing Renewed Technical Strength: Vertex Pharmaceuticals", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-vertex-pharmaceuticals-3/", "time_published": "20231130T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Vertex Pharmaceuticals ( VRTX ) entered a new percentile Thursday, with a rise from 78 to 81. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.27916, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.647749", "ticker_sentiment_score": "0.327287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMGN", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Health Canada Grants Market Authorization for KALYDECO\u00ae  ( ivacaftor )  for Eligible Children With Cystic Fibrosis Ages 2 Months and Older", "url": "https://www.newswire.ca/news-releases/health-canada-grants-market-authorization-for-kalydeco-r-ivacaftor-for-eligible-children-with-cystic-fibrosis-ages-2-months-and-older-836626413.html", "time_published": "20231129T185900", "authors": ["Vertex Pharmaceuticals (Canada) Inc."], "summary": "Health Canada Grants Market Authorization for KALYDECO\u00ae ( ivacaftor ) for Eligible Children With Cystic Fibrosis Ages ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2288423/Vertex_Pharmaceuticals__Canada__Inc__Health_Canada_Grants_Market.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.096097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129983", "ticker_sentiment_score": "0.116245", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Next For Crispr After Its 'Historic' Gene-Editing Approval?", "url": "https://www.investors.com/research/the-new-america/crsp-stock-what-is-next-as-shares-fly-on-a-historic-crispr-gene-editing-approval/", "time_published": "20231129T130000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "CRSP Stock: What's Next As Shares Fly On A 'Historic' CRISPR ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/wNApie120423-.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.17174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.0699", "ticker_sentiment_score": "0.152805", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arcturus'  ( ARCT )  CF Drug Gets FDA's Orphan Status, Stock Up", "url": "https://www.zacks.com/stock/news/2190147/arcturus-arct-cf-drug-gets-fdas-orphan-status-stock-up", "time_published": "20231128T125600", "authors": ["Zacks Equity Research"], "summary": "Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.135764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.211191", "ticker_sentiment_score": "0.083487", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.159218", "ticker_sentiment_score": "0.21889", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.496915", "ticker_sentiment_score": "0.322351", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.211191", "ticker_sentiment_score": "-0.146513", "ticker_sentiment_label": "Neutral"}]}, {"title": "The CRISPR Era Is Here", "url": "https://www.theatlantic.com/health/archive/2023/11/crispr-sickle-cell-disease-cure/676151/", "time_published": "20231127T183854", "authors": ["Sarah Zhang"], "summary": "The First CRISPR Therapy Is Here The Atlantic ...", "banner_image": "https://cdn.theatlantic.com/thumbor/ar98RrK-p_sx1_-18HNEuwDRiIA=/0x0:2000x1125/960x540/media/img/mt/2023/11/CRSPRfinal-1/original.png", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.038517, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.023035", "ticker_sentiment_score": "0.188574", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Biotech Stocks To Watch Before December 2023", "url": "https://stockmarket.com/featured/3-biotech-stocks-to-watch-before-december-2023-2023-11-27", "time_published": "20231127T153843", "authors": ["Jonathan Phillip"], "summary": "The biotechnology sector is a dynamic and innovative field that combines biological sciences with technology. It encompasses a range of companies focusing on medical research, pharmaceuticals, and genetic engineering. These companies work on groundbreaking treatments, vaccines, and technologies.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/07/REGN-Stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999896"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999987"}], "overall_sentiment_score": 0.14494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.296582", "ticker_sentiment_score": "-0.017807", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.296582", "ticker_sentiment_score": "-0.075704", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.296582", "ticker_sentiment_score": "0.136713", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Stocks You Can Confidently Invest $500 In Right Now", "url": "https://www.fool.com/investing/2023/11/27/5-stocks-you-can-confidently-invest-500-in-now/", "time_published": "20231127T103000", "authors": ["Adria Cimino"], "summary": "These companies could significantly grow your investment over the long haul.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756026%2Fgettyimages-woman-points-at-computer-with-a-pen-to-show-something-to-a-colleague.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999346"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.342983, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089629", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.044885", "ticker_sentiment_score": "0.1789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.264419", "ticker_sentiment_score": "0.361995", "ticker_sentiment_label": "Bullish"}, {"ticker": "KO", "relevance_score": "0.221616", "ticker_sentiment_score": "0.367979", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.221616", "ticker_sentiment_score": "0.201983", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.089629", "ticker_sentiment_score": "0.137094", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks That Could Soar in December", "url": "https://www.fool.com/investing/2023/11/26/2-biotech-stocks-that-could-soar-in-december/", "time_published": "20231126T214400", "authors": ["George Budwell"], "summary": "These two biotechs have important catalysts coming up in December.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756110%2Fgrowth-curve.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.214583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.077845", "ticker_sentiment_score": "0.136968", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.304114", "ticker_sentiment_score": "0.151194", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.304114", "ticker_sentiment_score": "0.246826", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.154951", "ticker_sentiment_score": "0.109825", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.154951", "ticker_sentiment_score": "0.140006", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Could Help Set You Up for Life", "url": "https://www.fool.com/investing/2023/11/25/2-healthcare-stocks-that-could-help-set-you-up-for/", "time_published": "20231125T120000", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies are leaders in their fields.", "banner_image": "https://media.ycharts.com/charts/7d79947a1c644f3e377073336c6b6af2.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.330324, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.121037", "ticker_sentiment_score": "0.15369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.180685", "ticker_sentiment_score": "0.192267", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCA", "relevance_score": "0.457566", "ticker_sentiment_score": "0.30018", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investing in These 3 Stocks Now Could Make You a Millionaire Retiree", "url": "https://www.fool.com/investing/2023/11/25/investing-in-these-3-stocks-now-could-make-you-a-m/", "time_published": "20231125T105000", "authors": ["Keith Speights"], "summary": "These innovators should have tremendous long-term growth prospects.", "banner_image": "https://g.foolcdn.com/editorial/images/755872/data-center-infrastructure-information-technology.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.229117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051663", "ticker_sentiment_score": "0.137476", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.302553", "ticker_sentiment_score": "0.259073", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMDX", "relevance_score": "0.254042", "ticker_sentiment_score": "0.186483", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 First-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip", "url": "https://www.fool.com/investing/2023/11/25/nasdaq-bear-market-4-growth-stocks-regret-not-buy/", "time_published": "20231125T100600", "authors": ["Sean Williams"], "summary": "The innovation-fueled Nasdaq Composite is still 11% below its all-time high, which means bargains abound for opportunistic investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756013%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.158967, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053509", "ticker_sentiment_score": "-0.001007", "ticker_sentiment_label": "Neutral"}, {"ticker": "FVRR", "relevance_score": "0.237358", "ticker_sentiment_score": "0.206045", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.337339", "ticker_sentiment_score": "0.113484", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP )  Rises More Than 40% in Past 3 Months: Here's Why", "url": "https://www.zacks.com/stock/news/2189212/crispr-crsp-rises-more-than-40-in-past-3-months-heres-why", "time_published": "20231124T165000", "authors": ["Zacks Equity Research"], "summary": "CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.220874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.07445", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.244723", "ticker_sentiment_score": "0.159358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.303175", "ticker_sentiment_score": "0.177061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTMX", "relevance_score": "0.359881", "ticker_sentiment_score": "0.051295", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Gets EU Nod for Kaftrio Use in 2-5 Year Kids", "url": "https://www.zacks.com/stock/news/2189211/vertex-vrtx-gets-eu-nod-for-kaftrio-use-in-2-5-year-kids", "time_published": "20231124T164800", "authors": ["Zacks Equity Research"], "summary": "The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.173075, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.20698", "ticker_sentiment_score": "0.151862", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.400265", "ticker_sentiment_score": "0.320331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTMX", "relevance_score": "0.400265", "ticker_sentiment_score": "0.055432", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals", "time_published": "20231124T141000", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.225302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.127795", "ticker_sentiment_score": "0.105904", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.171316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0854", "ticker_sentiment_score": "0.090184", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.021388", "ticker_sentiment_score": "0.106821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}]}, {"title": "VRTX: 3 Safe Biotech Stocks to Buy This Week", "url": "https://stocknews.com/news/vrtx-inva-acor-crsp-3-safe-biotech-stocks-to-buy-this-week/", "time_published": "20231124T125632", "authors": ["StockNews.com Staff"], "summary": "With the rising prevalence of chronic diseases worldwide, increased healthcare spending, favorable government policies and funding, and growing adoption of advanced technologies, demand for innovative drugs and treatments has been rising considerably, boosting the biotech industry's outlook.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.247967, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.230673", "ticker_sentiment_score": "0.167775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INVA", "relevance_score": "0.230673", "ticker_sentiment_score": "0.168708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACOR", "relevance_score": "0.208166", "ticker_sentiment_score": "0.12782", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Editing Will Change Medicine-and Maybe Health Investing Too", "url": "https://www.wsj.com/tech/biotech/gene-editing-changing-medicine-9cc02c7e", "time_published": "20231124T120000", "authors": ["David Wainer"], "summary": "The first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.", "banner_image": "https://images.wsj.net/im-889490?width=700&height=511", "source": "Wall Street Journal", "category_within_source": "Markets", "source_domain": "www.wsj.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.265987, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.282234", "ticker_sentiment_score": "0.266533", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Prediction: 3 Stocks That Could Trounce the Market", "url": "https://www.fool.com/investing/2023/11/23/prediction-3-stocks-that-could-trounce-the-market/", "time_published": "20231123T105000", "authors": ["Keith Speights"], "summary": "These stocks have what it takes to be huge winners over the next several years.", "banner_image": "https://g.foolcdn.com/editorial/images/755806/cheering-person-with-laptop.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.255981, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.107736", "ticker_sentiment_score": "0.160235", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMDX", "relevance_score": "0.265089", "ticker_sentiment_score": "0.180187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MA", "relevance_score": "0.315493", "ticker_sentiment_score": "0.363684", "ticker_sentiment_label": "Bullish"}, {"ticker": "MHTUF", "relevance_score": "0.053992", "ticker_sentiment_score": "0.203839", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright", "url": "https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright", "time_published": "20231122T130700", "authors": ["Ekta Bagri"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.111281", "ticker_sentiment_score": "0.139072", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.172148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.066908", "ticker_sentiment_score": "0.125817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.022326", "ticker_sentiment_score": "0.154669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}]}, {"title": "New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade", "url": "https://www.marketwatch.com/story/new-etf-invested-in-ozempic-maker-and-exposed-to-other-obesity-drugs-falls-in-first-day-of-trade-a489a9b0", "time_published": "20231122T130100", "authors": ["Christine Idzelis"], "summary": "The new Tema Cardiovascular and Metabolic ETF fell in its first day of trade. It is exposed to weight-loss drugs including Ozempic.", "banner_image": "https://images.mktw.net/im-75709773/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.297411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.388879", "ticker_sentiment_score": "0.04038", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is CRISPR Therapeutics the Best Gene-Editing Stock?", "url": "https://www.fool.com/investing/2023/11/22/is-crispr-therapeutics-the-best-gene-editing-stock/", "time_published": "20231122T123000", "authors": ["George Budwell"], "summary": "The biotech's first-mover advantage bodes well for its long-term prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755786%2Fresearcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.262065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.075043", "ticker_sentiment_score": "-0.004045", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.037563", "ticker_sentiment_score": "0.176057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRME", "relevance_score": "0.037563", "ticker_sentiment_score": "-0.096205", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotech Stocks That Could Be Millionaire Makers", "url": "https://www.fool.com/investing/2023/11/22/3-biotech-stocks-that-could-be-millionaire-makers/", "time_published": "20231122T103000", "authors": ["Adria Cimino"], "summary": "Many biotech stocks offer exciting long-term growth prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755778%2Fgettyimages-667652037.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.272056, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.054983", "ticker_sentiment_score": "0.060844", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.054983", "ticker_sentiment_score": "0.257973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.269776", "ticker_sentiment_score": "0.070063", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.054983", "ticker_sentiment_score": "0.039877", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.109705", "ticker_sentiment_score": "0.043593", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.054983", "ticker_sentiment_score": "0.257973", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ROIV: Is Roivant Sciences  ( ROIV )  the Right Biotech Stock for Your Portfolio?", "url": "https://stocknews.com/news/roiv-incy-otsky-vrtx-is-roivant-sciences-roiv-the-right-biotech-stock-for-your/", "time_published": "20231121T183324", "authors": ["StockNews.com Staff"], "summary": "ROIV: Is Roivant Sciences ( ROIV ) the Right Biotech Stock for Your ... ...", "banner_image": "https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587298.16932.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.105204, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROIV", "relevance_score": "0.530789", "ticker_sentiment_score": "0.118779", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057698", "ticker_sentiment_score": "0.172997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.057698", "ticker_sentiment_score": "0.172997", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/11/35902459/heres-how-much-100-invested-in-vertex-pharmaceuticals-20-years-ago-would-be-worth-today", "time_published": "20231121T180029", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 12.8% on an annualized basis producing an average annual return of 20.31%. Currently, Vertex Pharmaceuticals has a market capitalization of $92.18 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2187287/the-zacks-analyst-blog-highlights-procter-gamble-novartis-mondelez-international-elevance-health-and-vertex-pharmaceuticals", "time_published": "20231121T144800", "authors": ["Zacks Equity Research"], "summary": "Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/83/1423.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.176239, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.166169", "ticker_sentiment_score": "0.041787", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.400052", "ticker_sentiment_score": "0.011091", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.246999", "ticker_sentiment_score": "0.05657", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELV", "relevance_score": "0.166169", "ticker_sentiment_score": "0.041787", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.083541", "ticker_sentiment_score": "0.022776", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.325208", "ticker_sentiment_score": "0.176619", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These Stocks Are Exploding In November Rally", "url": "https://www.investors.com/research/these-stocks-explode-in-november-stock-market-rally/", "time_published": "20231121T130000", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "The November stock market rally is picking up steam and expanding into more than just the Magnificent Seven stocks. We created an IBD MarketSmith screen that identified stocks that rocked the most in the past month. Each has gained over 50% for the month.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-rocketchart-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.148434, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.413425", "ticker_sentiment_score": "-0.360418", "ticker_sentiment_label": "Bearish"}, {"ticker": "VRTX", "relevance_score": "0.143843", "ticker_sentiment_score": "0.233455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.214803", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GDHG", "relevance_score": "0.214304", "ticker_sentiment_score": "-0.238604", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JAKK", "relevance_score": "0.143843", "ticker_sentiment_score": "0.219779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Non-Cystic Fibrosis Pipeline Boosts Stock This Year", "url": "https://www.zacks.com/stock/news/2187003/vertex-vrtx-non-cystic-fibrosis-pipeline-boosts-stock-this-year", "time_published": "20231121T110000", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.033553, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.155786", "ticker_sentiment_score": "-0.187907", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.160053", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.15864", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2186419/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20231120T112007", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.159934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068112", "ticker_sentiment_score": "0.034069", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street", "url": "https://www.fool.com/investing/2023/11/20/2-beaten-down-growth-stocks-that-could-rocket-42-t/", "time_published": "20231120T103600", "authors": ["Cory Renauer"], "summary": "Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755459%2Finvestor-shopping-for-dividend-stocks-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.194917, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05749", "ticker_sentiment_score": "0.080024", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.436009", "ticker_sentiment_score": "0.247358", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.05749", "ticker_sentiment_score": "0.088957", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRA", "relevance_score": "0.529185", "ticker_sentiment_score": "0.327681", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?", "url": "https://www.fool.com/investing/2023/11/19/crispr-therapeutics-stock-make-you-a-millionaire/", "time_published": "20231119T103000", "authors": ["Adria Cimino"], "summary": "The stock is trading below its peak, reached a couple of years ago.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755461%2Fgettyimages-1135625573.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.977154"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.246915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.049526", "ticker_sentiment_score": "0.08824", "ticker_sentiment_label": "Neutral"}]}, {"title": "Barron's Weekend Stock Picks: Disney, Palantir And Cisco's Calamitous Outlook - Cisco Systems  ( NASDAQ:CSCO ) , Walt Disney  ( NYSE:DIS ) ", "url": "https://www.benzinga.com/news/23/11/35864021/barrons-weekend-stock-picks-disney-palantir-and-ciscos-calamitous-outlook", "time_published": "20231119T011808", "authors": ["Justin Chan"], "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In \"Disney Now Faces Two Activist Investors,\" Carleton English writes that, now, two activist investors, ValueAct Capital and Trian Fund Management, are pressuring Walt Disney Co DIS to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/18/shutterstock_2242822493.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.022247, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.262522", "ticker_sentiment_score": "-0.325941", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CSCO", "relevance_score": "0.38489", "ticker_sentiment_score": "-0.527047", "ticker_sentiment_label": "Bearish"}, {"ticker": "TSLA", "relevance_score": "0.1331", "ticker_sentiment_score": "0.037535", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Monster Stocks in the Making", "url": "https://www.fool.com/investing/2023/11/18/3-monster-stocks-in-the-making/", "time_published": "20231118T114900", "authors": ["Keith Speights", "and Prosper Junior Bakiny", "David Jagielski"], "summary": "These stocks could grow much larger over the next few years.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.229784, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.365524", "ticker_sentiment_score": "0.148479", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.03792", "ticker_sentiment_score": "0.043251", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.260719", "ticker_sentiment_score": "0.313641", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "You Don't Have to Pick a Winner in Biotech. Here's Why.", "url": "https://www.fool.com/investing/2023/11/18/you-dont-have-to-pick-biotech-winner-heres-why/", "time_published": "20231118T100000", "authors": ["Adria Cimino"], "summary": "If you invest over the long term, you'll increase your chances of victory.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755345%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999981"}], "overall_sentiment_score": 0.339494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.056943", "ticker_sentiment_score": "0.093937", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.093937", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.015155", "ticker_sentiment_label": "Neutral"}]}, {"title": "United Kingdom MHRA authorised Vertex and CRISPR Therapeutics's gene edited therapy for sickle cell disease and thalassemia", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/united-kingdom-mhra-authorised-vertex-and-crispr-therapeuticss-gene-edited-therapy-for-sickle-cell-disease-and-thalassemia/3310191/", "time_published": "20231117T170241", "authors": ["Health Desk"], "summary": "Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced on Thursday that the United Kingdom ( U.K. ) Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted conditional marketing authorization for CASGEVY ( exagamglogene autotemcel [exa-cel] ) , a CRISPR/Cas9 ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/blood-g01a495f20_1920-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.279245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.104228", "ticker_sentiment_score": "0.105417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CRISPR Therapeutics Stock Is Jumping Again Today", "url": "https://www.fool.com/investing/2023/11/17/why-crispr-therapeutics-stock-is-jumping-again-tod/", "time_published": "20231117T161215", "authors": ["Keith Speights"], "summary": "The stock continues to enjoy momentum from a key regulatory approval.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.313133, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.275867", "ticker_sentiment_score": "0.306885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.140076", "ticker_sentiment_score": "0.058726", "ticker_sentiment_label": "Neutral"}]}, {"title": "Williams-Sonoma, Uber And 2 Other Stocks Insiders Are Selling - Seagate Tech Hldgs  ( NASDAQ:STX ) , Uber Technologies  ( NYSE:UBER ) ", "url": "https://www.benzinga.com/news/23/11/35847310/williams-sonoma-uber-and-2-other-stocks-insiders-are-selling", "time_published": "20231117T132618", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher by 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/17/williams-sonoma_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.095485, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.406526", "ticker_sentiment_score": "0.175011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WSM", "relevance_score": "0.406526", "ticker_sentiment_score": "0.307485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DTST", "relevance_score": "0.085022", "ticker_sentiment_score": "0.029204", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.406526", "ticker_sentiment_score": "0.15705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STX", "relevance_score": "0.169081", "ticker_sentiment_score": "-0.035616", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics", "url": "https://www.zacks.com/stock/news/2185763/the-zacks-analyst-blog-highlights-arcellx-bristol-myers-squibb-solid-biosciences-vertex-pharmaceuticals-and-crispr-therapeutics", "time_published": "20231117T110000", "authors": ["Zacks Equity Research"], "summary": "Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.160843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.29176", "ticker_sentiment_score": "0.105073", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.197011", "ticker_sentiment_score": "0.022826", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.099271", "ticker_sentiment_score": "0.037281", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.29176", "ticker_sentiment_score": "0.064817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.049732", "ticker_sentiment_score": "-0.06097", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.148426", "ticker_sentiment_score": "0.02062", "ticker_sentiment_label": "Neutral"}]}, {"title": "The world's first gene therapy for sickle cell disease has been approved in Britain", "url": "https://apnews.com/article/sickle-cell-gene-therapy-treatment-uk-first-9bcf7c7d8b8909fb06e137fee17c767c", "time_published": "20231116T170000", "authors": ["MARIA CHENG"], "summary": "LONDON ( AP ) - Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K.", "banner_image": "https://dims.apnews.com/dims4/default/240e137/2147483647/strip/true/crop/1621x1080+149+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F32%2Fd8%2F506f39bee91eaf0afa37fd0cae9f%2F710392b627b84ac29ac636517ca96bd7", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.068933, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089965", "ticker_sentiment_score": "0.028603", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.045054", "ticker_sentiment_score": "0.164976", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMNF", "relevance_score": "0.045054", "ticker_sentiment_score": "0.131101", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP ) , Vertex Get UK Nod for First Gene Therapy Casgevy", "url": "https://www.zacks.com/stock/news/2185508/crispr-crsp-vertex-get-uk-nod-for-first-gene-therapy-casgevy", "time_published": "20231116T164700", "authors": ["Zacks Equity Research"], "summary": "CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972193"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.229606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.204647", "ticker_sentiment_score": "0.032132", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.396052", "ticker_sentiment_score": "0.20344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.396052", "ticker_sentiment_score": "0.266125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.204647", "ticker_sentiment_score": "0.12366", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod", "url": "https://www.zacks.com/stock/news/2185428/biotech-stock-roundup-bmys-drug-approval-vrtx-crsp-gene-therapy-get-mhra-nod", "time_published": "20231116T153000", "authors": ["Zacks Equity Research"], "summary": "Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.172496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.263373", "ticker_sentiment_score": "0.143413", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.159922", "ticker_sentiment_score": "0.039427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.107016", "ticker_sentiment_score": "0.038158", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.263373", "ticker_sentiment_score": "0.111584", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.053629", "ticker_sentiment_score": "-0.061006", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.107016", "ticker_sentiment_score": "0.043076", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crispr Surges After Winning The First CRISPR Gene-Editing Approval", "url": "https://www.investors.com/news/technology/crsp-stock-surges-after-winning-the-first-ever-crispr-gene-editing-approval/", "time_published": "20231116T142700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "In a world first, regulators in the UK approved Crispr Therapeutics' ( CRSP ) gene-editing treatment for two blood diseases on Thursday. CRSP stock surged on the news. The drug formerly known as exa-cel will sell under the brand name Casgevy following the approval.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/06/Stock-crispr-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.153063, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.013576", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZTA", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.316616", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.209365", "ticker_sentiment_score": "0.139264", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Crispr Therapeutics Stock Thursday? - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/news/23/11/35827548/whats-going-on-with-crispr-therapeutics-stock-thursday", "time_published": "20231116T142418", "authors": ["Adam Eckert"], "summary": "CRISPR Therapeutics AG CRSP shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene-edited therapy.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/dna-7090994_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.293252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.380012", "ticker_sentiment_score": "0.29009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.543004", "ticker_sentiment_score": "0.471388", "ticker_sentiment_label": "Bullish"}]}, {"title": "Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicine", "url": "https://www.marketwatch.com/story/crispr-therapeutics-vertex-get-worlds-first-regulatory-green-light-for-crispr-based-medicine-c051bb14", "time_published": "20231116T134900", "authors": ["Eleanor Laise"], "summary": "Shares of Crispr Therapeutics, Vertex gain ground after first regulatory clearance for medicine based on transformative gene-editing technology ...", "banner_image": "https://images.mktw.net/im-512397/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.224548, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.098659", "ticker_sentiment_score": "0.074008", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.195814", "ticker_sentiment_score": "0.209719", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGN: 3 Biotech Stocks Beating BioMarin Pharmaceutical  ( BMRN ) ", "url": "https://stocknews.com/news/amgn-vrtx-jazz-bmrn-3-biotech-stocks-beating-biomarin-pharmaceutical-bmrn/", "time_published": "20231116T134724", "authors": ["StockNews.com Staff"], "summary": "AMGN: 3 Biotech Stocks Beating BioMarin Pharmaceutical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/Dipanjan-Banchur_headshots_3.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}], "overall_sentiment_score": 0.255388, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.217834", "ticker_sentiment_score": "0.209854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.1372", "ticker_sentiment_score": "0.173495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.244245", "ticker_sentiment_score": "0.246887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.164282", "ticker_sentiment_score": "0.159799", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia - CRISPR Therapeutics  ( NASDAQ:CRSP ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35824646/uk-approves-first-crispr-gene-edited-therapy-for-sickle-cell-disease-beta-thalassemia", "time_published": "20231116T131707", "authors": ["Vandana Singh"], "summary": "The U.K. Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted conditional marketing authorization for Casgevy ( exagamglogene autotemcel [exa-cel] ) , a CRISPR/Cas9 gene-edited therapy for sickle cell disease ( SCD ) and transfusion-dependent beta-thalassemia ( TDT ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/crsp.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.130216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.399204", "ticker_sentiment_score": "0.300057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.399204", "ticker_sentiment_score": "0.300057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket - Acutus Medical  ( NASDAQ:AFIB ) , Alpine 4 Holdings  ( NASDAQ:ALPP ) ", "url": "https://www.benzinga.com/news/23/11/35825417/why-palo-alto-networks-shares-are-trading-lower-by-around-5-here-are-20-stocks-moving-premarket", "time_published": "20231116T130828", "authors": ["Lisa Levin"], "summary": "Shares of Palo Alto Networks, Inc. PANW fell in pre-market trading after reporting first-quarter results. Palo Alto Networks reported quarterly earnings of $1.38 per share, above the analyst consensus estimate of $1.16. Revenue of $1.88 billion beat the analyst consensus estimate of $1.84 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/palo_alto_networks_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.065223, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AFIB", "relevance_score": "0.206392", "ticker_sentiment_score": "0.183542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMMB", "relevance_score": "0.206392", "ticker_sentiment_score": "0.053499", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.031137", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBLG", "relevance_score": "0.138464", "ticker_sentiment_score": "0.319728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIVI", "relevance_score": "0.138464", "ticker_sentiment_score": "0.238465", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.069495", "ticker_sentiment_score": "0.087328", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLCN", "relevance_score": "0.138464", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.186691", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.069495", "ticker_sentiment_score": "0.151742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SDOT", "relevance_score": "0.206392", "ticker_sentiment_score": "-0.206225", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GMBL", "relevance_score": "0.138464", "ticker_sentiment_score": "0.043453", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.138464", "ticker_sentiment_score": "0.105434", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPP", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.080912", "ticker_sentiment_label": "Neutral"}, {"ticker": "TKLF", "relevance_score": "0.138464", "ticker_sentiment_score": "0.203092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSCS", "relevance_score": "0.138464", "ticker_sentiment_score": "0.043453", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUGX", "relevance_score": "0.138464", "ticker_sentiment_score": "0.061917", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRM", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.403343", "ticker_sentiment_label": "Bearish"}, {"ticker": "CISO", "relevance_score": "0.206392", "ticker_sentiment_score": "0.238383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHSN", "relevance_score": "0.138464", "ticker_sentiment_score": "0.165233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.062623", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Vertex Pharmaceuticals Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/11/16/is-vertex-pharmaceuticals-stock-a-buy-now/", "time_published": "20231116T124500", "authors": ["Prosper Junior Bakiny"], "summary": "The company is close to another breakthrough.", "banner_image": "https://media.ycharts.com/charts/ac9a79bb7b393cb01186fad3ff7a117e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.243264, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.061631", "ticker_sentiment_score": "0.021018", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.357293", "ticker_sentiment_score": "0.27714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.061631", "ticker_sentiment_score": "0.086194", "ticker_sentiment_label": "Neutral"}]}, {"title": "UK authorises gene therapy for blood disorders in world first", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/uk-authorises-gene-therapy-blood-disorders-world-first-2023-11-16/", "time_published": "20231116T105800", "authors": ["Reuters"], "summary": "A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/FORGYTZM7FK7XP7WMSAT6HI6ZU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.140751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.250386", "ticker_sentiment_score": "0.249432", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.K. Greenlights World's First Crispr Gene Editing Therapy", "url": "https://www.forbes.com/sites/roberthart/2023/11/16/uk-greenlights-worlds-first-crispr-gene-editing-therapy/", "time_published": "20231116T104050", "authors": ["Robert Hart"], "summary": "U.K. regulators on Thursday approved a therapy based for two blood disorders based on Crispr gene editing, the country's medicine's regulator said on Thursday, a world first for the lauded tool that has revolutionized the life sciences and is poised to transform medicine.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6555f0d86361d672d6689c78/0x0.jpg?format=jpg&crop=3764,2116,x0,y178,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.262854, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.066784", "ticker_sentiment_score": "0.04657", "ticker_sentiment_label": "Neutral"}]}, {"title": "After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy?", "url": "https://www.fool.com/investing/2023/11/16/after-stock-crash-1-day-verve-therapeutics-buy/", "time_published": "20231116T102000", "authors": ["Alex Carchidi"], "summary": "It reported some very bad news, but the market might be overreacting.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.017216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.040553", "ticker_sentiment_score": "0.008862", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.121241", "ticker_sentiment_score": "-0.033569", "ticker_sentiment_label": "Neutral"}]}, {"title": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Domp\u00e9 Farmaceutici", "url": "https://www.prnewswire.com/news-releases/type-1-diabetes-market-to-accelerate-substantially-during-the-study-period-20192032-predicts-delveinsight--leading-companies-developing-therapies---eli-lilly-vertex-bayer-novo-nordisk-rise-tolerion-biokier-dompe-farmac-301989755.html", "time_published": "20231115T220100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Predicts DelveInsight ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.208545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LABP", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADOCY", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.129655", "ticker_sentiment_score": "0.093706", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSTO", "relevance_score": "0.026042", "ticker_sentiment_score": "0.027777", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.052056", "ticker_sentiment_score": "0.078585", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELZ", "relevance_score": "0.052056", "ticker_sentiment_score": "0.092557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.026042", "ticker_sentiment_score": "0.044133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Price Strength: Neurocrine Biosciences", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-neurocrine-biosciences-3/", "time_published": "20231115T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Neurocrine Biosciences ( NBIX ) had its Relative Strength ( RS ) Rating upgraded from 80 to 83 Wednesday. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. IBD's unique rating measures market leadership with a 1 ( worst ) to 99 ( best ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.385864, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.38588", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.86962", "ticker_sentiment_score": "0.573905", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intra-Cellular Therapies Trying To Close In On Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/intra-cellular-therapies-trying-to-close-in-on-key-technical-benchmark-2/", "time_published": "20231115T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Intra-Cellular Therapies Trying To Close In On Key Technical ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.392429, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.16849", "ticker_sentiment_score": "0.187335", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITCI", "relevance_score": "0.605266", "ticker_sentiment_score": "0.441103", "ticker_sentiment_label": "Bullish"}, {"ticker": "NBIX", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rocket Pharmaceuticals Shows Market Leadership With Jump To 92 RS Rating", "url": "https://www.investors.com/ibd-data-stories/rocket-pharmaceuticals-shows-market-leadership-with-jump-to-92-rs-rating/", "time_published": "20231115T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Rocket Pharmaceuticals Shows Market Leadership With Jump To 92 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.33655, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCKT", "relevance_score": "0.702434", "ticker_sentiment_score": "0.523595", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.129183", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.129183", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Vertex Pharmaceuticals? - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35782728/how-is-the-market-feeling-about-vertex-pharmaceuticals", "time_published": "20231114T170019", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 9.01% since its last report. The company recently reported that it has 2.60 million shares sold short, which is 1.01% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks", "url": "https://www.fool.com/investing/2023/11/14/opportunity-buy-cathie-wood-stocks/", "time_published": "20231114T105000", "authors": ["Keith Speights"], "summary": "You might not get a better chance to invest in these disruptive companies.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.95493"}], "overall_sentiment_score": 0.246911, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.277748", "ticker_sentiment_score": "0.099475", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.113062", "ticker_sentiment_score": "0.280415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.056674", "ticker_sentiment_score": "0.087924", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.056674", "ticker_sentiment_score": "0.087924", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher", "url": "https://www.fool.com/investing/2023/11/14/2-stocks-to-buy-hand-over-fist-as-market-rallies/", "time_published": "20231114T100000", "authors": ["Adria Cimino"], "summary": "These stocks look reasonably priced today considering their long-term prospects.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754884%2Finvestor-excited-computer.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.366532, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.057079", "ticker_sentiment_score": "0.092943", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.609763", "ticker_sentiment_score": "0.498973", "ticker_sentiment_label": "Bullish"}]}, {"title": "Vaxcyte Shows Market Leadership With Jump To 84 RS Rating", "url": "https://www.investors.com/ibd-data-stories/vaxcyte-shows-market-leadership-with-jump-to-84-rs-rating/", "time_published": "20231114T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vaxcyte ( PCVX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 80 to 84. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.360858, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PCVX", "relevance_score": "0.514619", "ticker_sentiment_score": "0.539598", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Krystal Biotech Shows Rising Price Performance With Jump To 85 RS Rating", "url": "https://www.investors.com/ibd-data-stories/krystal-biotech-shows-rising-price-performance-with-jump-to-85-rs-rating/", "time_published": "20231113T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Krystal Biotech Shows Rising Price Performance With Jump To 85 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.324235, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRYS", "relevance_score": "0.498188", "ticker_sentiment_score": "0.325057", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/11/12/3-revolutionary-stocks-id-buy-right-now-without-he/", "time_published": "20231112T105000", "authors": ["Keith Speights"], "summary": "Most stocks aren't truly revolutionary. These really are.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.144753, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.106541", "ticker_sentiment_score": "0.206734", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.211191", "ticker_sentiment_score": "0.125834", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.26224", "ticker_sentiment_score": "-0.065665", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 No-Brainer Stock to Buy and Hold for 10 Years", "url": "https://www.fool.com/investing/2023/11/11/1-no-brainer-stock-to-buy-and-hold-for-10-years/", "time_published": "20231111T133000", "authors": ["Prosper Junior Bakiny"], "summary": "This company has been in the news for much of the year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.243618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.176287", "ticker_sentiment_score": "-0.004422", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.059194", "ticker_sentiment_score": "-0.06302", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Growth Stocks to Buy Right Now Without Any Hesitation", "url": "https://www.fool.com/investing/2023/11/11/3-growth-stocks-you-can-buy-right-now-without-any/", "time_published": "20231111T115000", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "Investors shouldn't have to deliberate for too long about these great stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.129431, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.159305", "ticker_sentiment_score": "0.197144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.274981", "ticker_sentiment_score": "0.193113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.274981", "ticker_sentiment_score": "0.102351", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip", "url": "https://www.fool.com/investing/2023/11/11/nasdaq-bear-market-4-growth-stocks-regret-not-buy/", "time_published": "20231111T100600", "authors": ["Sean Williams"], "summary": "A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754434%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.094789, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055173", "ticker_sentiment_score": "0.053434", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOVE", "relevance_score": "0.218079", "ticker_sentiment_score": "-0.040803", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.164468", "ticker_sentiment_score": "0.053136", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.027603", "ticker_sentiment_score": "-0.038813", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.244518", "ticker_sentiment_score": "0.085973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade", "url": "https://www.investors.com/news/technology/amphastar-pharmaceuticals-stock-earns-composite-rating-upgrade/", "time_published": "20231110T204300", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily", "JULIE MAK"], "summary": "Amphastar Pharmaceuticals ( AMPH ) stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. The new rating shows the stock is outpacing 98% of all stocks when it comes to the most important stock-picking criteria.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/IDS5.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.389305, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.259727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.492659", "ticker_sentiment_score": "0.308369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NBIX", "relevance_score": "0.259727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "VRTX: Vertex Pharmaceuticals  ( VRTX )  Post-Earnings Analysis: Is It Time to Buy the Stock?", "url": "https://stocknews.com/news/vrtx-gild-otsky-cort-vertex-pharmaceuticals-vrtx-post-earnings-analysis-is-it-time-to-buy/", "time_published": "20231110T192932", "authors": ["StockNews.com Staff"], "summary": "VRTX: Vertex Pharmaceuticals ( VRTX ) Post-Earnings Analysis: Is It ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/07/shutterstock_1110645284.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.243089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.568767", "ticker_sentiment_score": "0.3166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CORT", "relevance_score": "0.048278", "ticker_sentiment_score": "0.124896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048278", "ticker_sentiment_score": "0.124896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Pauses As Yields Rebound: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/", "time_published": "20231110T120000", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/01/INCOME_yield_013017_shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.017348, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.091746", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.070037", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.070036", "ticker_sentiment_score": "0.075537", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.162489", "ticker_sentiment_score": "-0.016092", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOUR", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.161943", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FN", "relevance_score": "0.046724", "ticker_sentiment_score": "0.060043", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.093289", "ticker_sentiment_score": "0.005589", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.006543", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.077475", "ticker_sentiment_label": "Neutral"}, {"ticker": "FANG", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GFS", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.093289", "ticker_sentiment_score": "0.02077", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.116461", "ticker_sentiment_score": "0.016621", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOSL", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.093289", "ticker_sentiment_score": "0.042954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSY", "relevance_score": "0.046724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIOD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.073194", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.116461", "ticker_sentiment_score": "-0.038586", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.085312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amphastar Pharm Earns Composite Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/amphastar-pharm-earns-composite-rating-upgrade/", "time_published": "20231110T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Amphastar Pharm ( AMPH ) saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. X The new rating shows the stock is outpacing 98% of all stocks when it comes to the most important stock-picking criteria.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.272716, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.318897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.318897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues", "url": "https://www.fool.com/investing/2023/11/09/this-program-for-a-common-problem-may-be-vertex-ph/", "time_published": "20231109T103000", "authors": ["Adria Cimino"], "summary": "Vertex shares look cheap today considering all the company has to offer.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754306%2Fgettyimages-876388422.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.024672, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.112008", "ticker_sentiment_score": "0.063334", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.056143", "ticker_sentiment_score": "0.195641", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Myers Industries  ( NYSE:MYE )  Downgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/11/09/myers-industries-nysemye-downgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T102301", "authors": ["Defense World Staff"], "summary": "Myers Industries ( NYSE:MYE ) Downgraded by StockNews.com to ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/myers-industries-inc-logo.png?v=20221207143450&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.257232, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MYE", "relevance_score": "0.780804", "ticker_sentiment_score": "0.432224", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.081552", "ticker_sentiment_score": "0.055691", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.081552", "ticker_sentiment_score": "0.055691", "ticker_sentiment_label": "Neutral"}, {"ticker": "KEY", "relevance_score": "0.081552", "ticker_sentiment_score": "-0.010364", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBS", "relevance_score": "0.162255", "ticker_sentiment_score": "0.222864", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sunstone Hotel Investors  ( NYSE:SHO )  Upgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/11/09/sunstone-hotel-investors-nysesho-upgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T102301", "authors": ["Defense World Staff"], "summary": "Sunstone Hotel Investors ( NYSE:SHO ) Upgraded by StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=SHO", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.333496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.128478", "ticker_sentiment_score": "0.221379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.064449", "ticker_sentiment_score": "0.161245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.128478", "ticker_sentiment_score": "0.221379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.064449", "ticker_sentiment_score": "0.055032", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.064449", "ticker_sentiment_score": "0.055032", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064449", "ticker_sentiment_score": "0.055032", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.064449", "ticker_sentiment_score": "0.161245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BEN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.221379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHO", "relevance_score": "0.830764", "ticker_sentiment_score": "0.536032", "ticker_sentiment_label": "Bullish"}]}, {"title": "RH  ( NYSE:RH )  Downgraded by StockNews.com to Sell", "url": "https://www.defenseworld.net/2023/11/09/rh-nyserh-downgraded-by-stocknews-com-to-sell.html", "time_published": "20231109T102300", "authors": ["Defense World Staff"], "summary": "StockNews.com cut shares of RH ( NYSE:RH - Free Report ) from a hold rating to a sell rating in a report published on Wednesday. RH has been the subject of a number of other reports.", "banner_image": "https://www.marketbeat.com/logos/rh-logo.png?v=20221111142032", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.247432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.059049", "ticker_sentiment_score": "0.139", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.059049", "ticker_sentiment_score": "0.139", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.059049", "ticker_sentiment_score": "0.005999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.059049", "ticker_sentiment_score": "0.005999", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.059049", "ticker_sentiment_score": "0.005999", "ticker_sentiment_label": "Neutral"}, {"ticker": "RH", "relevance_score": "0.89682", "ticker_sentiment_score": "0.40689", "ticker_sentiment_label": "Bullish"}]}, {"title": "Primerica  ( NYSE:PRI )  Upgraded to \"Buy\" by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/primerica-nysepri-upgraded-to-buy-by-stocknews-com.html", "time_published": "20231109T102300", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Primerica ( NYSE:PRI - Free Report ) from a hold rating to a buy rating in a research report report published on Wednesday.", "banner_image": "https://www.marketbeat.com/logos/primerica-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.273261, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.046006", "ticker_sentiment_score": "0.064165", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.046006", "ticker_sentiment_score": "0.103511", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.046006", "ticker_sentiment_score": "0.064165", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRI", "relevance_score": "0.751437", "ticker_sentiment_score": "0.447508", "ticker_sentiment_label": "Bullish"}, {"ticker": "KB", "relevance_score": "0.09186", "ticker_sentiment_score": "0.171655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.046006", "ticker_sentiment_score": "0.103511", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.046006", "ticker_sentiment_score": "0.064165", "ticker_sentiment_label": "Neutral"}, {"ticker": "RJF", "relevance_score": "0.09186", "ticker_sentiment_score": "0.171655", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "H&E Equipment Services  ( NASDAQ:HEES )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2023/11/09/he-equipment-services-nasdaqhees-downgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T102047", "authors": ["Defense World Staff"], "summary": "H&E Equipment Services ( NASDAQ:HEES ) Downgraded by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/hamp;e-equipment-services-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.270286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.076847", "ticker_sentiment_score": "0.10527", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.076847", "ticker_sentiment_score": "0.10527", "ticker_sentiment_label": "Neutral"}, {"ticker": "HEES", "relevance_score": "0.752955", "ticker_sentiment_score": "0.45575", "ticker_sentiment_label": "Bullish"}]}, {"title": "Sanmina  ( NASDAQ:SANM )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2023/11/09/sanmina-nasdaqsanm-downgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T102047", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Sanmina ( NASDAQ:SANM - Free Report ) from a buy rating to a hold rating in a report released on Wednesday morning. Shares of NASDAQ:SANM opened at $47.13 on Wednesday. The company has a market capitalization of $2.74 billion, a P/E ratio of 9.19 and a beta of ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/sanmina-co-logo.png?v=20221117145324&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.350067, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.049629", "ticker_sentiment_score": "0.169139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.099066", "ticker_sentiment_score": "0.266719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.049629", "ticker_sentiment_score": "0.169139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.049629", "ticker_sentiment_score": "0.000993", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANM", "relevance_score": "0.680677", "ticker_sentiment_score": "0.522135", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALIZF", "relevance_score": "0.099066", "ticker_sentiment_score": "0.266719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MET", "relevance_score": "0.099066", "ticker_sentiment_score": "0.266719", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Keysight Technologies  ( NYSE:KEYS )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/keysight-technologies-nysekeys-upgraded-to-buy-by-stocknews-com.html", "time_published": "20231109T095106", "authors": ["Defense World Staff"], "summary": "Keysight Technologies ( NYSE:KEYS ) Upgraded to Buy by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/keysight-technologies-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.256188, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.052112", "ticker_sentiment_score": "0.102876", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.052112", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.052112", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.052112", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.052112", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "KEYS", "relevance_score": "0.785701", "ticker_sentiment_score": "0.415084", "ticker_sentiment_label": "Bullish"}, {"ticker": "PUK", "relevance_score": "0.052112", "ticker_sentiment_score": "0.210863", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.052112", "ticker_sentiment_score": "0.102876", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.052112", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ladder Capital  ( NYSE:LADR )  Upgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/11/09/ladder-capital-nyseladr-upgraded-by-stocknews-com-to-buy.html", "time_published": "20231109T095105", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Ladder Capital ( NYSE:LADR - Free Report ) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. LADR has been the subject of several other reports.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/ladder-capital-corp-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.321356, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LADR", "relevance_score": "0.831503", "ticker_sentiment_score": "0.559708", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.078354", "ticker_sentiment_score": "0.197328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.078354", "ticker_sentiment_score": "0.197328", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Old Republic International  ( NYSE:ORI )  Upgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/11/09/old-republic-international-nyseori-upgraded-by-stocknews-com-to-buy.html", "time_published": "20231109T095105", "authors": ["Defense World Staff"], "summary": "Old Republic International ( NYSE:ORI ) Upgraded by StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/old-republic-international-co-logo.png?v=20221110143941", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.345192, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.069094", "ticker_sentiment_score": "0.139604", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.069094", "ticker_sentiment_score": "0.139604", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORI", "relevance_score": "0.859515", "ticker_sentiment_score": "0.556671", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moelis & Company  ( NYSE:MC )  Lowered to Sell at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/moelis-company-nysemc-lowered-to-sell-at-stocknews-com.html", "time_published": "20231109T095105", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of Moelis & Company ( NYSE:MC - Free Report ) from a hold rating to a sell rating in a research note published on Wednesday morning.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/moelis--company-logo.gif&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.35931, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.065327", "ticker_sentiment_score": "0.144259", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.065327", "ticker_sentiment_score": "0.144259", "ticker_sentiment_label": "Neutral"}, {"ticker": "MC", "relevance_score": "0.836514", "ticker_sentiment_score": "0.571645", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.065327", "ticker_sentiment_score": "0.04804", "ticker_sentiment_label": "Neutral"}]}, {"title": "National Health Investors  ( NYSE:NHI )  Downgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/national-health-investors-nysenhi-downgraded-to-hold-at-stocknews-com.html", "time_published": "20231109T095105", "authors": ["Defense World Staff"], "summary": "National Health Investors ( NYSE:NHI ) Downgraded to Hold at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=NHI", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.325363, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.059194", "ticker_sentiment_score": "0.188014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PNC", "relevance_score": "0.118064", "ticker_sentiment_score": "0.185923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.059194", "ticker_sentiment_score": "0.188014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.059194", "ticker_sentiment_score": "0.050989", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.118064", "ticker_sentiment_score": "0.185923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHI", "relevance_score": "0.818658", "ticker_sentiment_score": "0.522316", "ticker_sentiment_label": "Bullish"}, {"ticker": "RJF", "relevance_score": "0.118064", "ticker_sentiment_score": "0.185923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.059194", "ticker_sentiment_score": "0.188014", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Weis Markets  ( NYSE:WMK )  Upgraded to \"Strong-Buy\" by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/weis-markets-nysewmk-upgraded-to-strong-buy-by-stocknews-com.html", "time_published": "20231109T095104", "authors": ["Defense World Staff"], "summary": "Weis Markets ( NYSE:WMK ) Upgraded to \"Strong-Buy\" by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/weis-markets-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.399576, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.081276", "ticker_sentiment_score": "0.157947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.081276", "ticker_sentiment_score": "0.157947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.16171", "ticker_sentiment_score": "0.318804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENV", "relevance_score": "0.16171", "ticker_sentiment_score": "0.318804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMK", "relevance_score": "0.846873", "ticker_sentiment_score": "0.624757", "ticker_sentiment_label": "Bullish"}, {"ticker": "RFGPF", "relevance_score": "0.081276", "ticker_sentiment_score": "0.157947", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Transportadora de Gas del Sur  ( NYSE:TGS )  Upgraded to Strong-Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/transportadora-de-gas-del-sur-nysetgs-upgraded-to-strong-buy-at-stocknews-com.html", "time_published": "20231109T095104", "authors": ["Defense World Staff"], "summary": "Transportadora de Gas del Sur ( NYSE:TGS ) Upgraded to Strong ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/transportadora-de-gas-del-sur-sa-logo.png?v=20221129144413", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.259158, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.07887", "ticker_sentiment_score": "0.148046", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.07887", "ticker_sentiment_score": "0.148046", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGS", "relevance_score": "0.886842", "ticker_sentiment_score": "0.436827", "ticker_sentiment_label": "Bullish"}, {"ticker": "LPLA", "relevance_score": "0.07887", "ticker_sentiment_score": "0.137653", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.07887", "ticker_sentiment_score": "0.137653", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tredegar  ( NYSE:TG )  Lowered to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/tredegar-nysetg-lowered-to-sell-at-stocknews-com.html", "time_published": "20231109T095104", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Tredegar ( NYSE:TG - Free Report ) from a hold rating to a sell rating in a research note published on Wednesday. Separately, TheStreet cut Tredegar from a c rating to a d rating in a research report on Thursday, August 10th.", "banner_image": "https://www.marketbeat.com/logos/tredegar-co-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.32375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.089305", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.089305", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.150592", "ticker_sentiment_score": "0.276418", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TG", "relevance_score": "0.81619", "ticker_sentiment_score": "0.518249", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGGNF", "relevance_score": "0.150592", "ticker_sentiment_score": "0.276418", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Occidental Petroleum  ( NYSE:OXY )  Upgraded to Hold by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/occidental-petroleum-nyseoxy-upgraded-to-hold-by-stocknews-com.html", "time_published": "20231109T095104", "authors": ["Defense World Staff"], "summary": "Occidental Petroleum ( NYSE:OXY ) Upgraded to Hold by StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/occidental-petroleum-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.290872, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.040969", "ticker_sentiment_score": "0.150618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.719308", "ticker_sentiment_score": "0.464921", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.040969", "ticker_sentiment_score": "0.034874", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.040969", "ticker_sentiment_score": "0.034874", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.040969", "ticker_sentiment_score": "0.163523", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ocwen Financial  ( NYSE:OCN )  Downgraded to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/ocwen-financial-nyseocn-downgraded-to-sell-at-stocknews-com.html", "time_published": "20231109T095104", "authors": ["Defense World Staff"], "summary": "Ocwen Financial ( NYSE:OCN ) Downgraded to \"Sell\" at StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/ocwen-financial-corp-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.295876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.100729", "ticker_sentiment_score": "0.135449", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.100729", "ticker_sentiment_score": "0.135449", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCN", "relevance_score": "0.8362", "ticker_sentiment_score": "0.483528", "ticker_sentiment_label": "Bullish"}, {"ticker": "WFC", "relevance_score": "0.199859", "ticker_sentiment_score": "0.240382", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clarus  ( NASDAQ:CLAR )  Lowered to Sell at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/clarus-nasdaqclar-lowered-to-sell-at-stocknews-com.html", "time_published": "20231109T095103", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of Clarus ( NASDAQ:CLAR - Free Report ) from a hold rating to a sell rating in a research report sent to investors on Wednesday.", "banner_image": "https://www.marketbeat.com/logos/clarus-co-logo.png?v=20221215063756", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.237496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.110462", "ticker_sentiment_score": "0.200902", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.055364", "ticker_sentiment_score": "0.074946", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.055364", "ticker_sentiment_score": "0.074946", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.055364", "ticker_sentiment_score": "0.036934", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLAR", "relevance_score": "0.812979", "ticker_sentiment_score": "0.412621", "ticker_sentiment_label": "Bullish"}]}, {"title": "AxoGen  ( NASDAQ:AXGN )  Downgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/11/09/axogen-nasdaqaxgn-downgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T095103", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of AxoGen ( NASDAQ:AXGN - Free Report ) from a buy rating to a hold rating in a research note issued to investors on Wednesday. Other equities analysts have also recently issued reports about the stock.", "banner_image": "https://www.marketbeat.com/logos/axogen-inc-logo.jpg?v=20221212220715", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.21802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AXGN", "relevance_score": "0.73871", "ticker_sentiment_score": "0.347954", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLK", "relevance_score": "0.105141", "ticker_sentiment_score": "0.199613", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.001001", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.001001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.105141", "ticker_sentiment_score": "0.199613", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CymaBay Therapeutics  ( NASDAQ:CBAY )  Downgraded to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/cymabay-therapeutics-nasdaqcbay-downgraded-to-sell-at-stocknews-com.html", "time_published": "20231109T095103", "authors": ["Defense World Staff"], "summary": "CymaBay Therapeutics ( NASDAQ:CBAY ) Downgraded to \"Sell\" at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=CBAY", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.274466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.09239", "ticker_sentiment_score": "0.171914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CBAY", "relevance_score": "0.754172", "ticker_sentiment_score": "0.436561", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.046273", "ticker_sentiment_score": "0.139916", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.046273", "ticker_sentiment_score": "0.139916", "ticker_sentiment_label": "Neutral"}]}, {"title": "Consumer Portfolio Services  ( NASDAQ:CPSS )  Upgraded to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/consumer-portfolio-services-nasdaqcpss-upgraded-to-buy-at-stocknews-com.html", "time_published": "20231109T095101", "authors": ["Defense World Staff"], "summary": "Consumer Portfolio Services ( NASDAQ:CPSS ) Upgraded to Buy at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/consumer-portfolio-services-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.296466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.088147", "ticker_sentiment_score": "0.093371", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.088147", "ticker_sentiment_score": "0.093371", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.175221", "ticker_sentiment_score": "0.270693", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.088147", "ticker_sentiment_score": "0.199531", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DLH  ( NASDAQ:DLHC )  Lowered to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/dlh-nasdaqdlhc-lowered-to-hold-at-stocknews-com.html", "time_published": "20231109T095059", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of DLH ( NASDAQ:DLHC - Free Report ) from a buy rating to a hold rating in a report released on Wednesday. Shares of NASDAQ DLHC opened at $14.37 on Wednesday. DLH has a 12 month low of $9.01 and a 12 month high of $15.42.", "banner_image": "https://www.marketbeat.com/logos/dlh-holdings-corp-logo.png?v=20221220145512", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.338635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.086556", "ticker_sentiment_score": "0.20555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.086556", "ticker_sentiment_score": "0.20555", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DLHC", "relevance_score": "0.842357", "ticker_sentiment_score": "0.54477", "ticker_sentiment_label": "Bullish"}]}, {"title": "Huron Consulting Group  ( NASDAQ:HURN )  Upgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/11/09/huron-consulting-group-nasdaqhurn-upgraded-by-stocknews-com-to-buy.html", "time_published": "20231109T095058", "authors": ["Defense World Staff"], "summary": "Huron Consulting Group ( NASDAQ:HURN ) Upgraded by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/huron-consulting-group-inc-logo.png?v=20221129142801", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.330274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.057352", "ticker_sentiment_score": "0.097955", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057352", "ticker_sentiment_score": "0.113", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.057352", "ticker_sentiment_score": "0.113", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYH", "relevance_score": "0.057352", "ticker_sentiment_score": "0.113", "ticker_sentiment_label": "Neutral"}, {"ticker": "HURN", "relevance_score": "0.778678", "ticker_sentiment_score": "0.52058", "ticker_sentiment_label": "Bullish"}]}, {"title": "JD.com  ( NASDAQ:JD )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/jd-com-nasdaqjd-upgraded-to-buy-by-stocknews-com.html", "time_published": "20231109T095056", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of JD.com ( NASDAQ:JD - Free Report ) from a hold rating to a buy rating in a research report sent to investors on Wednesday.", "banner_image": "https://www.marketbeat.com/logos/jdcom-inc-logo.png?v=20221021143024", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.239958, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "III", "relevance_score": "0.24289", "ticker_sentiment_score": "0.231874", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.061631", "ticker_sentiment_score": "0.124151", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.061631", "ticker_sentiment_score": "0.124151", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.061631", "ticker_sentiment_score": "0.01401", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.061631", "ticker_sentiment_score": "0.01401", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.061631", "ticker_sentiment_score": "0.01401", "ticker_sentiment_label": "Neutral"}]}, {"title": "Masimo  ( NASDAQ:MASI )  Upgraded to Hold by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/masimo-nasdaqmasi-upgraded-to-hold-by-stocknews-com.html", "time_published": "20231109T095054", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Masimo ( NASDAQ:MASI - Free Report ) from a sell rating to a hold rating in a report issued on Wednesday morning. MASI has been the subject of a number of other research reports.", "banner_image": "https://www.marketbeat.com/logos/masimo-corp-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266011, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081841", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.829177", "ticker_sentiment_score": "0.438056", "ticker_sentiment_label": "Bullish"}, {"ticker": "OXY", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081841", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.051999", "ticker_sentiment_score": "0.026891", "ticker_sentiment_label": "Neutral"}]}, {"title": "MacroGenics  ( NASDAQ:MGNX )  Upgraded to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/macrogenics-nasdaqmgnx-upgraded-to-buy-at-stocknews-com.html", "time_published": "20231109T095053", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of MacroGenics ( NASDAQ:MGNX - Free Report ) from a hold rating to a buy rating in a report released on Wednesday. Several other analysts have also issued reports on the stock.", "banner_image": "https://www.marketbeat.com/logos/macrogenics-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.284757, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.775361", "ticker_sentiment_score": "0.454989", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.056943", "ticker_sentiment_score": "0.035085", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.056943", "ticker_sentiment_score": "0.035085", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.113597", "ticker_sentiment_score": "0.203763", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ocular Therapeutix  ( NASDAQ:OCUL )  Downgraded by StockNews.com to Sell", "url": "https://www.defenseworld.net/2023/11/09/ocular-therapeutix-nasdaqocul-downgraded-by-stocknews-com-to-sell.html", "time_published": "20231109T095052", "authors": ["Defense World Staff"], "summary": "Ocular Therapeutix ( NASDAQ:OCUL ) Downgraded by StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/ocular-therapeutix-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.265354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.07157", "ticker_sentiment_score": "0.028685", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.07157", "ticker_sentiment_score": "0.028685", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUL", "relevance_score": "0.849318", "ticker_sentiment_score": "0.438244", "ticker_sentiment_label": "Bullish"}]}, {"title": "Astronics  ( NASDAQ:ATRO )  Downgraded by StockNews.com to \"Hold\"", "url": "https://www.defenseworld.net/2023/11/09/astronics-nasdaqatro-downgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T093046", "authors": ["Defense World Staff"], "summary": "StockNews.com cut shares of Astronics ( NASDAQ:ATRO - Free Report ) from a buy rating to a hold rating in a research note published on Wednesday. Separately, Truist Financial lifted their price objective on shares of Astronics from $15.00 to $17.00 and gave the company a hold rating in a ...", "banner_image": "https://www.marketbeat.com/logos/astronics-co-logo.png?v=20221214141953", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.331672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.093289", "ticker_sentiment_score": "0.076148", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.12546", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.093289", "ticker_sentiment_score": "0.12546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRO", "relevance_score": "0.84035", "ticker_sentiment_score": "0.535158", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ascendis Pharma A/S  ( NASDAQ:ASND )  Lowered to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/ascendis-pharma-a-s-nasdaqasnd-lowered-to-sell-at-stocknews-com.html", "time_published": "20231109T093044", "authors": ["Defense World Staff"], "summary": "Ascendis Pharma A/S ( NASDAQ:ASND ) Lowered to \"Sell\" at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=ASND", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.243701, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.058047", "ticker_sentiment_score": "0.080049", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.058047", "ticker_sentiment_score": "0.080049", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.058047", "ticker_sentiment_score": "0.040995", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASND", "relevance_score": "0.854693", "ticker_sentiment_score": "0.407095", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.058047", "ticker_sentiment_score": "0.040995", "ticker_sentiment_label": "Neutral"}]}, {"title": "Federal Signal  ( NYSE:FSS )  Lifted to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/federal-signal-nysefss-lifted-to-buy-at-stocknews-com-2.html", "time_published": "20231109T092050", "authors": ["Defense World Staff"], "summary": "Federal Signal ( NYSE:FSS - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued to clients and investors on Thursday. Other equities analysts have also recently issued research reports about the stock.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/federal-signal-co-logo.png?v=20221121145332&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.353154, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MCQEF", "relevance_score": "0.172713", "ticker_sentiment_score": "0.294387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.08687", "ticker_sentiment_score": "0.126279", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.08687", "ticker_sentiment_score": "0.126279", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAMG", "relevance_score": "0.172713", "ticker_sentiment_score": "0.294387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSS", "relevance_score": "0.809496", "ticker_sentiment_score": "0.557076", "ticker_sentiment_label": "Bullish"}]}, {"title": "BeiGene  ( NASDAQ:BGNE )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/beigene-nasdaqbgne-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20231109T082907", "authors": ["Defense World Staff"], "summary": "BeiGene ( NASDAQ:BGNE - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research report issued to clients and investors on Thursday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=BGNE", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.232583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCQEF", "relevance_score": "0.064797", "ticker_sentiment_score": "0.0741", "ticker_sentiment_label": "Neutral"}, {"ticker": "TD", "relevance_score": "0.064797", "ticker_sentiment_score": "0.139511", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.064797", "ticker_sentiment_score": "0.071335", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.806678", "ticker_sentiment_score": "0.381249", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.064797", "ticker_sentiment_score": "0.0741", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.129168", "ticker_sentiment_score": "0.165551", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.064797", "ticker_sentiment_score": "0.0741", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.064797", "ticker_sentiment_score": "0.071335", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.064797", "ticker_sentiment_score": "0.0741", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.064797", "ticker_sentiment_score": "0.0741", "ticker_sentiment_label": "Neutral"}]}, {"title": "RBC Bearings  ( NASDAQ:ROLL )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/rbc-bearings-nasdaqroll-receives-new-coverage-from-analysts-at-stocknews-com-2.html", "time_published": "20231109T082906", "authors": ["Defense World Staff"], "summary": "RBC Bearings ( NASDAQ:ROLL ) Receives New Coverage from ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rbc-bearings-incorporated-logo.png?v=20221003141248&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.300719, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.085629", "ticker_sentiment_score": "0.00208", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.085629", "ticker_sentiment_score": "0.00208", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBC", "relevance_score": "0.76311", "ticker_sentiment_score": "0.474854", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fluent  ( NASDAQ:FLNT )  Earns Hold Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/fluent-nasdaqflnt-earns-hold-rating-from-analysts-at-stocknews-com.html", "time_published": "20231109T082906", "authors": ["Defense World Staff"], "summary": "Fluent ( NASDAQ:FLNT ) Earns Hold Rating from Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/fluent-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.459294, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.080458", "ticker_sentiment_score": "0.087627", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.080458", "ticker_sentiment_score": "0.087627", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.160099", "ticker_sentiment_score": "0.406758", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.080458", "ticker_sentiment_score": "0.075689", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLNT", "relevance_score": "0.080458", "ticker_sentiment_score": "0.087627", "ticker_sentiment_label": "Neutral"}]}, {"title": "Xperi  ( NASDAQ:XPER )  Lifted to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/xperi-nasdaqxper-lifted-to-hold-at-stocknews-com.html", "time_published": "20231109T082906", "authors": ["Defense World Staff"], "summary": "Xperi ( NASDAQ:XPER - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued on Thursday. Separately, Rosenblatt Securities restated a \"buy\" rating and set a $15.00 price target on shares of Xperi in a report on ...", "banner_image": "https://www.marketbeat.com/logos/xperi-inc-logo.jpg?v=20221212222927", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.314718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.068112", "ticker_sentiment_score": "0.189829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BK", "relevance_score": "0.135729", "ticker_sentiment_score": "0.211369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.068112", "ticker_sentiment_score": "0.189829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XPER", "relevance_score": "0.76853", "ticker_sentiment_score": "0.496185", "ticker_sentiment_label": "Bullish"}]}, {"title": "StockNews.com Begins Coverage on Biocept  ( NASDAQ:BIOC ) ", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-begins-coverage-on-biocept-nasdaqbioc.html", "time_published": "20231109T082906", "authors": ["Defense World Staff"], "summary": "Analysts at StockNews.com began coverage on shares of Biocept ( NASDAQ:BIOC - Get Free Report ) in a research note issued to investors on Thursday. The firm set a \"hold\" rating on the medical research company's stock. Biocept has a 52-week low of $0.32 and a 52-week high of $27.00.", "banner_image": "https://www.marketbeat.com/logos/biocept-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.043159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.062271", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.062271", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOCQ", "relevance_score": "0.769861", "ticker_sentiment_score": "0.071707", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nabriva Therapeutics  ( NASDAQ:NBRV )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/nabriva-therapeutics-nasdaqnbrv-research-coverage-started-at-stocknews-com.html", "time_published": "20231109T082906", "authors": ["Defense World Staff"], "summary": "Nabriva Therapeutics ( NASDAQ:NBRV ) Research Coverage Started ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/nabriva-therapeutics-plc-logo.png?v=20230104110349", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.220433, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NBRVF", "relevance_score": "0.816498", "ticker_sentiment_score": "0.365821", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.068268", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.117486", "ticker_sentiment_score": "0.068268", "ticker_sentiment_label": "Neutral"}]}, {"title": "Old Point Financial  ( NASDAQ:OPOF )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/old-point-financial-nasdaqopof-receives-new-coverage-from-analysts-at-stocknews-com.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "Old Point Financial ( NASDAQ:OPOF ) Receives New Coverage from ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/old-point-financial-co-logo.jpg?v=20221221113812", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.342628, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.154951", "ticker_sentiment_score": "0.321139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.077845", "ticker_sentiment_score": "0.036694", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.077845", "ticker_sentiment_score": "0.036694", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.154951", "ticker_sentiment_score": "0.321139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.077845", "ticker_sentiment_score": "0.001016", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPOF", "relevance_score": "0.828712", "ticker_sentiment_score": "0.546699", "ticker_sentiment_label": "Bullish"}]}, {"title": "Host Hotels & Resorts  ( NASDAQ:HST )  Rating Increased to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/host-hotels-resorts-nasdaqhst-rating-increased-to-hold-at-stocknews-com.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "Host Hotels & Resorts ( NASDAQ:HST ) Rating Increased to Hold at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=HST", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.288645, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HST", "relevance_score": "0.795859", "ticker_sentiment_score": "0.464878", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.063258", "ticker_sentiment_score": "0.130474", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.063258", "ticker_sentiment_score": "0.130474", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.018007", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.018007", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.018007", "ticker_sentiment_label": "Neutral"}]}, {"title": "AtriCure  ( NASDAQ:ATRC )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/atricure-nasdaqatrc-upgraded-at-stocknews-com.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "AtriCure ( NASDAQ:ATRC - Get Free Report ) was upgraded by StockNews.com from a \"sell\" rating to a \"hold\" rating in a note issued to investors on Thursday. ATRC has been the subject of a number of other research reports.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=ATRC", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.210508, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.056808", "ticker_sentiment_score": "0.05899", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.056808", "ticker_sentiment_score": "0.05899", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRC", "relevance_score": "0.845894", "ticker_sentiment_score": "0.355038", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.056808", "ticker_sentiment_score": "0.077969", "ticker_sentiment_label": "Neutral"}]}, {"title": "Qualtrics International  ( BATS:XM )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/qualtrics-international-batsxm-research-coverage-started-at-stocknews-com-2.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "Qualtrics International ( BATS:XM ) Research Coverage Started at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/qualtrics-international-inc-logo.jpg?v=20230612073251", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.36848, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.197413", "ticker_sentiment_score": "0.302543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.197413", "ticker_sentiment_score": "0.302543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XM", "relevance_score": "0.866386", "ticker_sentiment_score": "0.589801", "ticker_sentiment_label": "Bullish"}]}, {"title": "SemiLEDs  ( NASDAQ:LEDS )  Now Covered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/semileds-nasdaqleds-now-covered-by-stocknews-com.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "Research analysts at StockNews.com assumed coverage on shares of SemiLEDs ( NASDAQ:LEDS - Get Free Report ) in a research report issued on Thursday. The brokerage set a \"sell\" rating on the semiconductor company's stock. Shares of LEDS stock opened at $1.20 on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/semileds-co-logo.gif&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.334724, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.108958", "ticker_sentiment_score": "0.253587", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.108958", "ticker_sentiment_score": "0.253587", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEDS", "relevance_score": "0.82927", "ticker_sentiment_score": "0.536811", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.108958", "ticker_sentiment_score": "0.160058", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "TRX Gold  ( NYSE:TRX )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/trx-gold-nysetrx-coverage-initiated-at-stocknews-com.html", "time_published": "20231109T082905", "authors": ["Defense World Staff"], "summary": "Equities research analysts at StockNews.com began coverage on shares of TRX Gold ( NYSE:TRX - Get Free Report ) in a research report issued on Thursday. The firm set a \"hold\" rating on the stock. Separately, HC Wainwright lifted their price target on TRX Gold from $1.10 to $1.30 in a research ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/trx-gold-co-logo.png?v=20230608124221&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.458481, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.104228", "ticker_sentiment_score": "0.294644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BOM", "relevance_score": "0.104228", "ticker_sentiment_score": "0.199678", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.104228", "ticker_sentiment_score": "0.294644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.206685", "ticker_sentiment_score": "0.292486", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.206685", "ticker_sentiment_score": "0.292486", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Origin Agritech  ( NASDAQ:SEED )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/origin-agritech-nasdaqseed-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231109T082904", "authors": ["Defense World Staff"], "summary": "Origin Agritech ( NASDAQ:SEED ) Now Covered by Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/origin-agritech-limited-logo.jpg?v=20211203091850", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.302248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09989", "ticker_sentiment_score": "0.085154", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.09989", "ticker_sentiment_score": "0.085154", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.198221", "ticker_sentiment_score": "0.295279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.09989", "ticker_sentiment_score": "0.205879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SEED", "relevance_score": "0.868004", "ticker_sentiment_score": "0.497004", "ticker_sentiment_label": "Bullish"}, {"ticker": "UBS", "relevance_score": "0.198221", "ticker_sentiment_score": "0.295279", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Great Lakes Dredge & Dock  ( NASDAQ:GLDD )  Upgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/great-lakes-dredge-dock-nasdaqgldd-upgraded-to-hold-at-stocknews-com.html", "time_published": "20231109T082904", "authors": ["Defense World Staff"], "summary": "Great Lakes Dredge & Dock ( NASDAQ:GLDD ) Upgraded to Hold at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/great-lakes-dredge--dock-co-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.300191, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.086245", "ticker_sentiment_score": "0.128671", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.086245", "ticker_sentiment_score": "0.128671", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLDD", "relevance_score": "0.806275", "ticker_sentiment_score": "0.484224", "ticker_sentiment_label": "Bullish"}, {"ticker": "UBS", "relevance_score": "0.171485", "ticker_sentiment_score": "0.243531", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Orion Energy Systems  ( NASDAQ:OESX )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/orion-energy-systems-nasdaqoesx-coverage-initiated-at-stocknews-com.html", "time_published": "20231109T082904", "authors": ["Defense World Staff"], "summary": "Orion Energy Systems ( NASDAQ:OESX ) Coverage Initiated at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/orion-energy-systems-inc-logo.jpg?v=20230104123430&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.313408, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.076358", "ticker_sentiment_score": "0.158029", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.076358", "ticker_sentiment_score": "0.158029", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENV", "relevance_score": "0.076358", "ticker_sentiment_score": "0.213469", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OESX", "relevance_score": "0.820356", "ticker_sentiment_score": "0.504375", "ticker_sentiment_label": "Bullish"}]}, {"title": "MEI Pharma  ( NASDAQ:MEIP )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/mei-pharma-nasdaqmeip-research-coverage-started-at-stocknews-com.html", "time_published": "20231109T082904", "authors": ["Defense World Staff"], "summary": "MEI Pharma ( NASDAQ:MEIP ) Research Coverage Started at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=MEIP", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.216291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.065866", "ticker_sentiment_score": "0.010065", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.065866", "ticker_sentiment_score": "0.010065", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.752738", "ticker_sentiment_score": "0.303608", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.131284", "ticker_sentiment_score": "0.210876", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBS", "relevance_score": "0.131284", "ticker_sentiment_score": "0.210876", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Digital Ally  ( NASDAQ:DGLY )  Earns Sell Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/digital-ally-nasdaqdgly-earns-sell-rating-from-analysts-at-stocknews-com.html", "time_published": "20231109T082904", "authors": ["Defense World Staff"], "summary": "Digital Ally ( NASDAQ:DGLY ) Earns Sell Rating from Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/digital-ally-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.170614, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.105141", "ticker_sentiment_score": "0.109513", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.105141", "ticker_sentiment_score": "0.109513", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGLY", "relevance_score": "0.709611", "ticker_sentiment_score": "0.27143", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Lowers LSB Industries  ( NYSE:LXU )  to Hold", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-lowers-lsb-industries-nyselxu-to-hold.html", "time_published": "20231109T082043", "authors": ["Defense World Staff"], "summary": "LSB Industries ( NYSE:LXU - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report issued on Thursday. Separately, TheStreet lowered shares of LSB Industries from a \"b-\" rating to a \"c\" rating in a research report on Thursday, ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/lsb-industries-inc-logo.png?v=20221130171213&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.258352, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.172713", "ticker_sentiment_score": "0.218148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.08687", "ticker_sentiment_score": "0.074046", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.172713", "ticker_sentiment_score": "0.218148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.172713", "ticker_sentiment_score": "0.218148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LXU", "relevance_score": "0.809496", "ticker_sentiment_score": "0.423806", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.08687", "ticker_sentiment_score": "0.074046", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.172713", "ticker_sentiment_score": "0.218148", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regis  ( NYSE:RGS )  Upgraded by StockNews.com to Hold", "url": "https://www.defenseworld.net/2023/11/09/regis-nysergs-upgraded-by-stocknews-com-to-hold.html", "time_published": "20231109T082043", "authors": ["Defense World Staff"], "summary": "Regis ( NYSE:RGS - Get Free Report ) was upgraded by StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued on Thursday. NYSE RGS opened at $0.47 on Thursday. Regis has a fifty-two week low of $0.47 and a fifty-two week high of $1.85.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/regis-co-logo.png?v=20230104112501&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.356002, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.077593", "ticker_sentiment_score": "0.188515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.077593", "ticker_sentiment_score": "0.188515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHW", "relevance_score": "0.154455", "ticker_sentiment_score": "0.292048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.154455", "ticker_sentiment_score": "0.292048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.154455", "ticker_sentiment_score": "0.292048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RGS", "relevance_score": "0.827318", "ticker_sentiment_score": "0.565061", "ticker_sentiment_label": "Bullish"}]}, {"title": "New York Times  ( NYSE:NYT )  Rating Lowered to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/new-york-times-nysenyt-rating-lowered-to-hold-at-stocknews-com-2.html", "time_published": "20231109T082043", "authors": ["Defense World Staff"], "summary": "New York Times ( NYSE:NYT ) Rating Lowered to Hold at StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/the-new-york-times-company-logo.png?v=20221114201925&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.994953"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.260911, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.785701", "ticker_sentiment_score": "0.423125", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.052112", "ticker_sentiment_score": "0.103809", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.052112", "ticker_sentiment_score": "0.103809", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.052112", "ticker_sentiment_score": "0.01591", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.052112", "ticker_sentiment_score": "0.01591", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.052112", "ticker_sentiment_score": "0.01591", "ticker_sentiment_label": "Neutral"}]}, {"title": "Navios Maritime  ( NYSE:NM )  Earns Hold Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/navios-maritime-nysenm-earns-hold-rating-from-analysts-at-stocknews-com.html", "time_published": "20231109T082042", "authors": ["Defense World Staff"], "summary": "Navios Maritime ( NYSE:NM ) Earns Hold Rating from Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/navios-maritime-holdings-inc-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.281081, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.085629", "ticker_sentiment_score": "0.054331", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.085629", "ticker_sentiment_score": "0.054331", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.085629", "ticker_sentiment_score": "0.002061", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.085629", "ticker_sentiment_score": "0.212732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.085629", "ticker_sentiment_score": "0.212732", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NM", "relevance_score": "0.837842", "ticker_sentiment_score": "0.462014", "ticker_sentiment_label": "Bullish"}]}, {"title": "StockNews.com Initiates Coverage on Textainer Group  ( NYSE:TGH ) ", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-initiates-coverage-on-textainer-group-nysetgh.html", "time_published": "20231109T082042", "authors": ["Defense World Staff"], "summary": "Analysts at StockNews.com initiated coverage on shares of Textainer Group ( NYSE:TGH - Get Free Report ) in a research report issued to clients and investors on Thursday. The firm set a \"hold\" rating on the transportation company's stock. Other research analysts also recently issued reports ...", "banner_image": "https://www.marketbeat.com/logos/textainer-group-holdings-limited-logo.png?v=20221129142640", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.264861, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.085324", "ticker_sentiment_score": "0.049033", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.085324", "ticker_sentiment_score": "0.049033", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGH", "relevance_score": "0.801457", "ticker_sentiment_score": "0.430934", "ticker_sentiment_label": "Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.169676", "ticker_sentiment_score": "0.225147", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Initiates Coverage on Navios Maritime  ( NYSE:NM ) ", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-initiates-coverage-on-navios-maritime-nysenm-2.html", "time_published": "20231109T082042", "authors": ["Defense World Staff"], "summary": "Research analysts at StockNews.com initiated coverage on shares of Navios Maritime ( NYSE:NM - Get Free Report ) in a report released on Thursday. The firm set a \"hold\" rating on the shipping company's stock. Shares of NYSE:NM opened at $2.22 on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/navios-maritime-holdings-inc-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.247369, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.085022", "ticker_sentiment_score": "0.067615", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.085022", "ticker_sentiment_score": "0.067615", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.085022", "ticker_sentiment_score": "0.171309", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.085022", "ticker_sentiment_score": "0.171309", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NM", "relevance_score": "0.864997", "ticker_sentiment_score": "0.416024", "ticker_sentiment_label": "Bullish"}]}, {"title": "Comstock  ( NYSE:LODE )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/comstock-nyselode-receives-new-coverage-from-analysts-at-stocknews-com-2.html", "time_published": "20231109T082042", "authors": ["Defense World Staff"], "summary": "Comstock ( NYSE:LODE ) Receives New Coverage from Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/comstock-inc-logo.png?v=20230718054302", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.264885, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.084127", "ticker_sentiment_score": "0.132257", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.084127", "ticker_sentiment_score": "0.132257", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.167322", "ticker_sentiment_score": "0.280303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTRS", "relevance_score": "0.167322", "ticker_sentiment_score": "0.280303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PEDEVCO  ( NYSE:PED )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/pedevco-nyseped-now-covered-by-analysts-at-stocknews-com.html", "time_published": "20231109T082042", "authors": ["Defense World Staff"], "summary": "StockNews.com began coverage on shares of PEDEVCO ( NYSE:PED - Get Free Report ) in a report issued on Thursday. The firm set a \"sell\" rating on the stock. PEDEVCO stock opened at $0.86 on Thursday. The stock has a market capitalization of $75.25 million, a price-to-earnings ratio of 28.83 and ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pedevco-corp-logo.png?v=20231017055649&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.269287, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.150592", "ticker_sentiment_score": "0.231966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.150592", "ticker_sentiment_score": "0.231966", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Textainer Group  ( NYSE:TGH )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/textainer-group-nysetgh-coverage-initiated-at-stocknews-com.html", "time_published": "20231109T082041", "authors": ["Defense World Staff"], "summary": "Equities research analysts at StockNews.com began coverage on shares of Textainer Group ( NYSE:TGH - Get Free Report ) in a report released on Thursday. The brokerage set a \"hold\" rating on the transportation company's stock. TGH has been the subject of several other research reports. B.", "banner_image": "https://www.marketbeat.com/logos/textainer-group-holdings-limited-logo.png?v=20221129142640", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.313132, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TGH", "relevance_score": "0.830322", "ticker_sentiment_score": "0.505977", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.084127", "ticker_sentiment_score": "0.083633", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.084127", "ticker_sentiment_score": "0.083633", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regis  ( NYSE:RGS )  Raised to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/regis-nysergs-raised-to-hold-at-stocknews-com.html", "time_published": "20231109T082041", "authors": ["Defense World Staff"], "summary": "Regis ( NYSE:RGS - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research report issued to clients and investors on Thursday. Shares of NYSE:RGS opened at $0.47 on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/regis-co-logo.png?v=20230104112501&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.331533, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.082111", "ticker_sentiment_score": "0.21406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.082111", "ticker_sentiment_score": "0.21406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCHW", "relevance_score": "0.163354", "ticker_sentiment_score": "0.272213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.163354", "ticker_sentiment_score": "0.272213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.163354", "ticker_sentiment_score": "0.272213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RGS", "relevance_score": "0.851064", "ticker_sentiment_score": "0.535876", "ticker_sentiment_label": "Bullish"}]}, {"title": "Teck Resources  ( NYSE:TECK )  Earns Hold Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/teck-resources-nyseteck-earns-hold-rating-from-analysts-at-stocknews-com.html", "time_published": "20231109T082041", "authors": ["Defense World Staff"], "summary": "Teck Resources ( NYSE:TECK ) Earns Hold Rating from Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/teck-resources-limited-logo.png?v=20221104113200&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.288113, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.064797", "ticker_sentiment_score": "0.119357", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.064797", "ticker_sentiment_score": "0.119357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNS", "relevance_score": "0.064797", "ticker_sentiment_score": "0.010014", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064797", "ticker_sentiment_score": "0.010014", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.064797", "ticker_sentiment_score": "0.010014", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCKRF", "relevance_score": "0.806678", "ticker_sentiment_score": "0.466443", "ticker_sentiment_label": "Bullish"}]}, {"title": "Teck Resources  ( NYSE:TECK )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/teck-resources-nyseteck-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231109T082041", "authors": ["Defense World Staff"], "summary": "Teck Resources ( NYSE:TECK ) Coverage Initiated by Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/teck-resources-limited-logo.png?v=20221104113200&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.30282, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.064623", "ticker_sentiment_score": "0.085361", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.064623", "ticker_sentiment_score": "0.085361", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNS", "relevance_score": "0.064623", "ticker_sentiment_score": "0.003009", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.064623", "ticker_sentiment_score": "0.003009", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCKRF", "relevance_score": "0.776097", "ticker_sentiment_score": "0.480588", "ticker_sentiment_label": "Bullish"}]}, {"title": "Banco Santander-Chile  ( NYSE:BSAC )  Downgraded by StockNews.com to \"Sell\"", "url": "https://www.defenseworld.net/2023/11/09/banco-santander-chile-nysebsac-downgraded-by-stocknews-com-to-sell.html", "time_published": "20231109T081845", "authors": ["Defense World Staff"], "summary": "Banco Santander-Chile ( NYSE:BSAC ) Downgraded by StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/banco-santander-chile-logo.jpg?v=20221110153203&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.304134, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.066414", "ticker_sentiment_score": "0.160425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAN", "relevance_score": "0.72134", "ticker_sentiment_score": "0.471608", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.066414", "ticker_sentiment_score": "0.035041", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.066414", "ticker_sentiment_score": "0.035041", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.066414", "ticker_sentiment_score": "0.160425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITUB", "relevance_score": "0.066414", "ticker_sentiment_score": "0.178823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.066414", "ticker_sentiment_score": "0.035041", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSAC", "relevance_score": "0.72134", "ticker_sentiment_score": "0.471608", "ticker_sentiment_label": "Bullish"}, {"ticker": "FOREX:UYU", "relevance_score": "0.066414", "ticker_sentiment_score": "0.160425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:CLP", "relevance_score": "0.066414", "ticker_sentiment_score": "0.160425", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CACI International  ( NYSE:CACI )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/caci-international-nysecaci-stock-rating-upgraded-by-stocknews-com-2.html", "time_published": "20231109T081845", "authors": ["Defense World Staff"], "summary": "CACI International ( NYSE:CACI ) Stock Rating Upgraded by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/caci-international-inc-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.259438, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053749", "ticker_sentiment_score": "0.180782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.053749", "ticker_sentiment_score": "0.180782", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.053749", "ticker_sentiment_score": "0.066951", "ticker_sentiment_label": "Neutral"}, {"ticker": "CACI", "relevance_score": "0.822443", "ticker_sentiment_score": "0.410558", "ticker_sentiment_label": "Bullish"}, {"ticker": "WFC", "relevance_score": "0.053749", "ticker_sentiment_score": "0.066951", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.053749", "ticker_sentiment_score": "0.066951", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hess  ( NYSE:HES )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/hess-nysehes-receives-new-coverage-from-analysts-at-stocknews-com-3.html", "time_published": "20231109T081845", "authors": ["Defense World Staff"], "summary": "Hess ( NYSE:HES ) Receives New Coverage from Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/hess-corp-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.234876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.052112", "ticker_sentiment_score": "0.146921", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.052112", "ticker_sentiment_score": "0.146921", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.052112", "ticker_sentiment_score": "0.002981", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.052112", "ticker_sentiment_score": "0.002981", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.052112", "ticker_sentiment_score": "0.002981", "ticker_sentiment_label": "Neutral"}, {"ticker": "HES", "relevance_score": "0.808852", "ticker_sentiment_score": "0.387619", "ticker_sentiment_label": "Bullish"}]}, {"title": "HP  ( NYSE:HPQ )  Downgraded to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/hp-nysehpq-downgraded-to-buy-at-stocknews-com.html", "time_published": "20231109T081845", "authors": ["Defense World Staff"], "summary": "HP ( NYSE:HPQ - Get Free Report ) was downgraded by StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research report issued to clients and investors on Thursday. Other equities research analysts have also recently issued research reports about the company.", "banner_image": "https://www.marketbeat.com/logos/hp-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.19857, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.046999", "ticker_sentiment_score": "0.061299", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.046999", "ticker_sentiment_score": "0.008872", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.046999", "ticker_sentiment_score": "0.008872", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.046999", "ticker_sentiment_score": "0.008872", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.046999", "ticker_sentiment_score": "0.008872", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.093836", "ticker_sentiment_score": "0.109553", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.046999", "ticker_sentiment_score": "0.061299", "ticker_sentiment_label": "Neutral"}]}, {"title": "CEMEX  ( NYSE:CX )  Raised to \"Strong-Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/cemex-nysecx-raised-to-strong-buy-at-stocknews-com.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "CEMEX ( NYSE:CX - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued on Thursday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=CX", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.202381, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.087503", "ticker_sentiment_score": "0.035778", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.087503", "ticker_sentiment_score": "0.035778", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.087503", "ticker_sentiment_score": "0.023713", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.087503", "ticker_sentiment_score": "0.023713", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.087503", "ticker_sentiment_score": "0.023713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.087503", "ticker_sentiment_score": "0.023713", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Initiates Coverage on Mastech Digital  ( NYSEAMERICAN:MHH ) ", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-initiates-coverage-on-mastech-digital-nyseamericanmhh.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "StockNews.com Initiates Coverage on Mastech Digital ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/mastech-digital-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.304968, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.084127", "ticker_sentiment_score": "0.079814", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.084127", "ticker_sentiment_score": "0.079814", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Begins Coverage on iPower  ( NYSE:IPW ) ", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-begins-coverage-on-ipower-nyseipw-2.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "Stock analysts at StockNews.com assumed coverage on shares of iPower ( NYSE:IPW - Get Free Report ) in a report issued on Thursday. The brokerage set a \"hold\" rating on the stock. NYSE IPW opened at $0.60 on Thursday. iPower has a 52 week low of $0.35 and a 52 week high of $1.45.", "banner_image": "https://www.marketbeat.com/logos/ipower-inc-logo.png?v=20230608061654", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.182556, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.082963", "ticker_sentiment_score": "0.095619", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPW", "relevance_score": "0.855251", "ticker_sentiment_score": "0.310415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.082963", "ticker_sentiment_score": "0.095619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Haverty Furniture Companies  ( NYSE:HVT )  Lifted to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/haverty-furniture-companies-nysehvt-lifted-to-buy-at-stocknews-com.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "Haverty Furniture Companies ( NYSE:HVT ) Lifted to \"Buy\" at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/haverty-furniture-companies-inc-logo.jpg?v=20221209142145", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.345082, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.078099", "ticker_sentiment_score": "0.130907", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.078099", "ticker_sentiment_score": "0.130907", "ticker_sentiment_label": "Neutral"}]}, {"title": "Greenhill & Co., Inc.  ( NYSE:GHL )  Now Covered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/greenhill-co-inc-nyseghl-now-covered-by-stocknews-com.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "Analysts at StockNews.com assumed coverage on shares of Greenhill & Co., Inc. ( NYSE:GHL - Get Free Report ) in a note issued to investors on Thursday. The brokerage set a \"hold\" rating on the financial services provider's stock.", "banner_image": "https://www.marketbeat.com/logos/greenhill--co-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.272983, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMHLF", "relevance_score": "0.077845", "ticker_sentiment_score": "0.207362", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.077845", "ticker_sentiment_score": "0.038617", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.077845", "ticker_sentiment_score": "0.038617", "ticker_sentiment_label": "Neutral"}, {"ticker": "GHL", "relevance_score": "0.882069", "ticker_sentiment_score": "0.456677", "ticker_sentiment_label": "Bullish"}, {"ticker": "ENV", "relevance_score": "0.154951", "ticker_sentiment_score": "0.266586", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jefferies Financial Group  ( NYSE:JEF )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/jefferies-financial-group-nysejef-stock-rating-lowered-by-stocknews-com.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "Jefferies Financial Group ( NYSE:JEF ) Stock Rating Lowered by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/jefferies-financial-group-inc-logo.png?v=20221109155720&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.282409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053992", "ticker_sentiment_score": "0.092928", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.053992", "ticker_sentiment_score": "0.092928", "ticker_sentiment_label": "Neutral"}, {"ticker": "JEF", "relevance_score": "0.777141", "ticker_sentiment_score": "0.453166", "ticker_sentiment_label": "Bullish"}, {"ticker": "GS", "relevance_score": "0.053992", "ticker_sentiment_score": "0.088751", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.053992", "ticker_sentiment_score": "0.088751", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Lowers Jefferies Financial Group  ( NYSE:JEF )  to Sell", "url": "https://www.defenseworld.net/2023/11/09/stocknews-com-lowers-jefferies-financial-group-nysejef-to-sell.html", "time_published": "20231109T081844", "authors": ["Defense World Staff"], "summary": "Jefferies Financial Group ( NYSE:JEF - Get Free Report ) was downgraded by StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Thursday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/jefferies-financial-group-inc-logo.png?v=20221109155720&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.263019, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05339", "ticker_sentiment_score": "0.093899", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.05339", "ticker_sentiment_score": "0.093899", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.106541", "ticker_sentiment_score": "0.211956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.819522", "ticker_sentiment_score": "0.432381", "ticker_sentiment_label": "Bullish"}, {"ticker": "GS", "relevance_score": "0.05339", "ticker_sentiment_score": "0.051765", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.05339", "ticker_sentiment_score": "0.051765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Holly Energy Partners  ( NYSE:HEP )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/holly-energy-partners-nysehep-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "Holly Energy Partners ( NYSE:HEP ) Now Covered by Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/holly-energy-partners-lp-logo.gif&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.227493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.079921", "ticker_sentiment_score": "0.009302", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.079921", "ticker_sentiment_score": "0.009302", "ticker_sentiment_label": "Neutral"}, {"ticker": "HEP", "relevance_score": "0.807885", "ticker_sentiment_score": "0.375229", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.079921", "ticker_sentiment_score": "0.047701", "ticker_sentiment_label": "Neutral"}]}, {"title": "American Realty Investors  ( NYSE:ARL )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/american-realty-investors-nysearl-coverage-initiated-at-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "American Realty Investors ( NYSE:ARL ) Coverage Initiated at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/american-realty-investors-inc-logo.png?v=20220302155116", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.339808, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.150592", "ticker_sentiment_score": "0.26755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.099021", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.099021", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.150592", "ticker_sentiment_score": "0.26755", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARL", "relevance_score": "0.845568", "ticker_sentiment_score": "0.547438", "ticker_sentiment_label": "Bullish"}]}, {"title": "Equinor ASA  ( NYSE:EQNR )  Upgraded to Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/equinor-asa-nyseeqnr-upgraded-to-buy-by-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "Equinor ASA ( NYSE:EQNR - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report issued on Thursday. A number of other equities analysts have also weighed in on the stock.", "banner_image": "https://www.marketbeat.com/logos/equinor-asa-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.380203, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "EQNR", "relevance_score": "0.867528", "ticker_sentiment_score": "0.604512", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.070517", "ticker_sentiment_score": "0.226659", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.070517", "ticker_sentiment_score": "0.226659", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.070517", "ticker_sentiment_score": "0.100487", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.070517", "ticker_sentiment_score": "0.100487", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.070517", "ticker_sentiment_score": "0.100487", "ticker_sentiment_label": "Neutral"}]}, {"title": "CEMEX  ( NYSE:CX )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/cemex-nysecx-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "CEMEX ( NYSE:CX - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report issued on Thursday. A number of other research firms have also weighed in on CX. Barclays raised their price target on shares of CEMEX from $8.00 to $9.00 ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=CX", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.334457, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.068306", "ticker_sentiment_score": "0.013152", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.068306", "ticker_sentiment_score": "0.070259", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.068306", "ticker_sentiment_score": "0.070259", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.068306", "ticker_sentiment_score": "0.070259", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.068306", "ticker_sentiment_score": "0.070259", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.068306", "ticker_sentiment_score": "0.013152", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.136113", "ticker_sentiment_score": "0.296702", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Equinor ASA  ( NYSE:EQNR )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/equinor-asa-nyseeqnr-upgraded-at-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "Equinor ASA ( NYSE:EQNR - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Thursday. EQNR has been the subject of a number of other reports.", "banner_image": "https://www.marketbeat.com/logos/equinor-asa-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.374467, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "EQNR", "relevance_score": "0.866386", "ticker_sentiment_score": "0.596689", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.062926", "ticker_sentiment_score": "0.210269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.062926", "ticker_sentiment_score": "0.210269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.062926", "ticker_sentiment_score": "0.068018", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.062926", "ticker_sentiment_score": "0.068018", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.062926", "ticker_sentiment_score": "0.068018", "ticker_sentiment_label": "Neutral"}]}, {"title": "HP  ( NYSE:HPQ )  Downgraded by StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/hp-nysehpq-downgraded-by-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "HP ( NYSE:HPQ - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued to investors on Thursday.", "banner_image": "https://www.marketbeat.com/logos/hp-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.256179, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.045224", "ticker_sentiment_score": "0.102342", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.045224", "ticker_sentiment_score": "0.05224", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.045224", "ticker_sentiment_score": "0.05224", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.045224", "ticker_sentiment_score": "0.05224", "ticker_sentiment_label": "Neutral"}, {"ticker": "PUK", "relevance_score": "0.045224", "ticker_sentiment_score": "0.167024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPQ", "relevance_score": "0.090304", "ticker_sentiment_score": "0.074862", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.045224", "ticker_sentiment_score": "0.102342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Payments  ( NYSE:GPN )  Lifted to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/11/09/global-payments-nysegpn-lifted-to-buy-at-stocknews-com.html", "time_published": "20231109T081843", "authors": ["Defense World Staff"], "summary": "Global Payments ( NYSE:GPN - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued to clients and investors on Thursday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&Symbol=GPN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.282271, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.044386", "ticker_sentiment_score": "0.120912", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMR", "relevance_score": "0.044386", "ticker_sentiment_score": "0.187725", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GPN", "relevance_score": "0.088635", "ticker_sentiment_score": "0.105967", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.044386", "ticker_sentiment_score": "0.0895", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.088635", "ticker_sentiment_score": "0.197075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "0.120912", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.044386", "ticker_sentiment_score": "0.0895", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.044386", "ticker_sentiment_score": "0.0895", "ticker_sentiment_label": "Neutral"}]}, {"title": "TG Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating", "url": "https://www.investors.com/ibd-data-stories/tg-therapeutics-shows-rising-price-performance-with-jump-to-81-rs-rating/", "time_published": "20231109T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "TG Therapeutics Shows Rising Price Performance With Jump To 81 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.403155, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TGTX", "relevance_score": "0.640349", "ticker_sentiment_score": "0.567385", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.353059", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Gene Therapy Stock to Buy and Hold for the Long Haul", "url": "https://www.fool.com/investing/2023/11/08/1-gene-therapy-stock-to-buy-and-hold-for-the-long/", "time_published": "20231108T151500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech has what it takes to overcome recent obstacles.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.237945, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.060694", "ticker_sentiment_score": "0.269104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.180685", "ticker_sentiment_score": "0.224886", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why CRISPR Therapeutics Stock Could Be About to Take Off", "url": "https://www.fool.com/investing/2023/11/08/why-crispr-therapeutics-could-be-about-to-take-off/", "time_published": "20231108T150700", "authors": ["David Jagielski"], "summary": "CRISPR's financial prospects could soon get an upgrade.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.263999, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.071784", "ticker_sentiment_score": "0.079647", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2180608/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe", "time_published": "20231108T112004", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.175411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.254973", "ticker_sentiment_score": "0.091126", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked", "url": "https://www.fool.com/investing/2023/11/08/4-reasons-to-worry-about-vertex-pharmaceuticals-de/", "time_published": "20231108T105000", "authors": ["Keith Speights"], "summary": "No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.024063, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.061609", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYCC", "relevance_score": "0.047092", "ticker_sentiment_score": "-0.052908", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35654688/these-analysts-revise-their-forecasts-on-vertex-pharmaceuticals-after-q3-results", "time_published": "20231107T183649", "authors": ["Lisa Levin"], "summary": "Vertex Pharmaceuticals Incorporated VRTX reported upbeat earnings for its third quarter, while sales missed estimates. Vertex Pharmaceuticals posted adjusted earnings of $4.08 per share, beating market estimates of $3.98 per share.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/07/vertex_pharmaceuticals_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021454, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.944494", "ticker_sentiment_score": "0.06817", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Climbs Despite Renewed Fed Rate Fears; Netflix Raises Prices As Disney Looms", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-paused-as-fed-rate-fears-return-netflix-raises-prices-for-holidays-as-disney-looms/", "time_published": "20231107T162100", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Climbs Despite Renewed Fed Rate Fears. Netflix Raises ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-disney-mickey-07-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.998947"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.004798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.105604", "ticker_sentiment_score": "0.31443", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CELH", "relevance_score": "0.105604", "ticker_sentiment_score": "0.03754", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.105604", "ticker_sentiment_score": "0.071812", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSW", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.052812", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FICO", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.105604", "ticker_sentiment_score": "0.068986", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRL", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.339551", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LI", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.157827", "ticker_sentiment_score": "-0.08511", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.052918", "ticker_sentiment_score": "-0.311917", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "CRISPR Therapeutics  ( CRSP )  Q3 Loss Narrower Than Expected", "url": "https://www.zacks.com/stock/news/2180153/crispr-therapeutics-crsp-q3-loss-narrower-than-expected", "time_published": "20231107T151100", "authors": ["Zacks Equity Research"], "summary": "CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.089891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.067048", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.164656", "ticker_sentiment_score": "0.088527", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.322374", "ticker_sentiment_score": "-0.018796", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.322374", "ticker_sentiment_score": "0.215926", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Q3 Earnings Beat, Sales Miss, Raises '23 View", "url": "https://www.zacks.com/stock/news/2179872/vertex-vrtx-q3-earnings-beat-sales-miss-raises-23-view", "time_published": "20231107T125000", "authors": ["Zacks Equity Research"], "summary": "Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.994953"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.059528, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.219147", "ticker_sentiment_score": "0.023976", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIX", "relevance_score": "0.219147", "ticker_sentiment_score": "0.029464", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto - Celsius Holdings  ( NASDAQ:CELH ) , Matterport  ( NASDAQ:MTTR ) , Choice Hotels Intl  ( NYSE:CHH ) , TripAdvisor  ( NASDAQ:TRIP ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35640681/s-p-500-nasdaq-set-to-break-6-day-rally-today-traders-await-fed-cues-analyst-says-seasonal-rally-ha", "time_published": "20231107T121527", "authors": ["Shanthi Rexaline"], "summary": "Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. Reaction to earnings has been mixed, adding to the prevailing uncertainty.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/stock_charts_3_10.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.102995, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELH", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTTR", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHH", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRIP", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAM", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03786", "ticker_sentiment_score": "0.062228", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANM", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIS", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRB", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIS", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNF", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAIN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/11/07/2774849/0/en/Verve-Therapeutics-Highlights-Recent-Company-Progress-and-Reports-Third-Quarter-2023-Financial-Results.html", "time_published": "20231107T113000", "authors": ["Verve Therapeutics"], "summary": "U.S. Food and Drug Administration ( FDA ) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2a4edc4b-98df-4e32-ade8-159b39872434", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.149548, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.040348", "ticker_sentiment_score": "0.025348", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02018", "ticker_sentiment_score": "0.032129", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.06049", "ticker_sentiment_score": "0.075025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/vertex-pharmaceuticals-vrtx-q3-2023-earnings-call/", "time_published": "20231107T061536", "authors": ["Motley Fool Transcribing"], "summary": "VRTX earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.993856"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.197676, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.004908", "ticker_sentiment_score": "0.120451", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004908", "ticker_sentiment_score": "0.074064", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.004908", "ticker_sentiment_score": "0.20039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.004908", "ticker_sentiment_score": "0.130016", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.009816", "ticker_sentiment_score": "0.071999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharma misses sales estimates on weak demand for older CF treatments", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/vertex-pharma-misses-sales-estimates-weak-demand-older-cf-treatments-2023-11-06/", "time_published": "20231106T230200", "authors": ["Reuters"], "summary": "A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/SCHYTQGEVBIUZCYMVLV4Q5RMFE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.047851, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.280958", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Tops Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2179574/vertex-pharmaceuticals-vrtx-tops-q3-earnings-estimates", "time_published": "20231106T222505", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) delivered earnings and revenue surprises of 4.08% and 0.06%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default142.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.151166, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYRS", "relevance_score": "0.210579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.14131", "ticker_sentiment_score": "0.096884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tech Leader Slips Despite Beating Views, Raising Outlook", "url": "https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q3-2023/", "time_published": "20231106T212100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "VRTX Stock Slips, But IBD Tech Leader Boosts Outlook On Strong ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/02/Stock-Vertex-lab-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.306822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.769861", "ticker_sentiment_score": "0.291868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.18967", "ticker_sentiment_score": "0.526375", "ticker_sentiment_label": "Bullish"}]}, {"title": "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/11/06/2774541/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2023-Financial-Results.html", "time_published": "20231106T211500", "authors": ["CRISPR Therapeutics AG"], "summary": "-Advisory Committee meeting for exagamglogene autotemcel ( exa-cel ) for the treatment of severe sickle cell disease ( SCD ) completed October 31, 2023. exa-cel assigned Prescription Drug User Fee Act ( PDUFA ) target action date of December 8, 2023 for ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.138536, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.036001", "ticker_sentiment_score": "0.067565", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.036001", "ticker_sentiment_score": "0.099452", "ticker_sentiment_label": "Neutral"}]}, {"title": "England's young cystic fibrosis patients face new treatment worry", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/englands-young-cystic-fibrosis-patients-face-new-treatment-worry-2023-11-06/", "time_published": "20231106T161400", "authors": ["Andy Bruce"], "summary": "A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/SCHYTQGEVBIUZCYMVLV4Q5RMFE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.101388, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13459", "ticker_sentiment_score": "0.195361", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is It Worth Investing in Vertex  ( VRTX )  Based on Wall Street's Bullish Views?", "url": "https://www.zacks.com/stock/news/2179160/is-it-worth-investing-in-vertex-vrtx-based-on-wall-streets-bullish-views", "time_published": "20231106T143006", "authors": ["Zacks Equity Research"], "summary": "Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?", "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/VRTX_11062023.png", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.270355, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05387", "ticker_sentiment_score": "0.14275", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's ARKK Had Its Best Week Due To 11 Huge Winners", "url": "https://www.investors.com/news/cathie-wood-ark-innovation-just-had-its-best-week-ever-thanks-to-11-huge-winners/", "time_published": "20231106T124500", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Cathie Wood's Ark Innovation ETF ( ARKK ) typically outpaces the overall market to the upside and downside. Last week, the S&P 500, Dow Jones and Nasdaq had their best gains of 2023. But the Ark Innovation ETF had its best week ever, up 18.6%. Credit massive moves among key components.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.995973"}], "overall_sentiment_score": 0.216493, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.185543", "ticker_sentiment_score": "0.068227", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.275177", "ticker_sentiment_score": "0.089746", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.215757", "ticker_sentiment_score": "-0.055256", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.275177", "ticker_sentiment_score": "0.342629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.155051", "ticker_sentiment_score": "0.120388", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.124325", "ticker_sentiment_score": "0.149851", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.062352", "ticker_sentiment_score": "0.27244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERV", "relevance_score": "0.185543", "ticker_sentiment_score": "0.121474", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.245649", "ticker_sentiment_score": "0.080792", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.124325", "ticker_sentiment_score": "-0.128882", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.09341", "ticker_sentiment_score": "-0.024447", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.185543", "ticker_sentiment_score": "0.085341", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.062352", "ticker_sentiment_score": "0.19217", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields - Matterport  ( NASDAQ:MTTR ) , TripAdvisor  ( NASDAQ:TRIP ) , Adtran  ( NASDAQ:ADTN ) , NXP Semiconductors  ( NASDAQ:NXPI ) ", "url": "https://www.benzinga.com/markets/equities/23/11/35615654/us-stocks-set-to-extend-5-day-winning-streak-today-traders-anxiously-watch-fed-speech-climbing-b", "time_published": "20231106T114718", "authors": ["Shanthi Rexaline"], "summary": "The market looks set to extend last week's gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. Some mega-cap techs gained ground in the premarket, which bodes well for the broader market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/NYSE.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.495866"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.136845, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MTTR", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRIP", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTN", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.044222", "ticker_sentiment_score": "0.254765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXPI", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANM", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICUI", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.044222", "ticker_sentiment_score": "0.217677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GT", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FANG", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DISH", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPLA", "relevance_score": "0.044222", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THS", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIS", "relevance_score": "0.088309", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.088309", "ticker_sentiment_score": "0.140145", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures indicate stocks will look on Monday to extend their latest rally, though additional gains will be meager", "url": "https://www.marketwatch.com/story/s-p-500-futures-show-stocks-extending-latest-rally-4a0996e2", "time_published": "20231106T101000", "authors": ["Jamie Chisholm"], "summary": "U.S. stock futures nudged higher early Monday, as hopes the Federal Reserve has finished raising borrowing costs continued to underpin sentiment.", "banner_image": "https://images.mktw.net/im-881143/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.188797, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.188928", "ticker_sentiment_score": "-0.195476", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TRIP", "relevance_score": "0.188928", "ticker_sentiment_score": "-0.195476", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBER", "relevance_score": "0.188928", "ticker_sentiment_score": "-0.195476", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NXPI", "relevance_score": "0.188928", "ticker_sentiment_score": "-0.195476", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "CRISPR Therapeutics Announces Preclinical Data at the American Heart Association  ( AHA )  Scientific Sessions 2023", "url": "https://www.globenewswire.com/news-release/2023/11/06/2773808/0/en/CRISPR-Therapeutics-Announces-Preclinical-Data-at-the-American-Heart-Association-AHA-Scientific-Sessions-2023.html", "time_published": "20231106T100100", "authors": ["CRISPR Therapeutics AG"], "summary": "-CTX310\u2122 led to durable reductions of angiopoietin-like 3 protein ( ANGPTL3 ) and triglyceride levels in non-human primates ( NHPs ) after a single ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.127768, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.033421", "ticker_sentiment_score": "0.121171", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.100029", "ticker_sentiment_score": "0.12744", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Announces Preclinical Data at the American Heart Association  ( AHA )  Scientific Sessions 2023 - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35614028/crispr-therapeutics-announces-preclinical-data-at-the-american-heart-association-aha-scientific-se", "time_published": "20231106T100100", "authors": ["Globe Newswire"], "summary": "-CTX310\u2122 led to durable reductions of angiopoietin-like 3 protein ( ANGPTL3 ) and triglyceride levels in non-human primates ( NHPs ) after a single dose- -CTX320\u2122 led to durable reductions of lipoprotein ( a ) ( Lp ( a ) ) levels in NHPs after a single dose-", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.120486, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.032781", "ticker_sentiment_score": "0.120893", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.098121", "ticker_sentiment_score": "0.125649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaxcyte Earns Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/vaxcyte-earns-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20231106T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vaxcyte Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.294494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PCVX", "relevance_score": "0.662945", "ticker_sentiment_score": "0.468192", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.368773", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.368773", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rhythm Pharmaceuticals Shows Market Leadership With Jump To 92 RS Rating", "url": "https://www.investors.com/ibd-data-stories/rhythm-pharmaceuticals-shows-market-leadership-with-jump-to-92-rs-rating/", "time_published": "20231106T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Rhythm Pharmaceuticals Shows Market Leadership With Jump To ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.325296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.338582", "ticker_sentiment_score": "0.133973", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.726435", "ticker_sentiment_score": "0.437684", "ticker_sentiment_label": "Bullish"}, {"ticker": "NBIX", "relevance_score": "0.338582", "ticker_sentiment_score": "0.133973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Market Leadership: Rocket Pharmaceuticals Earns 90 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-market-leadership-rocket-pharmaceuticals-earns-90-rs-rating/", "time_published": "20231106T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Stocks Showing Market Leadership: Rocket Pharmaceuticals Earns ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.350601, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RCKT", "relevance_score": "0.588876", "ticker_sentiment_score": "0.435717", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.318897", "ticker_sentiment_score": "0.12787", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.318897", "ticker_sentiment_score": "0.12787", "ticker_sentiment_label": "Neutral"}]}, {"title": "Azenta Shows Rising Relative Price Performance; Still Shy Of Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/azenta-shows-rising-relative-price-performance-still-shy-of-key-benchmark/", "time_published": "20231106T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Azenta Shows Rising Relative Price Performance. Still Shy Of Key ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.308848, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZTA", "relevance_score": "0.570165", "ticker_sentiment_score": "0.414076", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ionis Pharmaceuticals Shows Market Leadership With Jump To 93 RS Rating", "url": "https://www.investors.com/ibd-data-stories/ionis-pharmaceuticals-shows-market-leadership-with-jump-to-93-rs-rating/", "time_published": "20231106T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Ionis Pharmaceuticals Shows Market Leadership With Jump To 93 ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.384547, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.290607", "ticker_sentiment_score": "0.1146", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.423843", "ticker_sentiment_score": "0.527513", "ticker_sentiment_label": "Bullish"}, {"ticker": "NBIX", "relevance_score": "0.290607", "ticker_sentiment_score": "0.1146", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotechs Bounce. New Highs For Ideaya, Olema And Vertex.", "url": "https://www.forbes.com/sites/johnnavin/2023/11/04/biotechs-bounce-new-highs-for-ideaya-olema-and-vertex/", "time_published": "20231104T142211", "authors": ["John Navin"], "summary": "Biotechs rallied this week, a strong indication that \"risk on\" is back on after Fed Chair Jerome Powell said interest rates won't be raised again right now. This sector is the non-value stock sector - investors going for growth like to place money here when they feel that a bottom may be in place.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/61bd05cabb6d3661cd1aaa39/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}], "overall_sentiment_score": 0.157053, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OLMA", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.087824", "ticker_sentiment_score": "0.10524", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDYA", "relevance_score": "0.087824", "ticker_sentiment_score": "0.075224", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Bluebird Bio Stock a Buy?", "url": "https://www.fool.com/investing/2023/11/04/is-bluebird-bio-stock-a-buy/", "time_published": "20231104T124500", "authors": ["Prosper Junior Bakiny"], "summary": "This biotech looks cheap, but is it a value trap?", "banner_image": "https://media.ycharts.com/charts/f085a82cd864aab6eb7a45d91141b11b.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.132521, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055236", "ticker_sentiment_score": "0.164891", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.420608", "ticker_sentiment_score": "0.087957", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/equities/23/11/35601229/fed-holds-rates-steady-powells-cautious-stance-soothes-investors-labor-market-softens-the-week-i", "time_published": "20231103T200339", "authors": ["Piero Cingari"], "summary": "Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and bonds, with investors embracing the Federal Reserve's decision to hold steady on interest rates.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shutterstock_176534375.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.99737"}], "overall_sentiment_score": 0.135775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.192694", "ticker_sentiment_score": "0.209739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.129168", "ticker_sentiment_score": "0.364054", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.129168", "ticker_sentiment_score": "0.185591", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.064797", "ticker_sentiment_score": "-0.080072", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.129168", "ticker_sentiment_score": "0.364054", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.129168", "ticker_sentiment_score": "0.185591", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}]}, {"title": "It's Time To Find Breakouts As Growth Stocks Get A Lift; Microsoft Is One", "url": "https://www.investors.com/stock-lists/ibd-50/growth-stocks-in-ibd-to-are-near-buy-points/", "time_published": "20231103T181354", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Growth stocks In IBD 50 Are Near Buy Points Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.345447, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.22421", "ticker_sentiment_score": "0.326156", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.150592", "ticker_sentiment_score": "0.223047", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INSW", "relevance_score": "0.22421", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.364987", "ticker_sentiment_score": "0.234468", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.150592", "ticker_sentiment_score": "0.225596", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Rally Back In Force As Yields Plunge: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/", "time_published": "20231103T165559", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-bullfightingbear-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.004916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.070882", "ticker_sentiment_score": "0.015254", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.061816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.040029", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.053192", "ticker_sentiment_score": "0.124905", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044243", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.352867", "ticker_sentiment_label": "Bearish"}, {"ticker": "ALGM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.040517", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.158635", "ticker_sentiment_score": "-0.062061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044087", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.088537", "ticker_sentiment_score": "0.057142", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.028361", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMC", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.017742", "ticker_sentiment_score": "0.107", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.088537", "ticker_sentiment_score": "-0.014717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.024925", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.0443", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RELY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.006008", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.035476", "ticker_sentiment_score": "0.147308", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.053192", "ticker_sentiment_score": "0.167262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.15563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.001911", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBOE", "relevance_score": "0.035476", "ticker_sentiment_score": "0.13248", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCJ", "relevance_score": "0.088537", "ticker_sentiment_score": "0.001072", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.019707", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETSY", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.020024", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "TM", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CRISPR Therapeutics Stock Charged Northward This Week", "url": "https://www.fool.com/investing/2023/11/03/why-crispr-therapeutics-stock-charged-northward-th/", "time_published": "20231103T135647", "authors": ["George Budwell"], "summary": "Gene correction technology took a big step forward this week.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.213677, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.115787", "ticker_sentiment_score": "0.040005", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.115787", "ticker_sentiment_score": "0.199444", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA", "url": "https://www.fool.com/investing/2023/11/03/heres-what-investors-need-to-know-about-vertex-pha/", "time_published": "20231103T120500", "authors": ["Alex Carchidi"], "summary": "The meeting went almost as well as could be expected.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.086177, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.1437", "ticker_sentiment_score": "0.031677", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcellx Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/arcellx-earns-relative-strength-rating-upgrade/", "time_published": "20231103T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Arcellx ( ACLX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Friday, rising from 88 to 95. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.334335, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.48268", "ticker_sentiment_score": "0.46377", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.334008", "ticker_sentiment_score": "0.120999", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.334008", "ticker_sentiment_score": "0.120999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Rises Higher Than Market: Key Facts", "url": "https://www.zacks.com/stock/news/2177676/vertex-pharmaceuticals-vrtx-rises-higher-than-market-key-facts", "time_published": "20231102T214506", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default95.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.176749, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.570165", "ticker_sentiment_score": "0.281396", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna  ( MRNA )  Beats on Q3 Earnings & Sales, Expects Lower COVID Demand", "url": "https://www.zacks.com/stock/news/2177609/moderna-mrna-beats-on-q3-earnings-sales-expects-lower-covid-demand", "time_published": "20231102T161900", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.02383, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.038223", "ticker_sentiment_score": "0.112084", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.114318", "ticker_sentiment_score": "0.072729", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.114318", "ticker_sentiment_score": "0.076205", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.434763", "ticker_sentiment_score": "-0.014556", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.038223", "ticker_sentiment_score": "0.012818", "ticker_sentiment_label": "Neutral"}]}, {"title": "One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?", "url": "https://www.fool.com/investing/2023/11/02/is-crispr-therapeutics-a-buy-before-big-moment/", "time_published": "20231102T093000", "authors": ["Adria Cimino"], "summary": "This stock could be a long-term winner, thanks to its game-changing technology.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753219%2Fgettyimages-1139704348.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.215531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.058188", "ticker_sentiment_score": "0.103034", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Pain Pill Could Replace Opioids. It's an Opportunity.", "url": "https://www.barrons.com/articles/vertex-pain-pill-non-opioid-573cae68", "time_published": "20231102T060000", "authors": ["Josh Nathan-Kazis"], "summary": "Americans filled roughly one opioid pain prescription for every two U.S. adults in 2020-despite a raging opioid epidemic, where 80,000 people a year fatally overdose. Everyone knows the drugs are dangerous, but patients need pain relief, and the alternatives are limited.", "banner_image": "https://images.barrons.com/im-35040148?width=940&height=627", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.226202, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.368773", "ticker_sentiment_score": "0.259141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Muted After Fed Leaves Rates Unchanged, As Expected", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-climbs-ahead-of-fed-announcement-this-leader-plummets-nearly-40/", "time_published": "20231101T182342", "authors": ["Investor's Business Daily", "JUAN CARLOS ARANCIBIA"], "summary": "The stock market had an unusually moderate reaction to the Fed's decision to leave interest rates unchanged Wednesday afternoon. Investors now wait for Chair Jerome Powell's press conference, which often moves stocks more than the Fed announcement itself.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/03/stock-Federal_Reserve-spring-12-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.95493"}], "overall_sentiment_score": 0.043067, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.049676", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.07913", "ticker_sentiment_score": "0.109697", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSN", "relevance_score": "0.07913", "ticker_sentiment_score": "0.159712", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.039614", "ticker_sentiment_score": "0.100127", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.003117", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.049676", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMA", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.068536", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTAI", "relevance_score": "0.07913", "ticker_sentiment_score": "0.163802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.086272", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.096874", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.039614", "ticker_sentiment_score": "0.067335", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.07913", "ticker_sentiment_score": "0.09238", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.188358", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMT", "relevance_score": "0.07913", "ticker_sentiment_score": "-0.140301", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crispr Therapeutics' stock soars as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved", "url": "https://www.marketwatch.com/story/crispr-therapeutics-stock-soars-premarket-after-positive-meeting-of-fda-panel-on-sickle-cell-disease-therapy-887fc893", "time_published": "20231101T160700", "authors": ["Ciara Linnane"], "summary": "Crispr Therapeutics' stock rallied 12% Wednesday amid hopes a treatment for sickle-cell disease will win regulatory approval.", "banner_image": "https://images.mktw.net/im-879446/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.46386, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.751437", "ticker_sentiment_score": "0.437407", "ticker_sentiment_label": "Bullish"}]}, {"title": "Crispr Rallies As The First-Ever Gene-Editing Drug Faces The FDA", "url": "https://www.investors.com/news/technology/crsp-stock-surges-as-fda-considers-the-first-ever-crispr-based-gene-editing-drug/", "time_published": "20231101T143100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "The Food and Drug Administration appears likely to approve Crispr Therapeutics' ( CRSP ) gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher. The bullish sentiment follows a \"relatively benign\" FDA advisory committee on Tuesday, Mizuho Securities ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/06/Stock-crispr-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.116938, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.110289", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall As AMD Slides; All Eyes On Fed, Powell", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amd-slides-all-eyes-on-fed-decision-powell/", "time_published": "20231101T112600", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Futures Fall As AMD Slides. All Eyes On Fed, Powell Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-AMD-ceolisasu-04-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999162"}], "overall_sentiment_score": 0.050857, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.09186", "ticker_sentiment_score": "-0.063792", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.046006", "ticker_sentiment_score": "-0.028957", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.182506", "ticker_sentiment_score": "-0.087113", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.160023", "ticker_sentiment_score": "0.111249", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.09186", "ticker_sentiment_score": "0.064944", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCJ", "relevance_score": "0.160023", "ticker_sentiment_score": "0.052436", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023013", "ticker_sentiment_score": "0.091576", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.182506", "ticker_sentiment_score": "-0.045689", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.09186", "ticker_sentiment_score": "-0.063792", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.160023", "ticker_sentiment_score": "-0.020095", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.09186", "ticker_sentiment_score": "0.155583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LI", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.044583", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.068962", "ticker_sentiment_score": "-0.213447", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "10 things you need to know today: November 1, 2023", "url": "https://theweek.com/digest/round-up/10-things-you-need-to-know-today-november-1-2023", "time_published": "20231101T111817", "authors": ["Harold Maass", "The Week US"], "summary": "1. Israel bombs refugee camp to kill a Hamas leader 2. Cornell student charged with threats against Jewish students 3. Senate confirms Jack Lew as ambassador to Israel 4. FBI director tells senators US faces growing terrorism threats 5. Biden to meet with Xi for 'constructive' talks", "banner_image": "https://cdn.mos.cms.futurecdn.net/eXjPf6ziVXwPV9HvDfpMjG-415-80.jpg", "source": "The Week News", "category_within_source": "n/a", "source_domain": "theweek.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.153046, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.061949", "ticker_sentiment_score": "-0.088448", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.020668", "ticker_sentiment_score": "0.037113", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRNWF", "relevance_score": "0.020668", "ticker_sentiment_score": "0.051459", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.020668", "ticker_sentiment_score": "0.037113", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.020668", "ticker_sentiment_score": "-0.078415", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.020668", "ticker_sentiment_score": "0.048791", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA considers first CRISPR gene editing treatment that may cure sickle cell", "url": "https://www.cnn.com/2023/10/31/health/fda-considers-crispr-treatment-cure-sickle-cell/index.html", "time_published": "20231031T232804", "authors": ["Jen Christensen"], "summary": "At age 45, Dr. Lakiea Bailey said, for the longest time, that she was the oldest person with sickle cell anemia that she knew. The executive director of the nonprofit patient advocacy group the Sickle Cell Consortium was diagnosed with sickle cell disease at age three.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/image-complete-human-sem-day-14.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.029217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.061949", "ticker_sentiment_score": "0.065649", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.030998", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-says-vertexcrispr-assess-safety-risks-gene-therapy-follow-up-study-2023-10-31/", "time_published": "20231031T223000", "authors": ["Reuters"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OV2PC52TJZNG5PW4JK4QPO2EU4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.019649, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.114137", "ticker_sentiment_score": "0.108329", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel  ( exa-cel )  for Severe Sickle Cell Disease", "url": "https://www.globenewswire.com/news-release/2023/10/31/2770707/0/en/CRISPR-Therapeutics-Announces-Completion-of-FDA-Advisory-Committee-Meeting-for-Exagamglogene-Autotemcel-exa-cel-for-Severe-Sickle-Cell-Disease.html", "time_published": "20231031T215300", "authors": ["CRISPR Therapeutics AG"], "summary": "-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.179078, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086372", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.134339", "ticker_sentiment_score": "0.102238", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application  ( BLA )  for Exagamglogene Autotemcel  ( exa-cel )  in Sickle Cell Disease  ( SCD ) ", "url": "https://www.globenewswire.com/news-release/2023/10/31/2770020/0/en/CRISPR-Therapeutics-Trading-Halted-Today-FDA-Advisory-Committee-to-Review-Biologics-License-Application-BLA-for-Exagamglogene-Autotemcel-exa-cel-in-Sickle-Cell-Disease-SCD.html", "time_published": "20231031T110500", "authors": ["CRISPR Therapeutics AG"], "summary": "ZUG, Switzerland and BOSTON, Oct. 31, 2023 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics ( Nasdaq: CRSP ) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company's common stock.", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.182891, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.123526", "ticker_sentiment_score": "0.146693", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.359014", "ticker_sentiment_score": "0.277284", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2175072/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20231031T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.216666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.175433", "ticker_sentiment_score": "0.221938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vericel Shows Market Leadership With Jump To 91 RS Rating", "url": "https://www.investors.com/ibd-data-stories/vericel-shows-market-leadership-with-jump-to-91-rs-rating/", "time_published": "20231031T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Tuesday, Vericel ( VCEL ) received an upgrade to its Relative Strength ( RS ) Rating, from 86 to 91. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.293216, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VCEL", "relevance_score": "0.501398", "ticker_sentiment_score": "0.247646", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.348103", "ticker_sentiment_score": "0.124912", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.348103", "ticker_sentiment_score": "0.124912", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Sees RS Rating Improve To 71", "url": "https://www.investors.com/ibd-data-stories/gilead-sciences-sees-rs-rating-improve-to-71/", "time_published": "20231031T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Gilead Sciences ( GILD ) jumped into a higher percentile Tuesday, as it got a lift from 67 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.332915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.141726", "ticker_sentiment_score": "0.138896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.524949", "ticker_sentiment_score": "0.41869", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90", "url": "https://www.investors.com/news/apellis-pharmaceuticals-joins-rank-of-stocks-with-rs-ratings-over-90/", "time_published": "20231031T080000", "authors": ["GLENN LARKIN", "Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Apellis Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.253143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.483434", "ticker_sentiment_score": "0.354612", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.254307", "ticker_sentiment_score": "0.099105", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.254307", "ticker_sentiment_score": "0.099105", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Expected to Beat Earnings Estimates: Should You Buy?", "url": "https://www.zacks.com/stock/news/2174558/vertex-pharmaceuticals-vrtx-expected-to-beat-earnings-estimates-should-you-buy", "time_published": "20231030T140042", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default82.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.167748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.087824", "ticker_sentiment_score": "0.033384", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.174587", "ticker_sentiment_score": "0.078247", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest", "url": "https://www.cnbc.com/2023/10/30/here-are-16-stocks-jim-cramer-is-watching-including-microsoft-chevron-southwest.html", "time_published": "20231030T133820", "authors": ["Jim Cramer"], "summary": "Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook: ...", "banner_image": "https://image.cnbcfm.com/api/v1/image/104955709-20180119-1683-2543-1.jpg?v=1686584829&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.002451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NWL", "relevance_score": "0.140076", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.018309", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.129035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.07031", "ticker_sentiment_score": "0.073845", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.208764", "ticker_sentiment_score": "0.120683", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.208764", "ticker_sentiment_score": "-0.271352", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.027826", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.114869", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.241673", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.140076", "ticker_sentiment_score": "0.333719", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LUV", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.171226", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.208764", "ticker_sentiment_score": "0.042868", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.086674", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.140076", "ticker_sentiment_score": "0.089648", "ticker_sentiment_label": "Neutral"}, {"ticker": "HES", "relevance_score": "0.140076", "ticker_sentiment_score": "0.091783", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.091484", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.334928", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMD", "relevance_score": "0.208764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.140076", "ticker_sentiment_score": "-0.109502", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.07031", "ticker_sentiment_score": "-0.151856", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.140076", "ticker_sentiment_score": "0.233796", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 Reasons Beam Therapeutics Remains a Risky Stock", "url": "https://www.fool.com/investing/2023/10/30/reasons-why-beam-therapeutics-remains-risky-stock/", "time_published": "20231030T131815", "authors": ["Jim Halley"], "summary": "Shares of the gene-editing biotech might not have hit rock bottom yet.", "banner_image": "https://g.foolcdn.com/editorial/images/752495/scientist-altering-dna-genome-project.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}, {"topic": "Earnings", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.083141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.40858", "ticker_sentiment_score": "0.147936", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.047559", "ticker_sentiment_score": "0.089913", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.047559", "ticker_sentiment_score": "0.089913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2174363/vertex-vrtx-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231030T130000", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/667.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.138299, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.361626", "ticker_sentiment_score": "0.020466", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.185781", "ticker_sentiment_score": "0.037942", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.185781", "ticker_sentiment_score": "0.061407", "ticker_sentiment_label": "Neutral"}]}, {"title": "With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?", "url": "https://www.fool.com/investing/2023/10/30/with-1-roadblock-down-is-verve-therapeutics-a-buy/", "time_published": "20231030T123000", "authors": ["Alex Carchidi"], "summary": "It takes more than starting a clinical trial to make for a good investment.", "banner_image": "https://g.foolcdn.com/editorial/images/752392/chemist-team-looking-beaker-of-green-chemical.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.247479, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.049526", "ticker_sentiment_score": "0.145115", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.049526", "ticker_sentiment_score": "0.145115", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.098862", "ticker_sentiment_score": "0.049007", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient", "url": "https://www.fool.com/investing/2023/10/30/gene-therapy-could-be-on-the-cusp-of-major-breakth/", "time_published": "20231030T123000", "authors": ["George Budwell"], "summary": "This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752824%2Fpharma-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.12974, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.051999", "ticker_sentiment_score": "0.013965", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.155118", "ticker_sentiment_score": "0.002808", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA staff raises concerns over lack of safety data for Sickle-Cell treatment", "url": "https://www.financialexpress.com/healthcare/news-healthcare/fda-staff-raises-concerns-over-lack-of-safety-data-for-sickle-cell-treatment/3290517/", "time_published": "20231030T033000", "authors": ["Bloomberg"], "summary": "The Food and Drug Administration's staff raised concerns about safety data on a potential gene-editing treatment for sickle cell disease, ahead of a closely watched meeting where scientific experts will weigh the first therapy using Crispr technology.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/06/red-blood-cell-4302097__340-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.024248, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.065685", "ticker_sentiment_score": "-0.167382", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRSP", "relevance_score": "0.065685", "ticker_sentiment_score": "-0.167382", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade", "url": "https://www.fool.com/investing/2023/10/28/want-1-million-in-retirement-invest-250000-in-thes/", "time_published": "20231028T095000", "authors": ["Keith Speights"], "summary": "4x returns in just a decade is quite an attainable result for these companies.", "banner_image": "https://g.foolcdn.com/editorial/images/751791/young-woman-smiling-hands-behind-head.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.192689, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEP", "relevance_score": "0.270773", "ticker_sentiment_score": "0.068254", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.09186", "ticker_sentiment_score": "0.051923", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.355588", "ticker_sentiment_score": "0.295692", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Declines More Than Market: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2174050/vertex-pharmaceuticals-vrtx-declines-more-than-market-some-information-for-investors", "time_published": "20231027T214516", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $355.28, denoting a -1.66% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default361.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.106554, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.654859", "ticker_sentiment_score": "0.128276", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher", "url": "https://www.investors.com/news/technology/rocket-pharmaceuticals-stock-sees-rs-rating-pops-higher/", "time_published": "20231027T184900", "authors": ["JULIE MAK", "Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Rocket Pharmaceuticals ( RCKT ) stock saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an increase from 69 to 74. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.445663, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RCKT", "relevance_score": "0.595343", "ticker_sentiment_score": "0.591509", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.261117", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.261117", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches - CRISPR Therapeutics  ( NASDAQ:CRSP ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35468228/questions-surround-vertexcrisprs-sickle-cell-gene-therapy-as-fda-adcomm-meeting-approaches", "time_published": "20231027T165700", "authors": ["Vandana Singh"], "summary": "The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next week, Tuesday, 31 October, to discuss whether Vertex Pharmaceuticals Inc VRTX and CRISPR Therapeutics AG's CRSP sickle cell disease ( SCD ) gene therapy candidate.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/27/vrtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.068552, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.3007", "ticker_sentiment_score": "0.094266", "ticker_sentiment_label": "Neutral"}]}, {"title": "US FDA advisers to determine need for more studies of Vertex/CRISPR gene therapy", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-consider-need-more-studies-vertexcrispr-gene-therapy-2023-10-27/", "time_published": "20231027T155700", "authors": ["Sriparna Roy"], "summary": "[1/2] Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Oct 27 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4QXBW6RP45FBRHDZQXLNRGX5UY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.080712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.110462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A new cure for sickle cell disease may be coming. Health advisers will review it next week", "url": "https://apnews.com/article/sickle-cell-gene-therapy-crispr-8ded5e3a35b30bd257ac756f8a223c51", "time_published": "20231027T154700", "authors": ["LAURA UNGAR"], "summary": "The only cure for painful sickle cell disease today is a bone marrow transplant. But soon there may be a new cure that attacks the disorder at its genetic source. On Tuesday, advisers to the Food and Drug Administration will review a gene therapy for the inherited blood disorder, which in the ...", "banner_image": "https://dims.apnews.com/dims4/default/fc0d84e/2147483647/strip/true/crop/1920x1080+0+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F32%2Fd8%2F506f39bee91eaf0afa37fd0cae9f%2F710392b627b84ac29ac636517ca96bd7", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.077006, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.043421", "ticker_sentiment_score": "-0.073293", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.043421", "ticker_sentiment_score": "0.106845", "ticker_sentiment_label": "Neutral"}, {"ticker": "HHH", "relevance_score": "0.043421", "ticker_sentiment_score": "0.164442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Incyte  ( INCY )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2173871/incyte-incy-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231027T153600", "authors": ["Zacks Equity Research"], "summary": "Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999917"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.189324, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.161349", "ticker_sentiment_score": "0.048938", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.722509", "ticker_sentiment_score": "0.243069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.161349", "ticker_sentiment_score": "0.146135", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.161349", "ticker_sentiment_score": "-0.001342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money", "url": "https://www.fool.com/investing/2023/10/27/got-1000-3-growth-stocks-to-buy-that-could-double/", "time_published": "20231027T141500", "authors": ["Rachel Warren"], "summary": "These companies come from very different industries, but each has businesses that investors may find compelling.", "banner_image": "https://g.foolcdn.com/editorial/images/752142/getty-smiling-person-with-phone.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.201372, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116161", "ticker_sentiment_score": "0.135385", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.266828", "ticker_sentiment_score": "0.190245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UPST", "relevance_score": "0.33884", "ticker_sentiment_score": "0.053564", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.038843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/10/27/2-healthcare-stocks-that-could-make-you-richer/", "time_published": "20231027T092000", "authors": ["Rachel Warren"], "summary": "The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.247522, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129052", "ticker_sentiment_score": "0.25619", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TDOC", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.102833", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.043186", "ticker_sentiment_score": "0.049687", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.043186", "ticker_sentiment_score": "0.007984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Azenta Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/azenta-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231027T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Azenta ( AZTA ) now clears that threshold, with a jump from 78 to 83 Friday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.287384, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZTA", "relevance_score": "0.618922", "ticker_sentiment_score": "0.358132", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.338582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.338582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Rhythm Pharmaceuticals Sees RS Rating Jump To 91", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-rhythm-pharmaceuticals-sees-rs-rating-jump-to-91/", "time_published": "20231027T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Stocks To Watch: Rhythm Pharmaceuticals Sees RS Rating Jump ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.410866, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.331765", "ticker_sentiment_score": "0.120368", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.169676", "ticker_sentiment_score": "0.294537", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.331765", "ticker_sentiment_score": "0.120368", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.608634", "ticker_sentiment_score": "0.506415", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rocket Pharmaceuticals Trying To Close In On Key Technical Measure", "url": "https://www.investors.com/ibd-data-stories/rocket-pharmaceuticals-trying-to-close-in-on-key-technical-measure/", "time_published": "20231027T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Rocket Pharmaceuticals Trying To Close In On Key Technical ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.476506, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RCKT", "relevance_score": "0.709186", "ticker_sentiment_score": "0.769715", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.327366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024", "url": "https://www.fool.com/investing/2023/10/26/this-market-beating-growth-stock-is-set-to-outperf/", "time_published": "20231026T140000", "authors": ["George Budwell"], "summary": "This rare disease company is on a roll.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752229%2Fgrowth-graph.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.269952, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.055364", "ticker_sentiment_score": "0.260988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.110462", "ticker_sentiment_score": "0.174915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.055364", "ticker_sentiment_score": "0.260988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.055364", "ticker_sentiment_score": "0.260988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.055364", "ticker_sentiment_score": "0.260988", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Healthcare Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/10/26/2-top-healthcare-stocks-defying-the-bear-market/", "time_published": "20231026T140000", "authors": ["Rachel Warren"], "summary": "These companies are building out their revenue and profit streams, and the proof is in the pudding.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.232862, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.107255", "ticker_sentiment_score": "0.248954", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.21258", "ticker_sentiment_score": "0.109427", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Best Healthcare Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/26/2-best-healthcare-stocks-to-buy-right-now/", "time_published": "20231026T131500", "authors": ["Rachel Warren"], "summary": "The healthcare industry is an explosive space full of promising, profitable companies.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.192651, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.113329", "ticker_sentiment_score": "0.194721", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.169279", "ticker_sentiment_score": "0.224401", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CRISPR  ( CRSP )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172563/crispr-crsp-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T122200", "authors": ["Zacks Equity Research"], "summary": "Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.119254, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.184834", "ticker_sentiment_score": "0.115115", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.184834", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.244723", "ticker_sentiment_score": "0.152148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.244723", "ticker_sentiment_score": "-0.027788", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly  ( LLY )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2172391/eli-lilly-lly-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231026T114000", "authors": ["Zacks Equity Research"], "summary": "On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.10472, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.417304", "ticker_sentiment_score": "0.022949", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.050098", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.216473", "ticker_sentiment_score": "0.025286", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.216473", "ticker_sentiment_score": "-0.026882", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals: Buy at the High?", "url": "https://www.fool.com/investing/2023/10/26/vertex-pharmaceuticals-buy-at-the-high/", "time_published": "20231026T101500", "authors": ["Adria Cimino"], "summary": "Vertex shares have been flying high in recent times.", "banner_image": "https://media.ycharts.com/charts/e991abaec0e078763739e30524d58c14.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.181345, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.057907", "ticker_sentiment_score": "-0.046965", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.115509", "ticker_sentiment_score": "0.033291", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Healthcare Stocks to Buy and Hold for the Next 10 Years", "url": "https://www.fool.com/investing/2023/10/26/healthcare-stocks-buy-and-hold-for-decade/", "time_published": "20231026T092000", "authors": ["Rachel Warren"], "summary": "Great healthcare businesses are out there and their stocks are ripe for the picking.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986714"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.079124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.088472", "ticker_sentiment_score": "0.113", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.175859", "ticker_sentiment_score": "0.143021", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.088472", "ticker_sentiment_score": "-0.168834", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "2 No-Brainer Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/26/2-no-brainer-growth-stocks-to-buy-right-now/", "time_published": "20231026T090500", "authors": ["Rachel Warren"], "summary": "These businesses are thriving and raking in profits.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.213973, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.056407", "ticker_sentiment_score": "0.098002", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.112532", "ticker_sentiment_score": "0.087797", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.520773", "ticker_sentiment_score": "0.22583", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Fantastic Growth Stocks to Buy Hand Over Fist", "url": "https://www.fool.com/investing/2023/10/26/2-fantastic-growth-stocks-to-buy-hand-over-fist/", "time_published": "20231026T090000", "authors": ["Adria Cimino"], "summary": "These stocks make great bargains today.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.275902, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.063763", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.424521", "ticker_sentiment_score": "0.347884", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bioventus  ( BVS )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2171824/bioventus-bvs-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231025T144800", "authors": ["Zacks Equity Research"], "summary": "On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.035925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.060241", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.181137", "ticker_sentiment_score": "0.103363", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.181137", "ticker_sentiment_score": "-0.002918", "ticker_sentiment_label": "Neutral"}, {"ticker": "BVS", "relevance_score": "0.59892", "ticker_sentiment_score": "0.158573", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Red-Hot Growth Stocks That Are Still Cheap Buys", "url": "https://www.fool.com/investing/2023/10/25/3-red-hot-growth-stocks-that-are-still-cheap-buys/", "time_published": "20231025T134500", "authors": ["David Jagielski"], "summary": "It's not too late to invest in these great businesses.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.188611, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.044636", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.148731", "ticker_sentiment_score": "0.131831", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.29234", "ticker_sentiment_score": "0.140743", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/10/25/2-biotech-stocks-you-can-buy-and-hold-for-the-next/", "time_published": "20231025T124500", "authors": ["Prosper Junior Bakiny"], "summary": "Neither has performed well on the stock market this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.121466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055751", "ticker_sentiment_score": "0.132896", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.273399", "ticker_sentiment_score": "0.068418", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2171289/amgen-amgn-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231025T112600", "authors": ["Zacks Equity Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.203947, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.219312", "ticker_sentiment_score": "0.114532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.215777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.272181", "ticker_sentiment_score": "0.030414", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.272181", "ticker_sentiment_score": "0.036737", "ticker_sentiment_label": "Neutral"}]}, {"title": "Axsome Therapeutics Hits 80-Plus Relative Strength Rating Benchmark", "url": "https://www.investors.com/ibd-data-stories/axsome-therapeutics-hits-80-plus-relative-strength-rating-benchmark/", "time_published": "20231025T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Axsome Therapeutics Hits 80-Plus Relative Strength Rating ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.33079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.495015", "ticker_sentiment_score": "0.217978", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcellx Clears Technical Benchmark, Hitting 90-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/arcellx-clears-technical-benchmark-hitting-90-plus-rs-rating/", "time_published": "20231025T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Wednesday, Arcellx ( ACLX ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 87 to 91. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.381172, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.598621", "ticker_sentiment_score": "0.49872", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.118507", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.166169", "ticker_sentiment_score": "0.294647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.325208", "ticker_sentiment_score": "0.118507", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sarepta Therapeutics Earns Relative Strength Rating Upgrade", "url": "https://www.investors.com/ibd-data-stories/sarepta-therapeutics-earns-relative-strength-rating-upgrade-2/", "time_published": "20231025T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, Sarepta Therapeutics ( SRPT ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 68 to 73. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.449638, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.705799", "ticker_sentiment_score": "0.750792", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/gilead-sciences-getting-closer-to-key-technical-benchmark/", "time_published": "20231025T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Gilead Sciences ( GILD ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 70 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.36311, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.159569", "ticker_sentiment_score": "0.145768", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.579393", "ticker_sentiment_score": "0.549012", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Apellis Pharmaceuticals Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-apellis-pharmaceuticals-shows-rising-relative-strength-4/", "time_published": "20231025T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Stock Upgrades: Apellis Pharmaceuticals Shows Rising Relative ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.311496, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.666827", "ticker_sentiment_score": "0.385131", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.301315", "ticker_sentiment_score": "0.113697", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.301315", "ticker_sentiment_score": "0.113697", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Market Leadership: Vericel Earns 92 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-market-leadership-vericel-earns-92-rs-rating-2/", "time_published": "20231025T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Vericel ( VCEL ) , which saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 88 to 92.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.428134, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.297661", "ticker_sentiment_score": "0.112591", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.151539", "ticker_sentiment_score": "0.274499", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.297661", "ticker_sentiment_score": "0.112591", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCEL", "relevance_score": "0.55533", "ticker_sentiment_score": "0.471294", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dynavax  ( DVAX )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2170685/dynavax-dvax-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231024T114500", "authors": ["Zacks Equity Research"], "summary": "On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999985"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.115226, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.060909", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.183895", "ticker_sentiment_score": "0.103042", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.301686", "ticker_sentiment_score": "0.232326", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.00295", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  to Report Q3 Earnings: Here's What to Expect", "url": "https://www.zacks.com/stock/news/2170681/pfizer-pfe-to-report-q3-earnings-heres-what-to-expect", "time_published": "20231024T113900", "authors": ["Zacks Equity Research"], "summary": "Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.057075, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.188928", "ticker_sentiment_score": "0.102132", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.234911", "ticker_sentiment_score": "0.026995", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.489057", "ticker_sentiment_score": "0.065703", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.234911", "ticker_sentiment_score": "0.032619", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.047654", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $5,000 In Right Now", "url": "https://www.fool.com/investing/2023/10/24/the-best-stocks-to-invest-5000-in-right-now/", "time_published": "20231024T093000", "authors": ["Adria Cimino"], "summary": "Today, the following three healthcare players look like fantastic bargains.", "banner_image": "https://media.ycharts.com/charts/9580ab8fffe7217f39b1987355fdd495.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.323116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.102668", "ticker_sentiment_score": "0.183773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.102668", "ticker_sentiment_score": "0.214111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.203643", "ticker_sentiment_score": "0.121416", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.102668", "ticker_sentiment_score": "0.175114", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ACADIA Pharmaceuticals Shows Market Leadership With Jump To 84 RS Rating", "url": "https://www.investors.com/ibd-data-stories/acadia-pharmaceuticals-shows-market-leadership-with-jump-to-84-rs-rating/", "time_published": "20231024T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "ACADIA Pharmaceuticals Shows Market Leadership With Jump To ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.326184, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.468029", "ticker_sentiment_score": "0.502693", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks With Rising Relative Price Strength: Viking Therapeutics", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-viking-therapeutics/", "time_published": "20231024T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Viking Therapeutics ( VKTX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an increase from 87 to 92. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.393054, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.31282", "ticker_sentiment_score": "0.117139", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.579393", "ticker_sentiment_score": "0.552021", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.117139", "ticker_sentiment_label": "Neutral"}]}, {"title": "Apellis Pharmaceuticals Stock Shows Rising Relative Strength", "url": "https://www.investors.com/news/stock-upgrades-apellis-pharmaceuticals-shows-rising-relative-strength-3/", "time_published": "20231024T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "GLENN LARKIN", "Investor's Business Daily"], "summary": "Stock Upgrades: Apellis Pharmaceuticals Shows Rising Relative ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.393879, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.465901", "ticker_sentiment_score": "0.434494", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.244109", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.123526", "ticker_sentiment_score": "0.152796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.244109", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Increases Despite Market Slip: Here's What You Need to Know", "url": "https://www.zacks.com/stock/news/2170469/vertex-pharmaceuticals-vrtx-increases-despite-market-slip-heres-what-you-need-to-know", "time_published": "20231023T215018", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $367.66, denoting a +1.6% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.995921"}], "overall_sentiment_score": 0.142759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.50605", "ticker_sentiment_score": "0.191827", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Intellia  ( NTLA )  Focuses on Developing Gene-Editing Therapies", "url": "https://www.zacks.com/stock/news/2170217/intellia-ntla-focuses-on-developing-gene-editing-therapies", "time_published": "20231023T134000", "authors": ["Zacks Equity Research"], "summary": "Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.261376, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.237358", "ticker_sentiment_score": "0.478488", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.159569", "ticker_sentiment_score": "0.053858", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.868974", "ticker_sentiment_score": "0.436411", "ticker_sentiment_label": "Bullish"}]}, {"title": "Merck  ( MRK )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2170134/merck-mrk-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231023T112500", "authors": ["Zacks Equity Research"], "summary": "Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.153023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.206245", "ticker_sentiment_score": "-0.024239", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.305058", "ticker_sentiment_score": "0.100231", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.052112", "ticker_sentiment_score": "0.171568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.256179", "ticker_sentiment_score": "-0.02884", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Unstoppable Stocks to Buy Sooner Rather Than Later", "url": "https://www.fool.com/investing/2023/10/22/3-unstoppable-stocks-to-buy-sooner-rather-than-lat/", "time_published": "20231022T105500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "Now is the time to invest in these great stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.172773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.287441", "ticker_sentiment_score": "0.100872", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.166743", "ticker_sentiment_score": "0.014889", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.326283", "ticker_sentiment_score": "0.046633", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics Stock: Bull vs. Bear", "url": "https://www.fool.com/investing/2023/10/21/crispr-therapeutics-stock-bull-vs-bear/", "time_published": "20231021T224500", "authors": ["Keith Speights and Adria Cimino"], "summary": "Here's the scoop on one of the most widely followed gene-editing stocks on the market.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}], "overall_sentiment_score": 0.19816, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.060085", "ticker_sentiment_score": "-0.031007", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.060085", "ticker_sentiment_score": "0.202055", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/21/vertex-pharmaceuticals-nasdaqvrtx-upgraded-at-stocknews-com.html", "time_published": "20231021T072644", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX ) Upgraded at StockNews ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.803643"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.317036, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSD", "relevance_score": "0.043186", "ticker_sentiment_score": "0.137505", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.043186", "ticker_sentiment_score": "0.081342", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.043186", "ticker_sentiment_score": "0.081342", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNB", "relevance_score": "0.086245", "ticker_sentiment_score": "0.19652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.744539", "ticker_sentiment_score": "0.471326", "ticker_sentiment_label": "Bullish"}, {"ticker": "FAST", "relevance_score": "0.043186", "ticker_sentiment_score": "0.137505", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUB", "relevance_score": "0.086245", "ticker_sentiment_score": "0.19652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VLEEF", "relevance_score": "0.086245", "ticker_sentiment_score": "0.19652", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/10/35358746/a-look-into-vertex-pharmaceuticals-incs-price-over-earnings", "time_published": "20231020T204538", "authors": ["Benzinga Insights"], "summary": "In the current market session, Vertex Pharmaceuticals Inc. VRTX stock price is at $361.86, after a 0.81% decrease. However, over the past month, the company's stock went up by 3.53%, and in the past year, by 16.54%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": -0.079629, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.419153", "ticker_sentiment_score": "-0.064286", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/10/20/3-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20231020T095000", "authors": ["Keith Speights"], "summary": "These big stocks could become a lot bigger.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.295631, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MA", "relevance_score": "0.104911", "ticker_sentiment_score": "0.176519", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.104911", "ticker_sentiment_score": "0.216626", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.355588", "ticker_sentiment_score": "0.356613", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intellia's  ( NTLA )  IND for Gene-Editing Therapy Gets FDA Clearance", "url": "https://www.zacks.com/stock/news/2169049/intellias-ntla-ind-for-gene-editing-therapy-gets-fda-clearance", "time_published": "20231019T154600", "authors": ["Zacks Equity Research"], "summary": "Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.206486, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.270773", "ticker_sentiment_score": "0.502456", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.182506", "ticker_sentiment_score": "0.059067", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.644033", "ticker_sentiment_score": "0.360918", "ticker_sentiment_label": "Bullish"}]}, {"title": "GILD or VRTX: Which Is the Better Value Stock Right Now?", "url": "https://www.zacks.com/stock/news/2169033/gild-or-vrtx-which-is-the-better-value-stock-right-now", "time_published": "20231019T154012", "authors": ["Zacks Equity Research"], "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.468652, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.606706", "ticker_sentiment_score": "0.49223", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.77735", "ticker_sentiment_score": "0.575786", "ticker_sentiment_label": "Bullish"}]}, {"title": "4 Ways to Grow $100,000 Into $1 Million for Retirement", "url": "https://www.fool.com/investing/2023/10/19/4-ways-to-grow-100000-into-1-million-for-retiremen/", "time_published": "20231019T131300", "authors": ["Jim Halley"], "summary": "Investing for big-time growth doesn't have to be risky.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.999966"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.206499, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.115787", "ticker_sentiment_score": "0.122393", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.077343", "ticker_sentiment_score": "0.050792", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.077343", "ticker_sentiment_score": "0.055791", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.115787", "ticker_sentiment_score": "0.097293", "ticker_sentiment_label": "Neutral"}, {"ticker": "O", "relevance_score": "0.115787", "ticker_sentiment_score": "0.0852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now", "url": "https://www.zacks.com/stock/news/2168656/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now", "time_published": "20231019T125005", "authors": ["Zacks Equity Research"], "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default356.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999326"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.358915, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.33446", "ticker_sentiment_score": "0.306402", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THC", "relevance_score": "0.396052", "ticker_sentiment_score": "0.398657", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Under-the-Radar Biotech Stocks to Buy in 2023", "url": "https://www.fool.com/investing/2023/10/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/", "time_published": "20231019T121500", "authors": ["Jim Halley"], "summary": "These three lesser-known biotech companies are profitable and growing revenue.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149308, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.20279", "ticker_sentiment_score": "0.048305", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051221", "ticker_sentiment_score": "0.070937", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.016493", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling - Gilead Sciences  ( NASDAQ:GILD ) , HubSpot  ( NYSE:HUBS ) ", "url": "https://www.benzinga.com/news/23/10/35326531/vertex-pharmaceuticals-gilead-sciences-and-2-other-stocks-insiders-are-selling", "time_published": "20231019T114201", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/19/gilead_sciences_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.02414, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.042918", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.495015", "ticker_sentiment_score": "-0.050696", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.421485", "ticker_sentiment_score": "0.130694", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.421485", "ticker_sentiment_score": "0.028882", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.088472", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks Set to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2168288/5-biotech-stocks-set-to-outpace-q3-earnings-estimates", "time_published": "20231018T152000", "authors": ["Zacks Equity Research"], "summary": "Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.170488, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.30569", "ticker_sentiment_score": "0.052098", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.353418", "ticker_sentiment_score": "-0.064866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.353418", "ticker_sentiment_score": "0.073833", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.399734", "ticker_sentiment_score": "0.11986", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.353418", "ticker_sentiment_score": "0.115454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stumbles As It Aims For A First-Ever In CRISPR Gene Editing", "url": "https://www.investors.com/news/technology/ntla-stock-stumbles-as-intellia-aims-for-a-first-ever-in-crispr-gene-editing/", "time_published": "20231018T143800", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "The Food and Drug Administration gave Intellia Therapeutics ( NTLA ) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed lower at the open.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-intelliatherapeutics-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.054805, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.034344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.192694", "ticker_sentiment_score": "0.359459", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.606706", "ticker_sentiment_score": "-0.145803", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hyloris Pharma wins US FDA approval for pain treatment", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/hyloris-pharma-wins-us-fda-approval-pain-treatment-2023-10-18/", "time_published": "20231018T001035", "authors": ["Reuters"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/MWQBX4AG7VIENJLNKQYZCBNVSQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.125905, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13459", "ticker_sentiment_score": "0.135121", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.13459", "ticker_sentiment_score": "0.213369", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Health Canada Grants Market Authorization for TRIKAFTA\u00ae  ( elexacaftor/tezacaftor/ivacaftor and ivacaftor )  in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation", "url": "https://www.newswire.ca/news-releases/health-canada-grants-market-authorization-for-trikafta-r-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-2-to-5-years-with-at-least-one-f508del-mutation-858010273.html", "time_published": "20231017T184400", "authors": ["Vertex Pharmaceuticals (Canada) Inc."], "summary": "Health Canada Grants Market Authorization for TRIKAFTA\u00ae ( elexacaftor/tezacaftor/ivacaftor and ivacaftor ) in Children ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/2249938/Vertex_Pharmaceuticals__Canada__Inc__Health_Canada_Grants_Market.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.13081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.131105", "ticker_sentiment_score": "0.13335", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges - bluebird bio  ( NASDAQ:BLUE ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35294513/cautious-optimism-for-bluebird-bios-sickle-cell-therapy-analyst-sees-financial-chal", "time_published": "20231017T184007", "authors": ["Vandana Singh"], "summary": "Cantor Fitzgerald initiated coverage on Bluebird Bio Inc BLUE, saying sickle cell disorder ( SCD ) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/aapharma_7.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.06938, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.143415", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.6338", "ticker_sentiment_score": "0.325467", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst - Editas Medicine  ( NASDAQ:EDIT ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35295251/editas-medicine-has-to-navigate-sickle-cell-therapy-competition-analyst", "time_published": "20231017T183555", "authors": ["Vandana Singh"], "summary": "Cantor Fitzgerald has downgraded Editas Medicine Inc EDIT to Neutral from Overweight. The analyst says that Editas' sickle cell therapy EDIT-301 is running approximately two years behind Vertex Pharmaceuticals/CRISPR Therapeutics AG's CRSP exa-cel and Bluebird Bio Inc's BLUE lovo-cel.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/edit.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.137726, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.268294", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.769861", "ticker_sentiment_score": "0.161563", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy - CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35295139/mixed-signals-for-crispr-therapeutics-analyst-weighs-barriers-potential-sales-for-sickle-cell-the", "time_published": "20231017T183307", "authors": ["Vandana Singh"], "summary": "Cantor Fitzgerald has downgraded CRISPR Therapeutics AG CRSP to Neutral from Overweight, noting that its sickle cell therapy, exa-cel, in partnership with Vertex Pharmaceuticals Inc VRTX, is expected to be approved on or around its PDUFA date ( 8 December ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/crsp.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.196698, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.295867", "ticker_sentiment_score": "0.015371", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.657566", "ticker_sentiment_score": "0.400092", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Vertex  ( VRTX )  is Poised to Beat Earnings Estimates Again", "url": "https://www.zacks.com/stock/news/2167418/why-vertex-vrtx-is-poised-to-beat-earnings-estimates-again", "time_published": "20231017T161009", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.334272, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.170275", "ticker_sentiment_score": "0.207948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vericel Scores Relative Strength Rating Upgrade; Hits Key Threshold", "url": "https://www.investors.com/ibd-data-stories/vericel-scores-relative-strength-rating-upgrade-hits-key-threshold/", "time_published": "20231017T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vericel Scores Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.358109, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VCEL", "relevance_score": "0.629492", "ticker_sentiment_score": "0.561156", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Nasdaq Biotechs With New 52-Week Highs", "url": "https://www.forbes.com/sites/johnnavin/2023/10/16/3-nasdaq-biotechs-with-new-52-week-highs/", "time_published": "20231017T010431", "authors": ["John Navin"], "summary": "Biotech stocks are having a bad year with the XBI trending downward for months now, but at least 3 Nasdaq-traded biotechnology companies are now hitting 52-week highs:...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/652ddc39658bdbc31402ec6f/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.095073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.086808", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLT", "relevance_score": "0.240489", "ticker_sentiment_score": "0.08856", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.053934", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Increases Yet Falls Behind Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2166753/vertex-pharmaceuticals-vrtx-increases-yet-falls-behind-market-what-investors-need-to-know", "time_published": "20231016T215019", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $374, denoting a +0.81% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.153602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.459624", "ticker_sentiment_score": "0.248314", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 4 Promising Biotech Stocks for Smart Investment Strategies", "url": "https://stocknews.com/news/gild-vrtx-uthr-jazz-4-promising-biotech-stocks-for-smart-investment-strategies/", "time_published": "20231016T192531", "authors": ["StockNews.com Staff"], "summary": "The biotechnology sector has thrived exceptionally over the past few years, catalyzed by continued innovations that fortify its status as a vanguard in crucial sectors like healthcare, agriculture, and the environment.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_357740228-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.333881, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.082464", "ticker_sentiment_score": "0.099953", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12342", "ticker_sentiment_score": "0.218092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.102976", "ticker_sentiment_score": "0.164116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.102976", "ticker_sentiment_score": "0.07271", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This Top 1% Biotech Just Surged Within Striking Distance Of A Breakout", "url": "https://www.investors.com/news/technology/mltx-stock-top-rated-biotech-surges-within-striking-distance-of-a-breakout/", "time_published": "20231016T144100", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Why This Top 1% Biotech Just Surged Within Striking Distance Of A ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-drug-opioid-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.207534, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.086245", "ticker_sentiment_score": "0.318982", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.254751", "ticker_sentiment_score": "0.3435", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MLTX", "relevance_score": "0.551622", "ticker_sentiment_score": "0.311099", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Moderna, BioNTech Leads Covid Sell-Off After Pfizer Slashes Outlook", "url": "https://www.investors.com/news/technology/moderna-stock-biontech-stock-lead-covid-sell-off-after-pfizer-slashes-guidance/", "time_published": "20231016T141800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Moderna ( MRNA ) stock and BioNTech ( BNTX ) led a sell-off Monday among Covid vaccine makers after Pfizer ( PFE ) slashed about $9 billion from its full-year guidance. Pfizer said it wrote off about $5.5 billion in inventory during the third quarter due to lower-than-expected demand for ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/08/stock-Pfizer-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}], "overall_sentiment_score": 0.091058, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.067919", "ticker_sentiment_score": "0.309934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.201507", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.329992", "ticker_sentiment_score": "-0.014699", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.651499", "ticker_sentiment_score": "0.118694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.449219", "ticker_sentiment_score": "-0.045032", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks Near 52-Week Highs Still Worth Buying", "url": "https://www.fool.com/investing/2023/10/16/2-healthcare-stocks-near-52-week-highs-still-worth/", "time_published": "20231016T132600", "authors": ["George Budwell"], "summary": "These two large-cap biopharma companies could have more room to run.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F751034%2Fgrowth-stock.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.329024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.349575", "ticker_sentiment_score": "0.21068", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.349575", "ticker_sentiment_score": "0.33828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.072217", "ticker_sentiment_score": "0.170891", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.143843", "ticker_sentiment_score": "0.230118", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street", "url": "https://www.fool.com/investing/2023/10/16/cathie-wood-stock-may-soar-says-wall-street/", "time_published": "20231016T093000", "authors": ["Adria Cimino"], "summary": "This Wood favorite is heading for a big moment.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.312727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.158173", "ticker_sentiment_score": "0.104372", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revolution Medicines Joins Elite Club Of Stocks With RS Ratings Over 90", "url": "https://www.investors.com/ibd-data-stories/revolution-medicines-joins-elite-club-of-stocks-with-rs-ratings-over-90-2/", "time_published": "20231016T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Revolution Medicines Joins Elite Club Of Stocks With RS Ratings ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.381377, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.11597", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.157483", "ticker_sentiment_score": "0.266406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.308891", "ticker_sentiment_score": "0.11597", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.573213", "ticker_sentiment_score": "0.345017", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ionis Pharmaceuticals Clears Key Benchmark, Hitting 90-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/ionis-pharmaceuticals-clears-key-benchmark-hitting-90-plus-rs-rating-2/", "time_published": "20231016T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Ionis Pharmaceuticals Clears Key Benchmark, Hitting 90-Plus RS ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.366708, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.115394", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.570165", "ticker_sentiment_score": "0.408389", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.306963", "ticker_sentiment_score": "0.115394", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Growth Stocks That Could Double Your Money, According to Wall Street", "url": "https://www.fool.com/investing/2023/10/15/2-growth-stocks-that-could-double-your-money-accor/", "time_published": "20231015T104700", "authors": ["Cory Renauer"], "summary": "Find out why investment bank analysts are pounding the table on these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750873%2Fsmart-investor-with-wall-street-journal-picking-stocks-to-buy.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.101185, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAK", "relevance_score": "0.057628", "ticker_sentiment_score": "0.088", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057628", "ticker_sentiment_score": "0.113972", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.335519", "ticker_sentiment_score": "0.162259", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Vertex Pharmaceuticals Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/10/15/is-vertex-pharmaceuticals-stock-a-buy-now/", "time_published": "20231015T101800", "authors": ["David Jagielski"], "summary": "Jim Cramer recently hyped up one of the company's promising drugs.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995015"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.386593, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.11894", "ticker_sentiment_score": "0.370904", "ticker_sentiment_label": "Bullish"}]}, {"title": "StockNews.com Downgrades Vertex Pharmaceuticals  ( NASDAQ:VRTX )  to Buy", "url": "https://www.defenseworld.net/2023/10/15/stocknews-com-downgrades-vertex-pharmaceuticals-nasdaqvrtx-to-buy.html", "time_published": "20231015T064254", "authors": ["Defense World Staff"], "summary": "StockNews.com Downgrades Vertex Pharmaceuticals ( NASDAQ ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.274591, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.047185", "ticker_sentiment_score": "0.075143", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.826469", "ticker_sentiment_score": "0.450451", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.047185", "ticker_sentiment_score": "0.075143", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years", "url": "https://www.fool.com/investing/2023/10/14/2-growth-stocks-that-could-deliver-parabolic-retur/", "time_published": "20231014T162022", "authors": ["George Budwell"], "summary": "These two gene-editing stocks could be diamonds in the rough.", "banner_image": "https://media.ycharts.com/charts/13a23d9c41fd1008fa98d5440b7c7580.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.21784, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055109", "ticker_sentiment_score": "0.127992", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.060122", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.128748", "ticker_sentiment_label": "Neutral"}, {"ticker": "IEX", "relevance_score": "0.055109", "ticker_sentiment_score": "0.060122", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.055109", "ticker_sentiment_score": "0.067012", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.552966", "ticker_sentiment_score": "0.358668", "ticker_sentiment_label": "Bullish"}]}, {"title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35248116/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-500-today", "time_published": "20231013T200025", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 7.47% on an annualized basis producing an average annual return of 17.0%. Currently, Vertex Pharmaceuticals has a market capitalization of $95.13 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Here's Why You May Invest in CRISPR Therapeutics  ( CRSP )  Stock", "url": "https://www.zacks.com/stock/news/2165644/heres-why-you-may-invest-in-crispr-therapeutics-crsp-stock", "time_published": "20231013T142200", "authors": ["Zacks Equity Research"], "summary": "Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.18024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DCPH", "relevance_score": "0.249744", "ticker_sentiment_score": "0.054496", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.188683", "ticker_sentiment_score": "0.088687", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIX", "relevance_score": "0.30928", "ticker_sentiment_score": "0.034508", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.249744", "ticker_sentiment_score": "0.236016", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Surprising Opportunity Driving Vertex Stock To A Record High", "url": "https://www.investors.com/research/the-new-america/vrtx-stock-breaks-out-to-a-record-high-the-surprising-opportunity/", "time_published": "20231012T191700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Almost three-quarters of prescribed pain meds are opioids, and Vertex Pharmaceuticals ( VRTX ) could change that, an analyst said before VRTX stock broke out to a record high Thursday. Leerink Partners analyst David Risinger drew parallels between the drug development arc for obesity drugs and ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/wNAvertPersc101623.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": -0.12148, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.50287", "ticker_sentiment_score": "0.052359", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.049221", "ticker_sentiment_score": "0.208107", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.049221", "ticker_sentiment_score": "0.208107", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.049221", "ticker_sentiment_score": "-0.117904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Falls As Nasdaq Holds Key Level; Bank Earnings Loom", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-after-economic-data-as-nasdaq-holds-key-level-bank-earnings-loom/", "time_published": "20231012T150700", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Falls As Nasdaq Holds Key Level. Bank Earnings Loom Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-GlobalFoundries-nasdaq-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999491"}, {"topic": "Earnings", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.108398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.104228", "ticker_sentiment_score": "0.117321", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.104228", "ticker_sentiment_score": "0.160705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EG", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.152018", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "C", "relevance_score": "0.104228", "ticker_sentiment_score": "0.117321", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.104228", "ticker_sentiment_score": "0.117321", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.104228", "ticker_sentiment_score": "0.199842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.152018", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDB", "relevance_score": "0.104228", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.019318", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.155786", "ticker_sentiment_score": "0.115069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.104228", "ticker_sentiment_score": "0.098951", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.052226", "ticker_sentiment_score": "0.089009", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.104228", "ticker_sentiment_score": "0.152018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARGX", "relevance_score": "0.104228", "ticker_sentiment_score": "0.129238", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAST", "relevance_score": "0.104228", "ticker_sentiment_score": "0.140081", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/12/2-top-biotech-stocks-to-buy-right-now/", "time_published": "20231012T133700", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies are known innovators.", "banner_image": "https://media.ycharts.com/charts/dbfc587c384e5d4e4783a3f4889228b7.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99737"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.159876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.367606", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.215415", "ticker_sentiment_score": "0.362586", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Top Healthcare Stocks to Buy for October", "url": "https://www.fool.com/investing/2023/10/12/3-top-healthcare-stocks-to-buy-for-october/", "time_published": "20231012T133648", "authors": ["Rachel Warren"], "summary": "These stocks have oodles of room left to run.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.269776, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089797", "ticker_sentiment_score": "0.185757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.134339", "ticker_sentiment_score": "0.046252", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Improved Relative Strength: Alkermes", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improved-relative-strength-alkermes/", "time_published": "20231012T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Alkermes ( ALKS ) had its Relative Strength ( RS ) Rating upgraded from 70 to 74 Thursday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.299596, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.712594", "ticker_sentiment_score": "0.304275", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Flashing Renewed Technical Strength: Sarepta Therapeutics", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-sarepta-therapeutics/", "time_published": "20231012T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Sarepta Therapeutics ( SRPT ) , which had its Relative Strength ( RS ) Rating upgraded from 78 to 81 Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.415855, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.149656", "ticker_sentiment_score": "0.223507", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCM", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.654522", "ticker_sentiment_score": "0.407939", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2164069/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20231011T102006", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default245.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}]}, {"title": "BEAM Focuses on Developing Gene Drug for Growth", "url": "https://www.zacks.com/stock/news/2163582/beam-focuses-on-developing-gene-drug-for-growth", "time_published": "20231010T140600", "authors": ["Zacks Equity Research"], "summary": "While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.136294, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.841282", "ticker_sentiment_score": "0.198586", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.237358", "ticker_sentiment_score": "0.060948", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.237358", "ticker_sentiment_score": "0.293729", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?", "url": "https://www.fool.com/investing/2023/10/10/cathie-wood-buys-crispr-therapeutics-should-you/", "time_published": "20231010T093000", "authors": ["Adria Cimino"], "summary": "Wood has outperformed the market so far this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.257338, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.103109", "ticker_sentiment_score": "0.069557", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Falls Amid Market Uptick: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2162978/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know", "time_published": "20231009T215018", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $355.20, indicating a -1.5% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.152229, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.598621", "ticker_sentiment_score": "0.250964", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight", "url": "https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html", "time_published": "20231009T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009725, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036338", "ticker_sentiment_score": "0.033442", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.124364", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.036338", "ticker_sentiment_score": "0.036038", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036338", "ticker_sentiment_score": "0.034129", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054483", "ticker_sentiment_score": "0.032874", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.029703", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPN", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.018173", "ticker_sentiment_score": "0.033264", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036338", "ticker_sentiment_score": "0.029364", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.018173", "ticker_sentiment_score": "0.026267", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.036338", "ticker_sentiment_score": "0.047119", "ticker_sentiment_label": "Neutral"}]}, {"title": "Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35149268/jim-cramers-take-on-vertex-tackling-opioid-addiction-with-new-drug-in-pipeline", "time_published": "20231009T182824", "authors": ["Vandana Singh"], "summary": "CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals VRTX, a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain. The company's potential candidate, known as VX-548, is being positioned to address the critical issue of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/09/vrtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.168745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.392948", "ticker_sentiment_score": "0.571781", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.507107", "ticker_sentiment_score": "0.089971", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Growth Stocks to Buy in October", "url": "https://www.fool.com/investing/2023/10/07/3-no-brainer-growth-stocks-to-buy-in-october/", "time_published": "20231007T105300", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "The time is right to invest in these great stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.274002, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.232439", "ticker_sentiment_score": "0.217617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.156207", "ticker_sentiment_score": "0.168497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.269776", "ticker_sentiment_score": "0.307637", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Rating Lowered to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/10/07/vertex-pharmaceuticals-nasdaqvrtx-rating-lowered-to-buy-at-stocknews-com.html", "time_published": "20231007T065646", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX ) Rating Lowered to Buy at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.933642"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.286586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.731711", "ticker_sentiment_score": "0.440448", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.044141", "ticker_sentiment_score": "0.037317", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.044141", "ticker_sentiment_score": "0.037317", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.044141", "ticker_sentiment_score": "0.167677", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer: This Company Is 'Arranging Deck Chairs On The Titanic... Not A Believer' - BlackBerry  ( NYSE:BB ) , Kyndryl Hldgs  ( NYSE:KD ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/10/35122422/jim-cramer-this-company-is-arranging-deck-chairs-on-the-titanic-not-a-believer", "time_published": "20231006T130802", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Topgolf Callaway Brands Corp. MODG is making money. \"I think it's a great experiential situation, but I have been wrong,\" he added. When asked about Under Armour, Inc. UA, he said, \"We got to see something, we got to see a good quarter.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/jim_cramer_nyse_shutter.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.086817, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BB", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.139638", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.013686", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODG", "relevance_score": "0.382925", "ticker_sentiment_score": "-0.164945", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CLSD", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.038851", "ticker_sentiment_label": "Neutral"}, {"ticker": "SABR", "relevance_score": "0.495015", "ticker_sentiment_score": "-0.041848", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.261117", "ticker_sentiment_score": "0.442191", "ticker_sentiment_label": "Bullish"}, {"ticker": "KD", "relevance_score": "0.382925", "ticker_sentiment_score": "0.149016", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.382925", "ticker_sentiment_score": "0.024465", "ticker_sentiment_label": "Neutral"}]}, {"title": "HP, Zoom Video And 2 Other Stocks Insiders Are Selling - HP  ( NYSE:HPQ ) , FirstCash Hldgs  ( NASDAQ:FCFS ) ", "url": "https://www.benzinga.com/news/23/10/35124492/hp-zoom-video-and-2-other-stocks-insiders-are-selling", "time_published": "20231006T120133", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed lower by over 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/zoom_video_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.175088, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.345674", "ticker_sentiment_score": "0.113542", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.059394", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.089129", "ticker_sentiment_score": "0.136751", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCFS", "relevance_score": "0.345674", "ticker_sentiment_score": "0.397567", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZM", "relevance_score": "0.424317", "ticker_sentiment_score": "0.311146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPE", "relevance_score": "0.089129", "ticker_sentiment_score": "0.016787", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Investment Ideas feature highlights: Applied Industrial, Applied Materials and Vertex Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2161280/zacks-investment-ideas-feature-highlights-applied-industrial-applied-materials-and-vertex-pharmaceuticals", "time_published": "20231006T083300", "authors": ["Zacks Investment Research"], "summary": "Applied Industrial, Applied Materials and Vertex Pharmaceuticals have been highlighted in this Investment Ideas article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6c/385.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.297374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AIT", "relevance_score": "0.3986", "ticker_sentiment_score": "0.194182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.290952", "ticker_sentiment_score": "0.070744", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.345674", "ticker_sentiment_score": "0.340578", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures: Jobs Report Looms; 7 Stocks Boasting This Bullish Trait", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-slash-sharp-losses-with-jobs-report-due-nvidia-meta-at-key-levels/", "time_published": "20231005T220200", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: Stocks Slash Losses With Jobs Report Due ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/03/BIGPIC-032316-shutterstock.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.088702, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AEHR", "relevance_score": "0.134741", "ticker_sentiment_score": "-0.107243", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLYS", "relevance_score": "0.161349", "ticker_sentiment_score": "0.130037", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.081092", "ticker_sentiment_score": "0.043715", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.213988", "ticker_sentiment_score": "0.063194", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.187775", "ticker_sentiment_score": "0.057362", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.291077", "ticker_sentiment_score": "0.134277", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.161349", "ticker_sentiment_score": "0.086501", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.081092", "ticker_sentiment_score": "0.047788", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Ranked Stocks with Superior Free Cash Flow Yield", "url": "https://www.zacks.com/commentary/2161054/3-top-ranked-stocks-with-superior-free-cash-flow-yield", "time_published": "20231005T183100", "authors": ["Ethan Feller"], "summary": "In this article, we'll introduce you to three standout stocks with impressive FCF yields, remarkable historical returns, and top Zacks Ranks ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/50121.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.303993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AIT", "relevance_score": "0.359014", "ticker_sentiment_score": "0.206919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.244109", "ticker_sentiment_score": "0.072995", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.302429", "ticker_sentiment_score": "0.35777", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street", "url": "https://www.fool.com/investing/2023/10/05/2-growth-stocks-that-can-rocket-98-to-108-higher-a/", "time_published": "20231005T093900", "authors": ["Cory Renauer"], "summary": "The analysts who follow these stocks have some big expectations for the year ahead.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749803%2Finvestment-advisor-with-client-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.145023, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.063594", "ticker_sentiment_score": "0.087047", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIMS", "relevance_score": "0.189175", "ticker_sentiment_score": "0.050037", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Stocks to Buy With $1,000 Right Now", "url": "https://www.fool.com/investing/2023/10/04/3-no-brainer-stocks-to-buy-with-1000-right-now/", "time_published": "20231004T092100", "authors": ["Sean Williams"], "summary": "A modest amount of money can go a long way when it's invested in highly profitable industry leaders with sustained competitive advantages.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749447%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999987"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.2413, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.118064", "ticker_sentiment_score": "0.040623", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.118064", "ticker_sentiment_score": "0.155717", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.147276", "ticker_sentiment_score": "0.188698", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?", "url": "https://www.fool.com/investing/2023/10/03/cathie-wood-is-buying-this-stock-hand-over-fist-la/", "time_published": "20231003T102700", "authors": ["Cory Renauer"], "summary": "The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749463%2Findividual-investor-devices-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}], "overall_sentiment_score": 0.038475, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.676963", "ticker_sentiment_score": "0.05652", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.056275", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.056275", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056275", "ticker_sentiment_score": "0.145936", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in October", "url": "https://www.fool.com/investing/2023/10/03/2-top-biotech-stocks-to-buy-in-october/", "time_published": "20231003T093000", "authors": ["Adria Cimino"], "summary": "Growth catalysts lie ahead for both of these players.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.314084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.173333", "ticker_sentiment_score": "0.17143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.058188", "ticker_sentiment_score": "0.174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.058188", "ticker_sentiment_score": "0.014064", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.173333", "ticker_sentiment_score": "0.118718", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2158860/vertex-pharmaceuticals-vrtx-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231002T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $347.83, marking a +0.03% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default222.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.194058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.663374", "ticker_sentiment_score": "0.374305", "ticker_sentiment_label": "Bullish"}]}, {"title": "Revvity's  ( RVTY )  New Launch to Widen Access to Editing Technology", "url": "https://www.zacks.com/stock/news/2158739/revvitys-rvty-new-launch-to-widen-access-to-editing-technology", "time_published": "20231002T141000", "authors": ["Zacks Equity Research"], "summary": "Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.271419, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.177475", "ticker_sentiment_score": "0.191238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVTR", "relevance_score": "0.177475", "ticker_sentiment_score": "0.19792", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTLT", "relevance_score": "0.177475", "ticker_sentiment_score": "0.203957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RVTY", "relevance_score": "0.305328", "ticker_sentiment_score": "0.244962", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Got $1,000? 2 No-Brainer Stocks to Buy", "url": "https://www.fool.com/investing/2023/10/02/got-1000-2-no-brainer-stocks-to-buy/", "time_published": "20231002T140700", "authors": ["Prosper Junior Bakiny"], "summary": "You can bet the farm on these companies.", "banner_image": "https://media.ycharts.com/charts/1feb20a0cd8df7bbad6c869c67537588.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.292878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MA", "relevance_score": "0.05833", "ticker_sentiment_score": "0.173", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.285526", "ticker_sentiment_score": "0.296181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.441698", "ticker_sentiment_score": "0.352882", "ticker_sentiment_label": "Bullish"}]}, {"title": "Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/10/02/better-gene-editing-stock-editas-medicine-vs-crisp/", "time_published": "20231002T140000", "authors": ["Alex Carchidi"], "summary": "The better of the pair should be able to beat Bluebird Bio.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.119722, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.05749", "ticker_sentiment_score": "0.088957", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.114682", "ticker_sentiment_score": "0.056753", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.281584", "ticker_sentiment_score": "0.091197", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Magnificent Stocks That Are Screaming Buys in October", "url": "https://www.fool.com/investing/2023/10/02/3-magnificent-stocks-that-are-screaming-buys-in-oc/", "time_published": "20231002T095300", "authors": ["Keith Speights"], "summary": "These stocks give investors something to yell about -- in a good way.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.231409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.073353", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.334008", "ticker_sentiment_score": "0.268748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.114409", "ticker_sentiment_score": "0.103512", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/10/01/3-revolutionary-stocks-id-buy-right-now-without-he/", "time_published": "20231002T020700", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are helping change medicine. they could make boatloads of money along the way.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.325233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09239", "ticker_sentiment_score": "0.086438", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.228287", "ticker_sentiment_score": "0.373606", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.272282", "ticker_sentiment_score": "0.123322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.046273", "ticker_sentiment_score": "0.292442", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Brilliant Growth Stocks to Invest $2,000 in Right Now", "url": "https://www.fool.com/investing/2023/10/01/2-brilliant-growth-stocks-to-invest-2000-in-right/", "time_published": "20231001T140000", "authors": ["Rachel Warren"], "summary": "These growth companies are capitalizing on underserved target markets.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15942, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.148453", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.315325", "ticker_sentiment_score": "0.120612", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Top Stocks for October", "url": "https://www.fool.com/investing/2023/10/01/5-top-stocks-for-october/", "time_published": "20231001T130900", "authors": ["and Trevor Jennewine", "Keith Speights", "Neha Chamaria", "Anders Bylund", "Daniel Foelber"], "summary": "Venture into October's investment landscape with our five experts, unveiling opportunities in an uneven market environment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749299%2Froll-of-hundred-dollar-bills-on-autumn-maple-leaves.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.999759"}], "overall_sentiment_score": 0.138913, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.042234", "ticker_sentiment_score": "0.174967", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TGT", "relevance_score": "0.366361", "ticker_sentiment_score": "-0.044692", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.147044", "ticker_sentiment_score": "0.219481", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.042234", "ticker_sentiment_score": "0.180198", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.063313", "ticker_sentiment_score": "0.178206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.063313", "ticker_sentiment_score": "-0.027064", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.042234", "ticker_sentiment_score": "0.174967", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVN", "relevance_score": "0.147044", "ticker_sentiment_score": "0.024915", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Growth Stocks to Buy in October", "url": "https://www.fool.com/investing/2023/10/01/3-no-brainer-growth-stocks-to-buy-in-october/", "time_published": "20231001T123000", "authors": ["George Budwell"], "summary": "These three top mid-cap stocks could be poised for a long-tailed growth spurt.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749291%2Fstart-of-fall.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.200804, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.311406", "ticker_sentiment_score": "0.284527", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMVT", "relevance_score": "0.13637", "ticker_sentiment_score": "0.087313", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.045655", "ticker_sentiment_score": "0.04609", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.43303", "ticker_sentiment_score": "0.267809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.045655", "ticker_sentiment_score": "0.133776", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $5,000 in Right Now", "url": "https://www.fool.com/investing/2023/09/30/the-best-stocks-to-invest-5000-in-right-now/", "time_published": "20230930T095200", "authors": ["Keith Speights"], "summary": "Now is a great time to buy Amazon, Enterprise Products Partners, and Vertex Pharmaceuticals.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.361216, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.04369", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.275867", "ticker_sentiment_score": "0.325564", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/09/35011961/100-invested-in-vertex-pharmaceuticals-15-years-ago-would-be-worth-this-much-today", "time_published": "20230929T203019", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 8.49% on an annualized basis producing an average annual return of 18.32%. Currently, Vertex Pharmaceuticals has a market capitalization of $89.75 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Editas Medicine Stock Is Soaring Today", "url": "https://www.fool.com/investing/2023/09/29/why-editas-medicine-stock-is-soaring-today/", "time_published": "20230929T152129", "authors": ["Keith Speights"], "summary": "Investors are cheering a big analyst upgrade for the gene-editing stock.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.361282, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.141726", "ticker_sentiment_score": "0.173513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.628066", "ticker_sentiment_score": "0.50251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is It Worth Investing in Vertex  ( VRTX )  Based on Wall Street's Bullish Views?", "url": "https://www.zacks.com/stock/news/2157747/is-it-worth-investing-in-vertex-vrtx-based-on-wall-streets-bullish-views", "time_published": "20230929T133005", "authors": ["Zacks Equity Research"], "summary": "Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?", "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/VRTX_09292023.png", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.25801, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053992", "ticker_sentiment_score": "0.120749", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2157520/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230929T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.239238, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061631", "ticker_sentiment_score": "0.074005", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crispr Gene-Editing Faces Its Make-Or-Break Moment", "url": "https://www.investors.com/news/technology/crsp-stock-and-crispr-gene-editing-face-their-make-or-break-moment/", "time_published": "20230928T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "CRSP Stock, And CRISPR Gene-Editing, Face Their Make-Or-Break ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/06/Stock-crispr-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.113931, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARGX", "relevance_score": "0.032078", "ticker_sentiment_score": "-0.182567", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.064104", "ticker_sentiment_score": "0.101623", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Bargain Growth Stocks to Buy Hand Over Fist", "url": "https://www.fool.com/investing/2023/09/28/2-bargain-growth-stocks-to-buy-hand-over-fist/", "time_published": "20230928T093000", "authors": ["Adria Cimino"], "summary": "Both stocks have declined in recent times.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.369124, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.454174", "ticker_sentiment_score": "0.509499", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.053509", "ticker_sentiment_score": "0.043796", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer  ( SITC )  38th Annual Meeting", "url": "https://www.globenewswire.com/news-release/2023/09/27/2750466/0/en/CRISPR-Therapeutics-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html", "time_published": "20230927T130100", "authors": ["CRISPR Therapeutics AG"], "summary": "ZUG, Switzerland and BOSTON, Sept. 27, 2023 ( GLOBE NEWSWIRE ) -- CRISPR Therapeutics ( Nasdaq: CRSP ) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/5dac7d0d-131d-4047-bab7-db8e0719bf58", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.118682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.14635", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.357293", "ticker_sentiment_score": "0.201755", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34923954/looking-into-vertex-pharmaceuticalss-recent-short-interest", "time_published": "20230926T191515", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 6.6% since its last report. The company recently reported that it has 2.92 million shares sold short, which is 1.13% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2155113/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know", "time_published": "20230925T215018", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) closed at $350.67 in the latest trading session, marking a +0.33% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default230.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.173398, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.709186", "ticker_sentiment_score": "0.366927", "ticker_sentiment_label": "Bullish"}]}, {"title": "This Is What Whales Are Betting On Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/23/09/34879667/this-is-what-whales-are-betting-on-vertex-pharmaceuticals", "time_published": "20230925T200149", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.146523, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.68039", "ticker_sentiment_score": "0.162363", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buying These 2 Remarkable Growth Stocks in Any Market Could Be a Genius Move", "url": "https://www.fool.com/investing/2023/09/25/buying-2-remarkable-growth-stocks-in-market/", "time_published": "20230925T162241", "authors": ["Rachel Warren"], "summary": "Great companies haven't gone anywhere.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.228135, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.403088", "ticker_sentiment_score": "0.280723", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.038345", "ticker_sentiment_score": "0.056599", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.227007", "ticker_sentiment_score": "0.15098", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Magnificent Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/24/3-magnificent-growth-stocks-to-buy-right-now/", "time_published": "20230924T105000", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "If you're looking for growth, these stocks could be just the ticket.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.352979, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.166743", "ticker_sentiment_score": "0.245837", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.12546", "ticker_sentiment_score": "0.201716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.287441", "ticker_sentiment_score": "0.437472", "ticker_sentiment_label": "Bullish"}]}, {"title": "Look Don't Touch: Meta Leads 5 Stocks For Watchlists", "url": "https://www.investors.com/news/meta-stock-leads-5-names-showing-resilience-in-market-downturn/", "time_published": "20230923T120000", "authors": ["Investor's Business Daily", "HARRISON MILLER"], "summary": "Meta Leads 5 Stocks Showing Resilience In Market Downturn Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/12/Stock-metafacebook-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.13301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.06203", "ticker_sentiment_score": "0.049003", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.184598", "ticker_sentiment_score": "0.065347", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.031038", "ticker_sentiment_score": "-0.135044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BG", "relevance_score": "0.244415", "ticker_sentiment_score": "0.04367", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.031038", "ticker_sentiment_score": "-0.007761", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEHC", "relevance_score": "0.06203", "ticker_sentiment_score": "0.112522", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.154257", "ticker_sentiment_score": "0.044798", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACGL", "relevance_score": "0.244415", "ticker_sentiment_score": "0.036645", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.184598", "ticker_sentiment_score": "0.041816", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Ambitious Antiracism Center Scales Back Amid a Funding Slowdown", "url": "https://www.nytimes.com/2023/09/23/us/politics/ibram-x-kendi-antiracism-boston-university.html", "time_published": "20230923T114952", "authors": ["Stephanie Saul"], "summary": "In the wake of George Floyd's murder in May 2020, protests, looting, and anger were boiling up in the streets of Boston, a city that has played host to both abolitionists and vicious race riots. At Boston University, Black students demanded action to address campus racism.", "banner_image": "https://static01.nyt.com/images/2023/09/21/multimedia/21Nat-Antiracist--01-lfcv/21Nat-Antiracist--01-lfcv-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.05579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.025679", "ticker_sentiment_score": "0.009975", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diving Back Into A Correction: Watchlists, Nike Earnings, Coal Stocks, Housing Data", "url": "https://www.investors.com/research/investing-action-plan/diving-back-into-a-correction-watchlists-nike-earnings-coal-stocks-housing-data/", "time_published": "20230922T212100", "authors": ["ALAN R. ELLIOTT", "Investor's Business Daily"], "summary": "Diving Back Into A Correction: Watchlists, Nike Earnings, Coal ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/FIFTY1-021616-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.099065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "BG", "relevance_score": "0.218817", "ticker_sentiment_score": "0.180572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCH", "relevance_score": "0.146916", "ticker_sentiment_score": "0.169497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACGL", "relevance_score": "0.218817", "ticker_sentiment_score": "0.180572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.541149", "ticker_sentiment_score": "0.087704", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.218817", "ticker_sentiment_score": "-0.169165", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GE", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.218817", "ticker_sentiment_score": "-0.169165", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "How To Handle The Correction; Is Tesla The Next To Break?", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-what-to-do-with-market-in-correction-is-tesla-next-leader-to-crack/", "time_published": "20230922T210300", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: What To Do With Market In Correction. Is Tesla ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-Teslalogo-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.058456, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.074126", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.074126", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.103442", "ticker_sentiment_score": "0.048525", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.074126", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.077677", "ticker_sentiment_score": "0.043663", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.15462", "ticker_sentiment_score": "-0.035865", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.103442", "ticker_sentiment_score": "0.056466", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.025929", "ticker_sentiment_score": "-0.21408", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COST", "relevance_score": "0.129099", "ticker_sentiment_score": "-0.034195", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.327366", "ticker_sentiment_score": "-0.01211", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.025929", "ticker_sentiment_score": "-0.071517", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.15462", "ticker_sentiment_score": "-0.106716", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACGL", "relevance_score": "0.025929", "ticker_sentiment_score": "-0.095003", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.129099", "ticker_sentiment_score": "0.065519", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.077677", "ticker_sentiment_score": "0.02555", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.05183", "ticker_sentiment_score": "-0.074126", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.103442", "ticker_sentiment_score": "0.018639", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.025929", "ticker_sentiment_score": "0.197546", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Price Over Earnings Overview: Vertex Pharmaceuticals - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/09/34827560/price-over-earnings-overview-vertex-pharmaceuticals", "time_published": "20230922T161522", "authors": ["Benzinga Insights"], "summary": "In the current market session, Vertex Pharmaceuticals Inc. VRTX stock price is at $353.85, after a 0.12% decrease. However, over the past month, the company's stock increased by 0.95%, and in the past year, by 27.68%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.063941, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.360752", "ticker_sentiment_score": "0.060733", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/09/22/2-healthcare-stocks-that-could-make-you-richer/", "time_published": "20230922T140700", "authors": ["Prosper Junior Bakiny"], "summary": "They've beaten the market before.", "banner_image": "https://media.ycharts.com/charts/8f84b5c945a42d6a6356362e19522775.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.229777, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.341699", "ticker_sentiment_score": "-0.00737", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.341699", "ticker_sentiment_score": "0.365333", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.058759", "ticker_sentiment_score": "0.141", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Stocks Keep Falling As Yields Soar; Tesla's New Buy Point", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp-500-marks-new-low-as-yields-spike-tesla-forges-new-buy-point/", "time_published": "20230921T204400", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: S&P 500 Marks New Low As Yields Spike ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/09/A1-091123-teslaprices-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.075417, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.017654", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.06751", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.067536", "ticker_sentiment_score": "0.037837", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.102974", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPG", "relevance_score": "0.13459", "ticker_sentiment_score": "0.01584", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.101154", "ticker_sentiment_score": "0.04423", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.033799", "ticker_sentiment_score": "-0.23623", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LULU", "relevance_score": "0.101154", "ticker_sentiment_score": "0.020726", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.101154", "ticker_sentiment_score": "0.020726", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.328236", "ticker_sentiment_score": "0.188957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.101154", "ticker_sentiment_score": "-0.019817", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.101154", "ticker_sentiment_score": "-0.019817", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACGL", "relevance_score": "0.101154", "ticker_sentiment_score": "0.020726", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.014739", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.067536", "ticker_sentiment_score": "-0.018222", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.13459", "ticker_sentiment_score": "0.006187", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Unstoppable Stocks to Buy and Hold for the Next 20 Years", "url": "https://www.fool.com/investing/2023/09/21/3-unstoppable-stocks-to-buy-and-hold-for-the-next/", "time_published": "20230921T095000", "authors": ["Keith Speights"], "summary": "These stocks are great long-term picks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.218162, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.263942", "ticker_sentiment_score": "0.209951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.107255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIPC", "relevance_score": "0.314151", "ticker_sentiment_score": "0.189805", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio", "url": "https://www.fool.com/investing/2023/09/20/better-growth-stock-crispr-therapeutics-vs-bluebir/", "time_published": "20230920T112100", "authors": ["Alex Carchidi"], "summary": "These two biotechs have a lot in common, but one is much better capitalized.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.218221, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.046633", "ticker_sentiment_score": "0.132912", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.230017", "ticker_sentiment_score": "0.174281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2152870/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230920T102005", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069294", "ticker_sentiment_score": "0.034094", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}]}, {"title": "6 Healthcare Stocks Analysts Still Like", "url": "https://www.barrons.com/articles/healthcare-stocks-analysts-like-8b0f4dd2", "time_published": "20230920T070000", "authors": ["Josh Nathan-Kazis"], "summary": "This has been an epically bad year for the healthcare sector, but there are still a few stocks out there that Wall Street analysts like. Some of them are even more beaten down than the rest of the industry. The S&P 500 Health Care sector index is down 3% this year, vastly behind the S&P 500, ...", "banner_image": "https://images.barrons.com/im-81046107?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.054264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TECH", "relevance_score": "0.240489", "ticker_sentiment_score": "0.079998", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.459624", "ticker_sentiment_score": "0.130657", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059347", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2152768/vertex-pharmaceuticals-vrtx-gains-as-market-dips-what-you-should-know", "time_published": "20230919T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $358.26, marking a +1.78% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.156989, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.665097", "ticker_sentiment_score": "0.222611", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Where Will CRISPR Therapeutics Be in 5 Years?", "url": "https://www.fool.com/investing/2023/09/19/where-will-crispr-therapeutics-be-in-5-years/", "time_published": "20230919T135300", "authors": ["Prosper Junior Bakiny"], "summary": "The company hasn't performed well in the past five years, but things could change.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.228427, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.151858", "ticker_sentiment_score": "0.180788", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Gets Positive CHMP Opinion for Kaftrio Expanded Use", "url": "https://www.zacks.com/stock/news/2151774/vertex-vrtx-gets-positive-chmp-opinion-for-kaftrio-expanded-use", "time_published": "20230918T120100", "authors": ["Zacks Equity Research"], "summary": "Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.118907, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANVS", "relevance_score": "0.234684", "ticker_sentiment_score": "-0.05306", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.138744", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIK", "relevance_score": "0.118647", "ticker_sentiment_score": "0.064061", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Trends to Invest $500 In Right Now", "url": "https://www.fool.com/investing/2023/09/18/2-top-trends-to-invest-500-in-right-now/", "time_published": "20230918T090000", "authors": ["Adria Cimino"], "summary": "Early investors in these trends may reap the rewards over time.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.344437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.094204", "ticker_sentiment_score": "0.139544", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.047185", "ticker_sentiment_score": "0.018814", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.094204", "ticker_sentiment_score": "0.139544", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.094204", "ticker_sentiment_score": "0.229371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.021192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 Years", "url": "https://www.fool.com/investing/2023/09/17/heres-the-1-cathie-wood-stock-most-likely-to-turn/", "time_published": "20230917T095000", "authors": ["Keith Speights"], "summary": "There's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.232343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.050465", "ticker_sentiment_score": "0.183316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.100729", "ticker_sentiment_score": "0.36073", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSLA", "relevance_score": "0.295867", "ticker_sentiment_score": "0.168548", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking for Growth? These Companies' Revenue May Skyrocket", "url": "https://www.fool.com/investing/2023/09/17/these-companies-revenue-may-skyrocket/", "time_published": "20230917T093000", "authors": ["Adria Cimino"], "summary": "Catalysts on the horizon could drive gains in these top stocks.", "banner_image": "https://media.ycharts.com/charts/0860f3894a954ca09bca6721c87f1455.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.301635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHWY", "relevance_score": "0.363009", "ticker_sentiment_score": "0.330634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.21258", "ticker_sentiment_score": "0.195774", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.107255", "ticker_sentiment_score": "0.066468", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today", "url": "https://www.fool.com/investing/2023/09/16/if-you-invested-30000-crispr-therapeutics-in-2016-/", "time_published": "20230916T132100", "authors": ["David Jagielski"], "summary": "The returns are impressive, but will they continue to be so?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}], "overall_sentiment_score": 0.265174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.064276", "ticker_sentiment_score": "0.108101", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Moderna Stock a Top Buy?", "url": "https://www.fool.com/investing/2023/09/15/is-moderna-stock-a-top-buy/", "time_published": "20230915T143000", "authors": ["George Budwell"], "summary": "Wall Street is bullish on the biotech's novel pipeline.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F747633%2Fgrowth.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.079808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.360752", "ticker_sentiment_score": "0.049296", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.024004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/09/15/better-growth-stock-recursion-vs-crispr/", "time_published": "20230915T140700", "authors": ["Alex Carchidi"], "summary": "They're both liable to grow by a lot, but one of them is a safer bet in the near term.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.28177, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.054857", "ticker_sentiment_score": "0.238949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.054857", "ticker_sentiment_score": "0.271979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RXRX", "relevance_score": "0.163539", "ticker_sentiment_score": "0.18919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.054857", "ticker_sentiment_score": "-0.084241", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 No-Brainer Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/09/15/2-no-brainer-stocks-that-could-make-you-richer/", "time_published": "20230915T123000", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies have trounced the market over the past five years.", "banner_image": "https://media.ycharts.com/charts/765239b02c796dae65aa059ba7819a3f.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.287647, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.050359", "ticker_sentiment_score": "0.013", "ticker_sentiment_label": "Neutral"}, {"ticker": "VEEV", "relevance_score": "0.51278", "ticker_sentiment_score": "0.207637", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.050359", "ticker_sentiment_score": "0.148268", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.050359", "ticker_sentiment_score": "0.148268", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.430251", "ticker_sentiment_score": "0.440128", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech Stocks Near An Inflection Point In Gene Therapy", "url": "https://www.investors.com/news/technology/biotech-stocks-near-a-significant-inflection-point-in-gene-therapy-but-watch-your-wallet/", "time_published": "20230915T120000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Get ready for a world of million-dollar drugs. Pricey gene therapies that could cure devastating genetic disorders in one fell swoop are gaining momentum, brightening the horizon for biotech stocks like Sarepta Therapeutics ( SRPT ) and BioMarin Pharmaceutical ( BMRN ) .", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-DNA-editing-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.208116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRYS", "relevance_score": "0.02695", "ticker_sentiment_score": "0.164324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.02695", "ticker_sentiment_score": "0.114418", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.02695", "ticker_sentiment_score": "0.031746", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.02695", "ticker_sentiment_score": "0.031746", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.067309", "ticker_sentiment_score": "0.061816", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02695", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.013477", "ticker_sentiment_score": "-0.185356", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "3 Top Healthcare Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/09/15/3-top-healthcare-stocks-defying-the-bear-market/", "time_published": "20230915T094900", "authors": ["Jim Halley"], "summary": "Revenue at all three companies improved last quarter, and their share prices have followed suit.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99994"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.179087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.240886", "ticker_sentiment_score": "0.104128", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.04076", "ticker_sentiment_score": "0.073671", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.081414", "ticker_sentiment_score": "-0.179842", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Better Bull Market Buy: CRISPR vs. Medtronic Stock", "url": "https://www.fool.com/investing/2023/09/14/better-bull-market-buy-crispr-vs-medtronic-stock/", "time_published": "20230914T101500", "authors": ["Adria Cimino and Keith Speights"], "summary": "Investors may look for growth stocks ahead of the next bull market.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.430936, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.609602", "ticker_sentiment_score": "0.685014", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.048919", "ticker_sentiment_score": "0.098104", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2148611/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know", "time_published": "20230913T215018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $346.84, marking a +0.08% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default48.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.165678, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.606946", "ticker_sentiment_score": "0.24523", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Score an 11% Yield at a Discount on This Superb Income Play", "url": "https://moneymorning.com/investing/score-an-11-yield-at-a-discount-on-this-superb-income-play/", "time_published": "20230913T182458", "authors": ["Shah Gilani"], "summary": "August inflation numbers came in today, with the Consumer Price Index rising 0.6% over last month and 3.7% over the prior year. This number was slightly higher than economists' forecasts of a 3.6% increase.", "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2018/11/Retina_Headshots_ShahGilani.jpg", "source": "Money Morning", "category_within_source": "GoogleRSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.250559, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.048919", "ticker_sentiment_score": "0.177597", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HESG", "relevance_score": "0.097655", "ticker_sentiment_score": "0.190661", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALC", "relevance_score": "0.097655", "ticker_sentiment_score": "0.109862", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.097655", "ticker_sentiment_score": "0.109862", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.097655", "ticker_sentiment_score": "0.109862", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.097655", "ticker_sentiment_score": "0.109862", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.097655", "ticker_sentiment_score": "0.109862", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMEZ", "relevance_score": "0.240965", "ticker_sentiment_score": "0.250588", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics", "url": "https://www.fool.com/investing/2023/09/12/more-likely-to-5x-first-bluebird-bio-vs-crispr/", "time_published": "20230912T110000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are innovators, something that can prove highly lucrative.", "banner_image": "https://media.ycharts.com/charts/3a12013d586a876aca8ae24d667bd2ad.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.305718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04823", "ticker_sentiment_score": "0.050332", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.283323", "ticker_sentiment_score": "0.249855", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 No-Brainer Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/12/2-no-brainer-biotech-stocks-to-buy-right-now/", "time_published": "20230912T100000", "authors": ["Adria Cimino"], "summary": "You can get in early on these potential winners.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.201995, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.062271", "ticker_sentiment_score": "0.069119", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.062271", "ticker_sentiment_score": "0.060935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.124164", "ticker_sentiment_score": "0.214556", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Upgraded to \"Strong-Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/09/12/vertex-pharmaceuticals-nasdaqvrtx-upgraded-to-strong-buy-at-stocknews-com.html", "time_published": "20230912T074043", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX ) Upgraded to \"Strong-Buy ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.270521, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.756917", "ticker_sentiment_score": "0.388806", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.046543", "ticker_sentiment_score": "0.031725", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.046543", "ticker_sentiment_score": "0.144805", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.046543", "ticker_sentiment_score": "0.031725", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.046543", "ticker_sentiment_score": "0.031725", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Bull Market Is  ( Still )  Coming: Here Are 3 Spectacular Stocks to Buy Sooner Rather Than Later", "url": "https://www.fool.com/investing/2023/09/10/a-bull-market-is-still-coming-here-are-3-spectacul/", "time_published": "20230910T095200", "authors": ["Keith Speights"], "summary": "These stocks should be even bigger winners than they already are when a new bull market takes hold.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.335519, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.119235", "ticker_sentiment_score": "0.244032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.119235", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.34729", "ticker_sentiment_score": "0.390572", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.451494", "ticker_sentiment_score": "0.268116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.119235", "ticker_sentiment_score": "0.246622", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Unstoppable Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/09/3-unstoppable-growth-stocks-to-buy-right-now/", "time_published": "20230909T105500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "These healthcare stocks show no signs of slowing down.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.247559, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.285526", "ticker_sentiment_score": "0.177763", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.165598", "ticker_sentiment_score": "0.085992", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.165598", "ticker_sentiment_score": "0.085386", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041682", "ticker_sentiment_score": "0.244904", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "1 Top Pharma Growth Stock to Buy Today and Hold Forever", "url": "https://www.fool.com/investing/2023/09/08/1-top-pharma-growth-stock-to-buy-today-and-hold/", "time_published": "20230908T141500", "authors": ["Alex Carchidi"], "summary": "Vertex's encouraging mix of recurring revenue and growth make it a leader.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.227029, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.135729", "ticker_sentiment_score": "0.082838", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in September", "url": "https://www.fool.com/investing/2023/09/08/2-top-biotech-stocks-to-buy-in-september/", "time_published": "20230908T135300", "authors": ["Prosper Junior Bakiny"], "summary": "There is rarely a bad time to buy stocks with massive upside potential.", "banner_image": "https://media.ycharts.com/charts/f058ce16f4e7ed1399492b8da1636e0c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.293448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.109956", "ticker_sentiment_score": "0.216707", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.109956", "ticker_sentiment_score": "0.216707", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.055109", "ticker_sentiment_score": "0.160116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Could These Be Vertex Pharmaceuticals' Most Promising Candidates?", "url": "https://www.fool.com/investing/2023/09/08/could-these-be-vertex-most-promising-candidates/", "time_published": "20230908T124500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech has no shortage of promising pipeline programs.", "banner_image": "https://media.ycharts.com/charts/fb2ed91ed6091b16f39c34598815cbd9.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.171332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.335519", "ticker_sentiment_score": "0.276435", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.057628", "ticker_sentiment_score": "0.139984", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.057628", "ticker_sentiment_score": "0.077958", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Must-Know Tricks for Investing in Big Pharma Stocks", "url": "https://www.fool.com/investing/2023/09/08/must-know-tricks-investing-in-big-pharma-stocks/", "time_published": "20230908T094600", "authors": ["Alex Carchidi"], "summary": "Using these tricks will help you appreciate where and when to invest.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}], "overall_sentiment_score": 0.138094, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.090474", "ticker_sentiment_score": "-0.041389", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.179788", "ticker_sentiment_score": "0.081938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Moves -0.1%: What You Should Know", "url": "https://www.zacks.com/stock/news/2146294/vertex-pharmaceuticals-vrtx-stock-moves--01-what-you-should-know", "time_published": "20230907T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $343.96, marking a -0.1% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.193826, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.659949", "ticker_sentiment_score": "0.287819", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2145173/should-you-invest-in-the-invesco-biotechnology-genome-pbe", "time_published": "20230906T102004", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default72.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.196183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.195287", "ticker_sentiment_score": "0.113137", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.130926", "ticker_sentiment_score": "0.070514", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street", "url": "https://www.fool.com/investing/2023/09/06/2-brilliant-growth-stocks-with-upsides-of-about-70/", "time_published": "20230906T101700", "authors": ["Cory Renauer"], "summary": "Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746454%2Finvestor-buying-growth-stocks-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.155557, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053992", "ticker_sentiment_score": "0.100055", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.053992", "ticker_sentiment_score": "0.135757", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.16099", "ticker_sentiment_score": "0.133272", "ticker_sentiment_label": "Neutral"}]}, {"title": "With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?", "url": "https://www.fool.com/investing/2023/09/05/is-wall-street-crispr-prediction-too-optimistic/", "time_published": "20230905T100000", "authors": ["Adria Cimino"], "summary": "Big news could come in December and in March.", "banner_image": "https://media.ycharts.com/charts/669f559164fa4900a7620332e57bf24c.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.376902, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.058615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Surefire Stocks That Can Build Generational Wealth in 20 Years", "url": "https://www.fool.com/investing/2023/09/04/5-stocks-can-build-generational-wealth-in-20-years/", "time_published": "20230904T090600", "authors": ["Sean Williams"], "summary": "Time is a trusted ally when you're invested in innovative businesses with sustained competitive advantages.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746242%2Fhourglass-coins-cash-bills-money-invest-rich-retirement-compound-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.339836, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.121496", "ticker_sentiment_score": "0.200759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.060925", "ticker_sentiment_score": "0.247193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FVRR", "relevance_score": "0.240192", "ticker_sentiment_score": "0.238584", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MA", "relevance_score": "0.030485", "ticker_sentiment_score": "0.26567", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.181364", "ticker_sentiment_score": "0.18946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.091277", "ticker_sentiment_score": "0.154276", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Spectacular Growth Stocks You Can Buy in September With No Hesitation", "url": "https://www.fool.com/investing/2023/09/03/2-spectacular-growth-stocks-you-can-buy-in-septemb/", "time_published": "20230903T095000", "authors": ["Keith Speights"], "summary": "There's no need for any anxiety with investing in these great stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745806%2Fsocial-security-benefits-application-retirement-income-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.332164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.114956", "ticker_sentiment_score": "0.133713", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.057628", "ticker_sentiment_score": "0.082161", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2143955/vertex-pharmaceuticals-vrtx-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230901T214515", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $351.13, marking a +0.8% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default96.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.193029, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.618922", "ticker_sentiment_score": "0.304273", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sarepta Therapeutics  ( SRPT )  Up 12.7% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2143804/sarepta-therapeutics-srpt-up-127-since-last-earnings-report-can-it-continue", "time_published": "20230901T153138", "authors": ["Zacks Equity Research"], "summary": "Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default92.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.118541, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.058903", "ticker_sentiment_score": "0.059985", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.288214", "ticker_sentiment_score": "0.303577", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs", "url": "https://www.marketwatch.com/story/as-medicare-drug-price-negotiations-inch-forward-some-states-are-flexing-new-powers-to-cut-costs-for-a-broader-swath-of-drugs-a4ca7f3e", "time_published": "20230901T153000", "authors": ["Eleanor Laise"], "summary": "States like Colorado are looking to set upper payment limits on certain drugs as soon as next year.", "banner_image": "https://images.mktw.net/im-837664/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.035458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.063678", "ticker_sentiment_score": "-0.049016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.063678", "ticker_sentiment_score": "-0.03203", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Down 2.1% Since Last Earnings Report: Can It Rebound?", "url": "https://www.zacks.com/stock/news/2143104/vertex-vrtx-down-21-since-last-earnings-report-can-it-rebound", "time_published": "20230831T153129", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.999816"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.140126, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.04406", "ticker_sentiment_score": "-0.003978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.04406", "ticker_sentiment_score": "0.058655", "ticker_sentiment_label": "Neutral"}]}, {"title": "Twist Bioscience Sees Relative Strength Rating Climb To 72", "url": "https://www.investors.com/ibd-data-stories/twist-bioscience-sees-relative-strength-rating-climb-to-72/", "time_published": "20230831T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Twist Bioscience ( TWST ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 67 to 72. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.32313, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.368773", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.368773", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.528475", "ticker_sentiment_score": "0.68184", "ticker_sentiment_label": "Bullish"}]}, {"title": "Neurocrine Biosciences Sees RS Rating Climb To 72", "url": "https://www.investors.com/ibd-data-stories/neurocrine-biosciences-sees-rs-rating-climb-to-72/", "time_published": "20230831T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "In a welcome move, Neurocrine Biosciences ( NBIX ) saw its Relative Strength Rating improve from 67 to 72 on Thursday. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.404759, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.629492", "ticker_sentiment_score": "0.711476", "ticker_sentiment_label": "Bullish"}]}, {"title": "Zentalis Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/zentalis-pharmaceuticals-scores-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20230831T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Zentalis Pharmaceuticals Scores Relative Strength Rating Upgrade ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.306188, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZNTL", "relevance_score": "0.598621", "ticker_sentiment_score": "0.200355", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex  ( VRTX )  Outperforms Industry Year to Date: Here's Why", "url": "https://www.zacks.com/stock/news/2142369/vertex-vrtx-outperforms-industry-year-to-date-heres-why", "time_published": "20230830T132700", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.045394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.21258", "ticker_sentiment_score": "-0.175302", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.21258", "ticker_sentiment_score": "0.127966", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORT", "relevance_score": "0.160277", "ticker_sentiment_score": "0.173384", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Exxon Mobil, The Home Depot, Intel, NextEra Energy and Vertex Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2142303/the-zacks-analyst-blog-highlights-exxon-mobil-the-home-depot-intel-nextera-energy-and-vertex-pharmaceuticals", "time_published": "20230830T114100", "authors": ["Zacks Equity Research"], "summary": "Exxon Mobil, The Home Depot, Intel, NextEra Energy and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fa/77.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}], "overall_sentiment_score": 0.207687, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.138863", "ticker_sentiment_score": "0.037466", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.459624", "ticker_sentiment_score": "0.151592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.273552", "ticker_sentiment_score": "0.189898", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEE", "relevance_score": "0.138863", "ticker_sentiment_score": "0.037466", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.338119", "ticker_sentiment_score": "0.185127", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Stock Rating Lowered by StockNews.com", "url": "https://www.defenseworld.net/2023/08/30/vertex-pharmaceuticals-nasdaqvrtx-stock-rating-lowered-by-stocknews-com.html", "time_published": "20230830T063042", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX ) Stock Rating Lowered by ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.336096, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.04406", "ticker_sentiment_score": "0.078577", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.796171", "ticker_sentiment_score": "0.532488", "ticker_sentiment_label": "Bullish"}, {"ticker": "SEIC", "relevance_score": "0.087985", "ticker_sentiment_score": "0.232386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNV", "relevance_score": "0.087985", "ticker_sentiment_score": "0.232386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.04406", "ticker_sentiment_score": "0.078577", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 3 Best Biotech Stocks for Health and Wealth", "url": "https://stocknews.com/news/amgn-vrtx-incy-repl-sndx-3-best-biotech-stocks-for-health-and-wealth/", "time_published": "20230829T175651", "authors": ["StockNews.com Staff"], "summary": "Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.33801, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.141034", "ticker_sentiment_score": "0.136199", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.164228", "ticker_sentiment_score": "0.13575", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.047231", "ticker_sentiment_score": "0.108521", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.047231", "ticker_sentiment_score": "0.026781", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.232885", "ticker_sentiment_score": "0.232763", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Top Growth Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/08/28/3-top-growth-stocks-id-buy-right-now-without/", "time_published": "20230828T123000", "authors": ["Prosper Junior Bakiny"], "summary": "These drugmakers are all leaders in their respective niches.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.254456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.275867", "ticker_sentiment_score": "0.183392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.18602", "ticker_sentiment_score": "0.127057", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.275867", "ticker_sentiment_score": "0.18988", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling - Moderna  ( NASDAQ:MRNA ) , DXC Technology  ( NYSE:DXC ) ", "url": "https://www.benzinga.com/news/23/08/34066417/ross-stores-vertex-pharmaceuticals-and-2-other-stocks-insiders-are-selling", "time_published": "20230828T121711", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/28/ross_stores_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROST", "relevance_score": "0.425746", "ticker_sentiment_score": "0.329398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.425746", "ticker_sentiment_score": "0.017448", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.425746", "ticker_sentiment_score": "-0.137067", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.089462", "ticker_sentiment_score": "-0.132682", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXC", "relevance_score": "0.425746", "ticker_sentiment_score": "0.084265", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Surprisingly Underrated Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/08/26/3-surprisingly-underrated-stocks-to-buy-right-now/", "time_published": "20230826T105500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "These stocks deserve more respect than they're getting.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745125%2Fartificial-intelligence-ai-on-circuit-board.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.136687, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.036587", "ticker_sentiment_score": "0.189238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.386151", "ticker_sentiment_score": "0.043606", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.036587", "ticker_sentiment_score": "0.167457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.320279", "ticker_sentiment_score": "0.086734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/08/34043286/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-10-years", "time_published": "20230825T143023", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 5.87% on an annualized basis producing an average annual return of 16.23%. Currently, Vertex Pharmaceuticals has a market capitalization of $89.73 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "PM360 Announces 2023 Trailblazer Award Finalists", "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html", "time_published": "20230824T130000", "authors": ["PM360"], "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.", "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.284744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GDRX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.27629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SUPN", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNH", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.066083", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.24502", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.04161", "ticker_sentiment_score": "0.075016", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGC", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04161", "ticker_sentiment_score": "0.080752", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.23749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.073367", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.013876", "ticker_sentiment_score": "0.273432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.071498", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.083107", "ticker_sentiment_score": "-0.072498", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.05546", "ticker_sentiment_score": "0.086858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.013876", "ticker_sentiment_score": "0.202947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXMD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.349415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSRGF", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.187445", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "2 No-Brainer Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/08/24/2-no-brainer-biotech-stocks-to-buy-right-now/", "time_published": "20230824T113000", "authors": ["Sushree Mohanty"], "summary": "These two companies make a compelling case for a high price.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744853%2Fa-scientist-working-in-a-lab.jpeg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995077"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.260023, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.102231", "ticker_sentiment_score": "0.066391", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.300088", "ticker_sentiment_score": "0.212101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.051221", "ticker_sentiment_score": "0.117067", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should Invesco S&P 500 Pure Growth ETF  ( RPG )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2140009/should-invesco-sp-500-pure-growth-etf-rpg-be-on-your-investing-radar", "time_published": "20230824T102005", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default318.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.322351, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.299478", "ticker_sentiment_score": "0.295477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUE", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLD", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Clever Tricks to Find Winning Biotech Stocks", "url": "https://www.fool.com/investing/2023/08/24/3-clever-tricks-to-find-winning-biotech-stocks/", "time_published": "20230824T095800", "authors": ["Alex Carchidi"], "summary": "You'll need to dig into company details, but the effort is worthwhile.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745046%2Fbiotech-stocks-doctors-research.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.244159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.075043", "ticker_sentiment_score": "0.062541", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.037563", "ticker_sentiment_score": "0.052335", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.075043", "ticker_sentiment_score": "0.054471", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.075043", "ticker_sentiment_score": "0.252275", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street", "url": "https://www.fool.com/investing/2023/08/23/these-2-stocks-could-skyrocket-by-54-and-119-accor/", "time_published": "20230823T122500", "authors": ["Prosper Junior Bakiny"], "summary": "Is the Street's optimism justified here?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744787%2Fthree-smiling-people-skydiving-together.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.15174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051221", "ticker_sentiment_score": "0.057817", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.559221", "ticker_sentiment_score": "0.171946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.051221", "ticker_sentiment_score": "0.057817", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.725201", "ticker_sentiment_score": "0.251154", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Revolutionary Stocks I'd Buy Right Now Without Hesitation", "url": "https://www.fool.com/investing/2023/08/22/3-revolutionary-stocks-id-buy-right-now-without/", "time_published": "20230822T140000", "authors": ["Prosper Junior Bakiny"], "summary": "Helping save and improve patients' lives in novel ways can be a lucrative activity.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744850%2Fa-blue-tesla-car-driving-on-an-open-road.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.268883, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.136447", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.274834", "ticker_sentiment_score": "0.245501", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.402045", "ticker_sentiment_score": "0.219254", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings", "url": "https://www.zacks.com/stock/news/2138556/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings", "time_published": "20230821T125004", "authors": ["Zacks Equity Research"], "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default335.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.379606, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.381949", "ticker_sentiment_score": "0.371196", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.322233", "ticker_sentiment_score": "0.248688", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Superlative Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip", "url": "https://www.fool.com/investing/2023/08/19/nasdaq-bear-market-4-growth-stocks-regret-not-buy/", "time_published": "20230819T090600", "authors": ["Sean Williams"], "summary": "With the Nasdaq Composite still 15% below its record-closing high, amazing deals are hiding in plain sight.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744338%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.134946, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.075476", "ticker_sentiment_score": "0.09495", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.050359", "ticker_sentiment_score": "0.082966", "ticker_sentiment_label": "Neutral"}, {"ticker": "JDHIF", "relevance_score": "0.025192", "ticker_sentiment_score": "0.133171", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.150278", "ticker_sentiment_score": "0.115422", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.150278", "ticker_sentiment_score": "0.117531", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33922199/peering-into-vertex-pharmaceuticalss-recent-short-interest", "time_published": "20230818T184520", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has risen 13.27% since its last report. The company recently reported that it has 2.86 million shares sold short, which is 1.11% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/08/18/3-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20230818T095000", "authors": ["Keith Speights"], "summary": "You can rest easy investing in these great stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.264424, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MA", "relevance_score": "0.256989", "ticker_sentiment_score": "0.420147", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.130217", "ticker_sentiment_score": "0.037364", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.318074", "ticker_sentiment_score": "0.12364", "ticker_sentiment_label": "Neutral"}]}, {"title": "bluebird's  ( BLUE )  Lovo-cel to Not Face Advisory Committee", "url": "https://www.zacks.com/stock/news/2137766/bluebirds-blue-lovo-cel-to-not-face-advisory-committee", "time_published": "20230817T170600", "authors": ["Zacks Equity Research"], "summary": "bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/287.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.204875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.208166", "ticker_sentiment_score": "0.13733", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.402403", "ticker_sentiment_score": "0.229329", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CORT", "relevance_score": "0.139669", "ticker_sentiment_score": "0.085133", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Excellent Stocks to Buy and Hold Forever", "url": "https://www.fool.com/investing/2023/08/17/2-excellent-stocks-to-buy-and-hold-forever/", "time_published": "20230817T132000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies have solid long-term potential.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743953%2Fa-digital-render-of-a-circuit-board-with-a-chip-in-the-center-inscribed-with-the-letters-ai.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.296693, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.472338", "ticker_sentiment_score": "0.338499", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2137310/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20230817T102007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.297511, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.176287", "ticker_sentiment_score": "0.279847", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.118064", "ticker_sentiment_score": "0.06168", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+", "url": "https://www.investors.com/news/stock-upgrades-vertex-pharmaceuticals-shows-rising-relative-strength-4/", "time_published": "20230816T200100", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily", "GLENN LARKIN"], "summary": "Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.344528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.262522", "ticker_sentiment_score": "0.55491", "ticker_sentiment_label": "Bullish"}, {"ticker": "KNSA", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-vertex-pharmaceuticals-shows-rising-relative-strength-4/", "time_published": "20230816T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Wednesday, Vertex Pharmaceuticals ( VRTX ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 78 to 81. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.282437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.382925", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.382925", "ticker_sentiment_score": "0.68233", "ticker_sentiment_label": "Bullish"}, {"ticker": "KNSA", "relevance_score": "0.382925", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33841959/heres-how-much-you-would-have-made-owning-vertex-pharmaceuticals-stock-in-the-last-10-years", "time_published": "20230814T190022", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 5.97% on an annualized basis producing an average annual return of 16.4%. Currently, Vertex Pharmaceuticals has a market capitalization of $90.22 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold", "url": "https://www.fool.com/investing/2023/08/14/missed-out-on-crispr-therapeutics-my-best-biotech/", "time_published": "20230814T101500", "authors": ["Sushree Mohanty"], "summary": "CRISPR Therapeutics is an intriguing biotech stock to consider now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743023%2Fscientist-working-in-a-lab.jpeg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.340542, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.055492", "ticker_sentiment_score": "0.113867", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want to Get Richer? Buy and Hold These 5 Unstoppable Stocks", "url": "https://www.fool.com/investing/2023/08/13/get-richer-buy-and-hold-5-unstoppable-stocks/", "time_published": "20230813T095200", "authors": ["Keith Speights"], "summary": "Buying these stocks and waiting should help you boost your personal wealth.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743587%2Fbull_market_1.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.278977, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.130926", "ticker_sentiment_score": "0.190233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.195287", "ticker_sentiment_score": "0.197239", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.195287", "ticker_sentiment_score": "0.119899", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEP", "relevance_score": "0.195287", "ticker_sentiment_score": "0.210295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.258351", "ticker_sentiment_score": "0.094601", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Ambrx Biopharma  ( AMAM ) , QuidelOrtho  ( QDEL )  and Aveanna Healthcare Holdings  ( AVAH ) ", "url": "https://markets.businessinsider.com/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ambrx-biopharma-amam-quidelortho-qdel-and-aveanna-healthcare-holdings-avah-1032548424", "time_published": "20230813T000037", "authors": ["Tipranks"], "summary": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Ambrx Biopharma (AMAM), QuidelOrtho (QDEL) and Aveanna Healthcare Holdings ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.228432, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BHG", "relevance_score": "0.092927", "ticker_sentiment_score": "0.111703", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAH", "relevance_score": "0.359447", "ticker_sentiment_score": "0.10838", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHC", "relevance_score": "0.092927", "ticker_sentiment_score": "0.111703", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.440549", "ticker_sentiment_score": "0.351103", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.092927", "ticker_sentiment_score": "0.108556", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.092927", "ticker_sentiment_score": "0.108556", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.184598", "ticker_sentiment_score": "0.152949", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.092927", "ticker_sentiment_score": "0.108556", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.092927", "ticker_sentiment_score": "0.111703", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.092927", "ticker_sentiment_score": "0.108556", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVI", "relevance_score": "0.092927", "ticker_sentiment_score": "0.108556", "ticker_sentiment_label": "Neutral"}, {"ticker": "QDEL", "relevance_score": "0.359447", "ticker_sentiment_score": "0.186352", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy", "url": "https://www.fool.com/investing/2023/08/11/ready-to-buy-the-dip-crispr-therapeutics-stock-is/", "time_published": "20230811T134500", "authors": ["Alex Carchidi"], "summary": "Its shares tumbled due to factors outside its control, but the biotech still has substantial long-term potential.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743206%2Fone-hundred-dollar-bill-cash-money-dividend-income-invest-wages-salary-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.079529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.062597", "ticker_sentiment_score": "0.145089", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2135485/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230811T102008", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184085, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/08/10/vertex-pharmaceuticals-stock-help-millionaire/", "time_published": "20230810T104000", "authors": ["David Jagielski"], "summary": "Vertex stock has been a growth beast in recent years -- can that trend continue?", "banner_image": "https://media.ycharts.com/charts/cd751161a8c73ea1a640b0eb6ddd47b5.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}], "overall_sentiment_score": 0.29759, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.151858", "ticker_sentiment_score": "0.203642", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2023/08/10/2722440/0/en/Verve-Therapeutics-Highlights-Recent-Company-Progress-and-Reports-Second-Quarter-2023-Financial-Results.html", "time_published": "20230810T103000", "authors": ["Verve Therapeutics"], "summary": "heart-1 Initial Clinical Data Expected in the Fourth Quarter of ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/2a4edc4b-98df-4e32-ade8-159b39872434", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.135882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.020317", "ticker_sentiment_score": "0.011651", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.0609", "ticker_sentiment_score": "0.075033", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Explosive Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/08/10/3-explosive-stocks-to-buy-right-now/", "time_published": "20230810T095000", "authors": ["Keith Speights"], "summary": "These stocks are poised to pop in the not-too-distant future.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742979%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.158964, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.132733", "ticker_sentiment_score": "0.022265", "ticker_sentiment_label": "Neutral"}, {"ticker": "JACK", "relevance_score": "0.132733", "ticker_sentiment_score": "0.101836", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.066598", "ticker_sentiment_score": "0.056024", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.132733", "ticker_sentiment_score": "0.047721", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Biotech Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/08/10/3-top-biotech-stocks-defying-the-bear-market/", "time_published": "20230810T092100", "authors": ["Jim Halley"], "summary": "Biotech is still booming, if you pick the right biotech stocks.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.13342, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.125025", "ticker_sentiment_score": "0.159439", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.083541", "ticker_sentiment_score": "0.079729", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.325208", "ticker_sentiment_score": "0.23977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTLT", "relevance_score": "0.041828", "ticker_sentiment_score": "-0.016836", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.083541", "ticker_sentiment_score": "0.146184", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.041828", "ticker_sentiment_score": "-0.036768", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Arcturus Therapeutics Sees Relative Strength Rating Jump To 91", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-arcturus-therapeutics-sees-relative-strength-rating-jump-to-91/", "time_published": "20230810T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Thursday, Arcturus Therapeutics ( ARCT ) earned an upgrade to its Relative Strength ( RS ) Rating, from 77 to 91. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.289991, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.535653", "ticker_sentiment_score": "0.315062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.374312", "ticker_sentiment_score": "0.144504", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.374312", "ticker_sentiment_score": "0.144504", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regeneron Pharmaceuticals Trying To Close In On Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-trying-to-close-in-on-key-technical-benchmark/", "time_published": "20230810T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Thursday, Regeneron Pharmaceuticals ( REGN ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 68 to 74. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.384273, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.827318", "ticker_sentiment_score": "0.551522", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.350564", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vericel Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/vericel-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20230810T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Thursday, Vericel ( VCEL ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 87, up from 80 the day before. X When you're researching the best stocks to buy and watch, be sure to pay attention to ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.41669, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.166169", "ticker_sentiment_score": "0.185624", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCEL", "relevance_score": "0.470894", "ticker_sentiment_score": "0.666186", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stock Upgrades: Zentalis Pharmaceuticals Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-zentalis-pharmaceuticals-shows-rising-relative-strength-2/", "time_published": "20230810T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Zentalis Pharmaceuticals ( ZNTL ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an upgrade from 68 to 78. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.394767, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZNTL", "relevance_score": "0.7887", "ticker_sentiment_score": "0.538565", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks Flashing Renewed Technical Strength: IDEAYA Biosciences", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-ideaya-biosciences/", "time_published": "20230810T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Thursday, IDEAYA Biosciences ( IDYA ) received an upgrade to its Relative Strength ( RS ) Rating, from 84 to 93. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.272857, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.31282", "ticker_sentiment_score": "0.125945", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDYA", "relevance_score": "0.579393", "ticker_sentiment_score": "-0.027728", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.31282", "ticker_sentiment_score": "0.125945", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Supercharged Growth Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/08/09/2-supercharged-growth-stocks-that-could-make-you-r/", "time_published": "20230809T183000", "authors": ["George Budwell"], "summary": "These two biotechs are poised for a sustained period of growth.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742997%2Fhealthcare.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.191848, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.188193", "ticker_sentiment_score": "0.130682", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.188193", "ticker_sentiment_score": "0.084371", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Great Stocks Under $100 to Buy and Hold for 10 Years", "url": "https://www.fool.com/investing/2023/08/09/2-great-stocks-under-100-to-buy-and-hold-for-10/", "time_published": "20230809T133000", "authors": ["Prosper Junior Bakiny"], "summary": "Neither has performed well over the past year, but investors would do well to focus on the longer term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742979%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.323148, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.095327", "ticker_sentiment_score": "0.214506", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SQ", "relevance_score": "0.410059", "ticker_sentiment_score": "0.304548", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.095327", "ticker_sentiment_score": "0.01187", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Vertex Pharmaceuticals Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/08/09/is-vertex-pharmaceuticals-stock-a-buy-now/", "time_published": "20230809T093500", "authors": ["Alex Carchidi"], "summary": "It's got upcoming catalysts, strong earnings, and a solid base of sales, too.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742930%2Fa-digital-rendering-of-a-computer-chip-conducting-lightning-with-blue-undertones.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.323575, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.181137", "ticker_sentiment_score": "0.465547", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks With Rising Relative Price Strength: Biomea Fusion", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-biomea-fusion/", "time_published": "20230809T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Wednesday, Biomea Fusion ( BMEA ) reached an important technical milestone, with its Relative Strength ( RS ) Rating entering into the 90-plus percentile with an improvement to 93, an increase from 90 the day before.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.435781, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BMEA", "relevance_score": "0.479683", "ticker_sentiment_score": "0.513298", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.331765", "ticker_sentiment_score": "0.127279", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.331765", "ticker_sentiment_score": "0.127279", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.169676", "ticker_sentiment_score": "0.254942", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Upgrades: Immunocore Holdings ADR Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-immunocore-holdings-adr-shows-rising-relative-strength/", "time_published": "20230809T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Wednesday, Immunocore Holdings ADR ( IMCR ) got an upgrade to its Relative Strength ( RS ) Rating, from 67 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary rating measures market leadership with a 1 ( worst ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.234821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMCR", "relevance_score": "0.679474", "ticker_sentiment_score": "0.208747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CRISPR Therapeutics Stock Is Jumping Today", "url": "https://www.fool.com/investing/2023/08/08/why-crispr-therapeutics-stock-is-jumping-today/", "time_published": "20230808T161452", "authors": ["Keith Speights"], "summary": "Analysts continue to like this gene-editing stock.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.231467, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.305058", "ticker_sentiment_score": "-0.318771", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Claire's Place Foundation Launches First East Coast Glow Ride for Cystic Fibrosis", "url": "https://www.benzinga.com/pressreleases/23/08/g33635377/claires-place-foundation-launches-first-east-coast-glow-ride-for-cystic-fibrosis", "time_published": "20230808T155017", "authors": ["Globe Newswire"], "summary": "Los Angeles, CA, Aug. 08, 2023 ( GLOBE NEWSWIRE ) -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis ( CF ) , is excited to expand its reach and bring the unique Glow Ride for CF experience to the East Coast for the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.372355, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.051221", "ticker_sentiment_score": "0.098964", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR Therapeutics  ( CRSP )  Q2 Loss Narrower Than Expected", "url": "https://www.zacks.com/stock/news/2133785/crispr-therapeutics-crsp-q2-loss-narrower-than-expected", "time_published": "20230808T150900", "authors": ["Zacks Equity Research"], "summary": "CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.070934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.217834", "ticker_sentiment_score": "0.05771", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.217834", "ticker_sentiment_score": "0.001746", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.321673", "ticker_sentiment_score": "0.016455", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.109956", "ticker_sentiment_score": "0.052382", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Rating Upgrades: Vertex Pharmaceuticals Flashes Improved Relative Price Strength", "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-vertex-pharmaceuticals-flashes-improved-relative-price-strength/", "time_published": "20230808T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Vertex Pharmaceuticals ( VRTX ) had its Relative Strength ( RS ) Rating upgraded from 67 to 72 Tuesday -- a welcome improvement, but still below the 80 or higher score you look for. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.410816, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.549581", "ticker_sentiment_score": "0.509917", "ticker_sentiment_label": "Bullish"}, {"ticker": "KNSA", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.149656", "ticker_sentiment_score": "0.200621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CRISPR  ( CRSP )  to Post Q2 Earnings: What's in the Offing?", "url": "https://www.zacks.com/stock/news/2133170/crispr-crsp-to-post-q2-earnings-whats-in-the-offing", "time_published": "20230807T150100", "authors": ["Zacks Equity Research"], "summary": "CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.121978, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.072024", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.261117", "ticker_sentiment_score": "0.053111", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.210274", "ticker_sentiment_score": "-0.029702", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.158519", "ticker_sentiment_score": "-0.021835", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in August", "url": "https://www.fool.com/investing/2023/08/06/2-top-biotech-stocks-to-buy-in-august/", "time_published": "20230806T131500", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies are performing exceedingly well.", "banner_image": "https://media.ycharts.com/charts/8b7caf0e6140dc8f707e88787653f233.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.300281, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.43465", "ticker_sentiment_score": "0.482343", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.206157", "ticker_sentiment_score": "0.254022", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street", "url": "https://www.fool.com/investing/2023/08/05/1-beaten-down-stock-that-could-soar-by-89-accordin/", "time_published": "20230805T134000", "authors": ["Prosper Junior Bakiny"], "summary": "Are you feeling brave?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.070194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.053629", "ticker_sentiment_score": "-0.033994", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.107016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Healthcare Stocks to Buy for August", "url": "https://www.fool.com/investing/2023/08/05/3-top-healthcare-stocks-to-buy-for-august/", "time_published": "20230805T131500", "authors": ["Jim Halley"], "summary": "Shares of Humana, Vertex Pharmaceuticals, and Idexx Laboratories have all increased by at least 20% so far this year.", "banner_image": "https://media.ycharts.com/charts/a0cc59d88b52f29ecb22c3f990629cbc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.241943, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.133841", "ticker_sentiment_score": "0.261916", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUM", "relevance_score": "0.263942", "ticker_sentiment_score": "0.164398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IDXX", "relevance_score": "0.089462", "ticker_sentiment_score": "0.171297", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.089462", "ticker_sentiment_score": "0.034636", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Fantastic Growth Stocks to Buy in August", "url": "https://www.fool.com/investing/2023/08/05/3-fantastic-growth-stocks-to-buy-in-august/", "time_published": "20230805T105500", "authors": ["Keith Speights", "and Prosper Junior Bakiny", "David Jagielski"], "summary": "These stocks could be poised to soar.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742339%2Fbear-market-stocks-plunge-crash-invest-correction-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.271353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.344473", "ticker_sentiment_score": "0.196689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.262052", "ticker_sentiment_score": "0.324917", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.176502", "ticker_sentiment_score": "0.079316", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.044469", "ticker_sentiment_score": "0.167724", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "VRTX: 3 Biotech Stocks With Strong Value in August", "url": "https://stocknews.com/news/vrtx-jazz-alks-lzagy-crsp-zyme-3-biotech-stocks-with-strong-value-in-august/", "time_published": "20230804T173227", "authors": ["StockNews.com Staff"], "summary": "Amid heightened product demand and intensified investor attention, the biotechnology sector remarkably performed during the global upheaval triggered by the COVID-19 pandemic, successfully drawing in a substantial influx of fresh capital.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.779048"}], "overall_sentiment_score": 0.253625, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.29234", "ticker_sentiment_score": "0.135408", "ticker_sentiment_label": "Neutral"}, {"ticker": "LZAGF", "relevance_score": "0.027195", "ticker_sentiment_score": "0.043423", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.054359", "ticker_sentiment_score": "0.142022", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.266828", "ticker_sentiment_score": "0.118615", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.214937", "ticker_sentiment_score": "0.103417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Under Pressure As Yields Soar: Weekly Review", "url": "https://www.investors.com/news/market-rally-under-pressure-as-yields-soar-amazon-elf-caterpillar-are-earnings-winners/", "time_published": "20230804T145100", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally came under pressure amid surging Treasury yields, fueled by a U.S. credit-rating downgrade as well, swelling Treasury issuance and improving U.S. economic growth. But yields pared gains following a mixed jobs report. Apple ( AAPL ) and Amazon ( AMZN ) capped a huge week of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/A1MAIN-bullsbears-100220-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.022066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.081111", "ticker_sentiment_score": "0.007297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.081111", "ticker_sentiment_score": "0.105986", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.04872", "ticker_sentiment_score": "0.015992", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.081111", "ticker_sentiment_score": "0.166261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.108704", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.064929", "ticker_sentiment_score": "0.132381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.040515", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "HWM", "relevance_score": "0.032491", "ticker_sentiment_score": "0.266242", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKNG", "relevance_score": "0.032491", "ticker_sentiment_score": "0.206139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.090092", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.081111", "ticker_sentiment_score": "-0.030628", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.032491", "ticker_sentiment_score": "0.13877", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.064929", "ticker_sentiment_score": "0.066645", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.081111", "ticker_sentiment_score": "0.023152", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNA", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.235891", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXPE", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNBR", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.198779", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGM", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLYS", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.108", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.010001", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.064929", "ticker_sentiment_score": "0.08922", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.065997", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.203852", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SQ", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.118638", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.016249", "ticker_sentiment_score": "-0.062612", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.121934", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.016249", "ticker_sentiment_score": "0.067967", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.032491", "ticker_sentiment_score": "0.023975", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SITM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.237782", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NIO", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.032491", "ticker_sentiment_score": "0.170055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GNRC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.23063", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.078464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.097259", "ticker_sentiment_score": "0.119103", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Nasdaq 100 Stocks That Are Surefire Buys in August and 1 to Avoid", "url": "https://www.fool.com/investing/2023/08/04/2-nasdaq-100-stocks-buy-in-august-and-1-to-avoid/", "time_published": "20230804T092100", "authors": ["Sean Williams"], "summary": "Two Nasdaq 100 components are plain-as-day bargains, while another Nasdaq 100 stock could struggle to live up to lofty expectations.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742129%2Fstock-chart-crash-correction-plunge-bounce-bear-market-bar-trend-invest-crypto-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.117372, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.081645", "ticker_sentiment_score": "0.120388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.267413", "ticker_sentiment_score": "0.086871", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.318211", "ticker_sentiment_score": "0.087543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  Beats on Q2 Earnings & Sales, Raises '23 View", "url": "https://www.zacks.com/stock/news/2132136/moderna-mrna-beats-on-q2-earnings-sales-raises-23-view", "time_published": "20230803T151500", "authors": ["Zacks Equity Research"], "summary": "Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.052601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.045139", "ticker_sentiment_score": "0.114229", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.503018", "ticker_sentiment_score": "0.041803", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.265859", "ticker_sentiment_score": "0.014157", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.090134", "ticker_sentiment_score": "0.051723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company News for Aug 3, 2023", "url": "https://www.zacks.com/stock/news/2131877/company-news-for-aug-3-2023", "time_published": "20230803T132300", "authors": ["Zacks Equity Research"], "summary": "Companies in The News Are: VRTX, DVN, AFL, HUM ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c5/1252.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.066407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.608634", "ticker_sentiment_score": "0.370666", "ticker_sentiment_label": "Bullish"}, {"ticker": "HUM", "relevance_score": "0.608634", "ticker_sentiment_score": "0.370666", "ticker_sentiment_label": "Bullish"}, {"ticker": "DVN", "relevance_score": "0.608634", "ticker_sentiment_score": "-0.342901", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AFL", "relevance_score": "0.608634", "ticker_sentiment_score": "-0.100357", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is Arguably the Single Best Stock to Buy Right Now", "url": "https://www.fool.com/investing/2023/08/03/single-best-stock-to-buy-right-now/", "time_published": "20230803T095100", "authors": ["Keith Speights"], "summary": "This stock appears to be in a league of its own.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742179%2Fgrowth-5.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.349686, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ELOX", "relevance_score": "0.05133", "ticker_sentiment_score": "0.071208", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.102449", "ticker_sentiment_score": "0.205731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.05133", "ticker_sentiment_score": "0.071208", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark", "url": "https://www.investors.com/ibd-data-stories/vertex-pharmaceuticals-shows-improved-relative-strength-still-shy-of-benchmark-2/", "time_published": "20230803T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Vertex Pharmaceuticals Shows Improved Relative Strength. Still Shy Of Benchmark Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.216174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.481177", "ticker_sentiment_score": "0.113825", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Investors Should Buy These 2 Medical Stocks After Earnings", "url": "https://www.zacks.com/stock/news/2131624/heres-why-investors-should-buy-these-2-medical-stocks-after-earnings", "time_published": "20230803T053100", "authors": ["Shaun Pruitt"], "summary": "Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.99237"}], "overall_sentiment_score": 0.240208, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.281422", "ticker_sentiment_score": "0.286481", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EHC", "relevance_score": "0.281422", "ticker_sentiment_score": "0.276916", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.071784", "ticker_sentiment_score": "0.112561", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.213048", "ticker_sentiment_score": "-0.010426", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.142989", "ticker_sentiment_score": "-0.061512", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts' Top Healthcare Picks: Tenet Healthcare  ( THC ) , Vertex Pharmaceuticals  ( VRTX ) ", "url": "https://markets.businessinsider.com/news/stocks/analysts-top-healthcare-picks-tenet-healthcare-thc-vertex-pharmaceuticals-vrtx-1032509298", "time_published": "20230803T023040", "authors": ["Tipranks"], "summary": "Analysts' Top Healthcare Picks: Tenet Healthcare (THC), Vertex Pharmaceuticals (VRTX) - Markets Insider ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.246204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVAH", "relevance_score": "0.100308", "ticker_sentiment_score": "0.184688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.199037", "ticker_sentiment_score": "0.066103", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.199037", "ticker_sentiment_score": "0.170906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BTAI", "relevance_score": "0.100308", "ticker_sentiment_score": "0.110656", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIMS", "relevance_score": "0.100308", "ticker_sentiment_score": "0.098894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVA", "relevance_score": "0.100308", "ticker_sentiment_score": "0.098894", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.294682", "ticker_sentiment_score": "0.280823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THC", "relevance_score": "0.622414", "ticker_sentiment_score": "0.245952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.100308", "ticker_sentiment_score": "0.110656", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQV", "relevance_score": "0.294682", "ticker_sentiment_score": "0.302748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSNUF", "relevance_score": "0.100308", "ticker_sentiment_score": "0.184688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXGN", "relevance_score": "0.100308", "ticker_sentiment_score": "0.098894", "ticker_sentiment_label": "Neutral"}, {"ticker": "MD", "relevance_score": "0.100308", "ticker_sentiment_score": "0.184688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMRN", "relevance_score": "0.100308", "ticker_sentiment_score": "0.110656", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 No-Brainer Cathie Wood Stock to Buy Hand Over Fist in August", "url": "https://www.fool.com/investing/2023/08/02/1-no-brainer-cathie-wood-stock-to-buy-hand-over-fi/", "time_published": "20230802T201500", "authors": ["George Budwell"], "summary": "Crispr Therapeutics could be incredibly undervalued right now.", "banner_image": "https://media.ycharts.com/charts/a483f71b6733dd1928f5c3e9200ae7bc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.268955, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.110973", "ticker_sentiment_score": "0.035423", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.055621", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33525374/vertex-pharma-raises-annual-forecast-on-strong-uptake-for-cystic-fibrosis-drug-anal", "time_published": "20230802T181049", "authors": ["Vandana Singh"], "summary": "Vertex Pharmaceuticals Inc's VRTX Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 billion. The increase was driven by the strong uptake of Trikafta/Kaftrio, including the launch in children with cystic fibrosis ( CF ) 2 to 5 years of age.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/02/vrtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.163387, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.065343", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.218817", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Beats on Q2 Earnings & Sales, Raises '23 View", "url": "https://www.zacks.com/stock/news/2131278/vertex-vrtx-beats-on-q2-earnings-sales-raises-23-view", "time_published": "20230802T160600", "authors": ["Zacks Equity Research"], "summary": "Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.999938"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.133398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.17813", "ticker_sentiment_score": "0.109711", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.089629", "ticker_sentiment_score": "0.053738", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Q2 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/08/01/vertex-pharmaceuticals-vrtx-q2-2023-earnings-call/", "time_published": "20230802T010025", "authors": ["Motley Fool Transcribing"], "summary": "VRTX earnings call for the period ending June 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.221494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.005084", "ticker_sentiment_score": "0.130204", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.005084", "ticker_sentiment_score": "0.168501", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.005084", "ticker_sentiment_score": "0.153199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.005084", "ticker_sentiment_score": "0.140755", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.005084", "ticker_sentiment_score": "0.128311", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.005084", "ticker_sentiment_score": "0.120629", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.005084", "ticker_sentiment_score": "0.025942", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Q2 Earnings and Revenues Top Estimates", "url": "https://www.zacks.com/stock/news/2130667/vertex-pharmaceuticals-vrtx-q2-earnings-and-revenues-top-estimates", "time_published": "20230801T211506", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) delivered earnings and revenue surprises of 1.04% and 3.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.193791, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.14131", "ticker_sentiment_score": "0.096884", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLRX", "relevance_score": "0.210579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/vertex-pharma-raises-full-year-revenue-forecast-cystic-fibrosis-treatment-2023-08-01/", "time_published": "20230801T204722", "authors": ["Reuters"], "summary": "Aug 1 ( Reuters ) - Vertex Pharmaceuticals ( VRTX.O ) raised its full-year sales forecast on Tuesday, banking on strong demand for its cystic fibrosis ( CF ) treatment. The company now sees full-year sales from its CF treatments to be between $9.7 billion and $9.8 billion, from a prior ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=151", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.139265", "ticker_sentiment_score": "0.092115", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.139265", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Tech Giant And Cash Machine Just Beat Expectations", "url": "https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q2-2023/", "time_published": "20230801T201500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "VRTX Stock: Tech Leader Beats And Raises, But Shares Dip Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.01699, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.800175", "ticker_sentiment_score": "-0.144347", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.202366", "ticker_sentiment_score": "-0.516542", "ticker_sentiment_label": "Bearish"}]}, {"title": "Peering Into Vertex Pharmaceuticals's Recent Short Interest - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33499790/peering-into-vertex-pharmaceuticalss-recent-short-interest", "time_published": "20230801T163023", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals's VRTX short percent of float has fallen 7.55% since its last report. The company recently reported that it has 2.51 million shares sold short, which is 0.98% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "ImmunoGen  ( IMGN )  Stock Down Despite Q2 Earnings & Sales Beat", "url": "https://www.zacks.com/stock/news/2130525/immunogen-imgn-stock-down-despite-q2-earnings-sales-beat", "time_published": "20230801T140900", "authors": ["Zacks Equity Research"], "summary": "ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.057258, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.109289", "ticker_sentiment_score": "0.142275", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.251495", "ticker_sentiment_score": "0.009769", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.109289", "ticker_sentiment_score": "-0.045839", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKYA", "relevance_score": "0.109289", "ticker_sentiment_score": "-0.045839", "ticker_sentiment_label": "Neutral"}]}, {"title": "Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer", "url": "https://www.benzinga.com/pressreleases/23/08/g33489909/auron-establishes-premier-scientific-advisory-board-to-support-the-advancement-of-its-ai-powered-p", "time_published": "20230801T113000", "authors": ["Globe Newswire"], "summary": "NEWTON, Mass., Aug. 01, 2023 ( GLOBE NEWSWIRE ) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity, today announced the members of its scientific advisory board ( SAB ) , comprised of ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038739, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KYMR", "relevance_score": "0.0226", "ticker_sentiment_score": "-0.003551", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.0226", "ticker_sentiment_score": "-0.025756", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.0226", "ticker_sentiment_score": "-0.025756", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBTX", "relevance_score": "0.0226", "ticker_sentiment_score": "-0.025756", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.0226", "ticker_sentiment_score": "-0.003551", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.0226", "ticker_sentiment_score": "0.145642", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rising Stars, Falling Trends: July's Industry ETF Winners and Losers - Invesco Solar ETF  ( ARCA:TAN ) , Deere  ( NYSE:DE ) , SLB  ( NYSE:SLB ) , Archer-Daniels Midland  ( NYSE:ADM ) , Mueller Industries  ( NYSE:MLI ) , Amgen  ( NASDAQ:AMGN ) , Ferguson  ( NYSE:FERG ) , Vanguard Real Estate ETF  ( ARCA:VNQ ) , VanEck Gold Miners ETF  ( ARCA:GDX ) , SPDR S&P 500  ( ARCA:SPY ) , American Tower  ( NYSE:AMT ) , SMA Solar Tech  ( OTC:SMTGF ) , VanEck Oil Services ETF  ( ARCA:OIH ) , VanEck Semiconductor ETF  ( NASDAQ:SMH ) , Taiwan Semiconductor  ( NYSE:TSM ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Antero Resources  ( NYSE:AR ) , First Solar  ( NASDAQ:FSLR ) , SPDR S&P Oil & Gas Explor & Product  ( ARCA:XOP ) , Biogen  ( NASDAQ:BIIB ) , SPDR S&P Regional Banking ETF  ( ARCA:KRE ) , Enphase Energy  ( NASDAQ:ENPH ) , Broadcom  ( NASDAQ:AVGO ) , Western Alliance  ( NYSE:WAL ) , CoStar Gr  ( NASDAQ:CSGP ) , iShares Biotechnology ETF  ( NASDAQ:IBB ) , Prologis  ( NYSE:PLD ) , Waters  ( NYSE:WAT ) , Ovintiv  ( NYSE:OVV ) , Danaher  ( NYSE:DHR ) , Invesco Water Resources ETF  ( NASDAQ:PHO ) , U.S. Global Jets ETF  ( ARCA:JETS ) , Lam Research  ( NASDAQ:LRCX ) , Zoetis  ( NYSE:ZTS ) , SM Energy  ( NYSE:SM ) , SPDR Dow Jones Industrial Average ETF  ( ARCA:DIA ) , iShares Russell 2000 ETF  ( ARCA:IWM ) , NVIDIA  ( NASDAQ:NVDA ) , Zions Bancorp  ( NASDAQ:ZION ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) , Crown Castle  ( NYSE:CCI ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , Southwest Airlines  ( NYSE:LUV ) , VanEck Agribusiness ETF  ( ARCA:MOO ) , Pinnacle Finl Partners  ( NASDAQ:PNFP ) , Delta Air Lines  ( NYSE:DAL ) , Ecolab  ( NYSE:ECL ) , APA  ( NASDAQ:APA ) , Halliburton  ( NYSE:HAL ) , SolarEdge Technologies  ( NASDAQ:SEDG ) , Valmont Industries  ( NYSE:VMI ) , Intel  ( NASDAQ:INTC ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33471902/rising-stars-falling-trends-julys-industry-etf-winners-and-losers", "time_published": "20230731T145922", "authors": ["Piero Cingari"], "summary": "As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month. Among the largest ETFs that represent major U.S. stock indices, the SPDR S&P 500 ETF Trust SPY returned 3.1% in July, marking its fifth consecutive month of gains.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Spanish,Bull,Running,In,The,Bullring,With,Big,Horns,On_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.166243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.056323", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSGP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLD", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.164656", "ticker_sentiment_score": "0.180471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "OVV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "FERG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.164656", "ticker_sentiment_score": "0.061707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.031505", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIONL", "relevance_score": "0.055236", "ticker_sentiment_score": "0.041883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.054977", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMTGF", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNFP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.045851", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "AR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.057668", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More", "url": "https://www.zacks.com/stock/news/2129900/drug-biotech-stocks-q2-earnings-due-on-aug-1-pfe-mrk-more", "time_published": "20230731T135800", "authors": ["Ahan Chakraborty"], "summary": "Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.160061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.043658", "ticker_sentiment_score": "0.134273", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.215702", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.415927", "ticker_sentiment_score": "0.104372", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.377776", "ticker_sentiment_score": "0.007815", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.087185", "ticker_sentiment_score": "0.141037", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.298437", "ticker_sentiment_score": "0.100076", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.087185", "ticker_sentiment_score": "0.141037", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Stocks Are Heading for a Big Moment. Time to Buy?", "url": "https://www.fool.com/investing/2023/07/31/2-stocks-heading-for-big-moment-time-to-buy/", "time_published": "20230731T093000", "authors": ["Adria Cimino"], "summary": "Both stocks have climbed in the double digits this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.266385, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09989", "ticker_sentiment_score": "0.119081", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  to Report Q2 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2128982/vertex-vrtx-to-report-q2-earnings-whats-in-the-cards", "time_published": "20230727T163800", "authors": ["Zacks Equity Research"], "summary": "On Vertex's (VRTX) Q2 earnings call, investors focus will likely be on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/29/1920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999985"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.159106, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.213048", "ticker_sentiment_score": "0.175148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.264515", "ticker_sentiment_score": "0.069497", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.213048", "ticker_sentiment_score": "0.056702", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Vertex Pharmaceuticals Stock Help You Retire a Millionaire?", "url": "https://www.fool.com/investing/2023/07/27/could-vertex-pharmaceuticals-stock-help-you-retire/", "time_published": "20230727T141500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech is currently firing on all cylinders, but can it last?", "banner_image": "https://media.ycharts.com/charts/67826a731c098fa5f19425f624c4f946.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.103534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.258351", "ticker_sentiment_score": "0.129023", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 No-Brainer Cathie Wood Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/07/26/2-no-brainer-cathie-wood-stocks-to-buy-right-now/", "time_published": "20230726T151500", "authors": ["George Budwell"], "summary": "Vertex Pharmaceuticals and Pfizer should be stellar long-term buys.", "banner_image": "https://media.ycharts.com/charts/4bbc700da502c181370f475a08e88101.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995015"}], "overall_sentiment_score": 0.356239, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.191675", "ticker_sentiment_score": "0.043791", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.372448", "ticker_sentiment_score": "0.340228", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Earnings Preview: Repligen  ( RGEN )  Q2 Earnings Expected to Decline", "url": "https://www.zacks.com/stock/news/2127919/earnings-preview-repligen-rgen-q2-earnings-expected-to-decline", "time_published": "20230726T140216", "authors": ["Zacks Equity Research"], "summary": "Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.11235, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RGEN", "relevance_score": "0.261117", "ticker_sentiment_score": "-0.028012", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.088472", "ticker_sentiment_score": "0.039149", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Moves 0.28%: What You Should Know", "url": "https://www.zacks.com/stock/news/2127326/vertex-pharmaceuticals-vrtx-stock-moves-028-what-you-should-know", "time_published": "20230725T215020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $358.06, marking a +0.28% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.196844, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.553265", "ticker_sentiment_score": "0.291722", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/23/07/33370813/a-look-into-vertex-pharmaceuticals-incs-price-over-earnings", "time_published": "20230725T143020", "authors": ["Benzinga Insights"], "summary": "In the current market session, Vertex Pharmaceuticals Inc. VRTX stock price is at $355.94, after a 0.31% drop. However, over the past month, the company's stock spiked by 2.54%, and in the past year, by 24.03%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": -0.075301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.428632", "ticker_sentiment_score": "-0.048765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Reports Next Week: Wall Street Expects Earnings Growth", "url": "https://www.zacks.com/stock/news/2126998/vertex-pharmaceuticals-vrtx-reports-next-week-wall-street-expects-earnings-growth", "time_published": "20230725T140124", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default242.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.150052, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.102449", "ticker_sentiment_score": "0.129645", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top ETFs to Buy Right Now", "url": "https://www.fool.com/investing/2023/07/24/3-top-etfs-to-buy-right-now/", "time_published": "20230724T214500", "authors": ["George Budwell"], "summary": "These three exchange-traded funds could be winning plays for patient investors.", "banner_image": "https://media.ycharts.com/charts/10c809fadfdf2cfdadbb0f05f36f42c8.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.857896"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.280327, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $2,500 Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33348153/100-invested-in-this-stock-20-years-ago-would-be-worth-2-500-today", "time_published": "20230724T150026", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 9.51% on an annualized basis producing an average annual return of 17.4%. Currently, Vertex Pharmaceuticals has a market capitalization of $92.58 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Better Big Biotech Buy: Vertex vs. Biogen", "url": "https://www.fool.com/investing/2023/07/24/better-big-biotech-buy-vertex-vs-biogen/", "time_published": "20230724T140927", "authors": ["Adria Cimino"], "summary": "These companies have a track record of billion-dollar earnings.", "banner_image": "https://media.ycharts.com/charts/e32e197244130a4e5abf93d4d9463607.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.244412, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.109705", "ticker_sentiment_score": "0.077802", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.109705", "ticker_sentiment_score": "0.255323", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.054983", "ticker_sentiment_score": "-0.018064", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.054983", "ticker_sentiment_score": "0.242959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.592095", "ticker_sentiment_score": "0.391347", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech wins fail to move stock indicators ahead of earnings", "url": "https://www.financialexpress.com/healthcare/news-healthcare/biotech-wins-fail-to-move-stock-indicators-ahead-of-earnings/3184760/", "time_published": "20230724T103525", "authors": ["Bloomberg"], "summary": "Biotech has had a pretty good year between a flurry of deals and approvals of new drugs for vexing diseases such as Alzheimer's. Yet that isn't showing up in stock performance. Two closely watched indicators lag far behind the overall market.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/pathology-rp.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.114137", "ticker_sentiment_score": "0.0994", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRPH", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOSS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.085371", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVRO", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.056944", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.117035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.144975", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.003412", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.057215", "ticker_sentiment_score": "0.209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.057215", "ticker_sentiment_score": "-0.003001", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.057215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Showing Improving Market Leadership: Twist Bioscience Earns 84 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-twist-bioscience-earns-84-rs-rating/", "time_published": "20230724T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Twist Bioscience ( TWST ) saw a positive improvement to its Relative Strength ( RS ) Rating on Monday, rising from 74 to 84. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.37685, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.348103", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.501398", "ticker_sentiment_score": "0.724772", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks Showing Improving Market Leadership: Immunocore Holdings ADR Earns 82 RS Rating", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-immunocore-holdings-adr-earns-82-rs-rating/", "time_published": "20230724T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Immunocore Holdings ADR ( IMCR ) , which had its Relative Strength ( RS ) Rating upgraded from 79 to 82 Monday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.32924, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMCR", "relevance_score": "0.669956", "ticker_sentiment_score": "0.360839", "ticker_sentiment_label": "Bullish"}]}, {"title": "Barron's Weekend Stock Picks: Barbie Bonanza, Vertex's Promising Drug And Tesla Doubts - Mattel  ( NASDAQ:MAT ) , AMC Enter Hldgs  ( NYSE:AMC ) ", "url": "https://www.benzinga.com/news/23/07/33333490/barrons-weekend-stock-picks-barbie-bonanza-vertexs-promising-drug-and-tesla-doubts", "time_published": "20230722T151357", "authors": ["Justin Chan"], "summary": "Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In \"It's the Summer of Barbie.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/22/barbie.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.229118, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.228073", "ticker_sentiment_score": "0.179426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAT", "relevance_score": "0.33628", "ticker_sentiment_score": "0.242062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROKU", "relevance_score": "0.33628", "ticker_sentiment_score": "0.242062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.43789", "ticker_sentiment_score": "0.290157", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.115232", "ticker_sentiment_score": "0.116114", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.115232", "ticker_sentiment_score": "0.116114", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Small-Cap Stocks That Could Be Big-Time Winners", "url": "https://www.fool.com/investing/2023/07/22/3-small-cap-stocks-that-could-be-big-time-winners/", "time_published": "20230722T101400", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "These stocks come with significant risks. But they could generate huge returns over time.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740358%2Felderly-woman-retirement-social-security-holding-one-hundred-dollar-bills-cash-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.156809, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.03853", "ticker_sentiment_score": "0.043021", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.153226", "ticker_sentiment_score": "-0.029814", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.153226", "ticker_sentiment_score": "0.124088", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIRM", "relevance_score": "0.03853", "ticker_sentiment_score": "0.216854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.153226", "ticker_sentiment_score": "0.073403", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Best Stocks to Invest $5,000 in Right Now", "url": "https://www.fool.com/investing/2023/07/22/the-best-stocks-to-invest-5000-in-right-now/", "time_published": "20230722T095000", "authors": ["Keith Speights"], "summary": "Investors won't have to worry about overpaying for any of these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740358%2Felderly-woman-retirement-social-security-holding-one-hundred-dollar-bills-cash-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.131751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEP", "relevance_score": "0.52612", "ticker_sentiment_score": "0.170803", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.12645", "ticker_sentiment_score": "0.203536", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Soaring Stocks With More Upside Potential", "url": "https://www.fool.com/investing/2023/07/21/2-soaring-stocks-with-more-upside-potential/", "time_published": "20230721T121500", "authors": ["Prosper Junior Bakiny"], "summary": "Are these mid-cap stocks giants in the making?", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.225865, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.083541", "ticker_sentiment_score": "0.151674", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRYS", "relevance_score": "0.325208", "ticker_sentiment_score": "0.188019", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Now a Good Time to Buy CRISPR Therapeutics?", "url": "https://www.fool.com/investing/2023/07/21/is-now-a-good-time-to-buy-crispr-therapeutics/", "time_published": "20230721T093000", "authors": ["Adria Cimino"], "summary": "CRISPR shares have climbed more than 40% this year.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740414%2Ftsla_sankey_q22023.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.266533, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.065866", "ticker_sentiment_score": "-0.034032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Flashing Renewed Technical Strength: Blueprint Medicines", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-blueprint-medicines/", "time_published": "20230721T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Blueprint Medicines ( BPMC ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an upgrade from 79 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.37192, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.343279", "ticker_sentiment_score": "0.721129", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks To Watch: Legend Biotech ADR Sees Relative Strength Rating Rise To 93", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-legend-biotech-adr-sees-relative-strength-rating-rise-to-93/", "time_published": "20230721T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Legend Biotech ADR ( LEGN ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Friday, rising from 90 to 93. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.37722, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.305058", "ticker_sentiment_score": "0.119142", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.305058", "ticker_sentiment_score": "0.119142", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.443626", "ticker_sentiment_score": "0.585587", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks With Rising Relative Strength: SpringWorks Therapeutics", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-springworks-therapeutics-2/", "time_published": "20230721T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, SpringWorks Therapeutics ( SWTX ) received an upgrade to its Relative Strength ( RS ) Rating, from 70 to 79. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.409176, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.154455", "ticker_sentiment_score": "0.204432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.757528", "ticker_sentiment_score": "0.520224", "ticker_sentiment_label": "Bullish"}]}, {"title": "Agios Pharmaceuticals Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/agios-pharmaceuticals-getting-closer-to-key-technical-benchmark-3/", "time_published": "20230721T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Agios Pharmaceuticals ( AGIO ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Friday, with an increase from 64 to 73. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.440573, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.297661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.660632", "ticker_sentiment_score": "0.591276", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.151539", "ticker_sentiment_score": "0.170045", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.297661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diabetic Peripheral Neuropathy Market Growing at a CAGR of ~6% by 2032 | DelveInsight", "url": "https://www.prnewswire.com/news-releases/diabetic-peripheral-neuropathy-market-growing-at-a-cagr-of-6-by-2032--delveinsight-301881945.html", "time_published": "20230720T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "The dynamics of the diabetic peripheral neuropathy market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.093177, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LABP", "relevance_score": "0.023909", "ticker_sentiment_score": "0.025607", "ticker_sentiment_label": "Neutral"}, {"ticker": "NURO", "relevance_score": "0.023909", "ticker_sentiment_score": "0.042639", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.023909", "ticker_sentiment_score": "0.025607", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.095422", "ticker_sentiment_score": "0.033481", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSTO", "relevance_score": "0.023909", "ticker_sentiment_score": "0.025607", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.047797", "ticker_sentiment_score": "0.089954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.023909", "ticker_sentiment_score": "0.022936", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLT", "relevance_score": "0.023909", "ticker_sentiment_score": "0.022936", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.023909", "ticker_sentiment_score": "0.042639", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.071641", "ticker_sentiment_score": "0.087492", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.071641", "ticker_sentiment_score": "0.087492", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNOV", "relevance_score": "0.023909", "ticker_sentiment_score": "0.022936", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.047797", "ticker_sentiment_score": "0.091942", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047797", "ticker_sentiment_score": "0.032496", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.071641", "ticker_sentiment_score": "0.093537", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.047797", "ticker_sentiment_score": "0.026576", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVA", "relevance_score": "0.023909", "ticker_sentiment_score": "0.022936", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRBO", "relevance_score": "0.023909", "ticker_sentiment_score": "0.042639", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADOCY", "relevance_score": "0.023909", "ticker_sentiment_score": "0.025607", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMEA", "relevance_score": "0.023909", "ticker_sentiment_score": "0.022936", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:VND", "relevance_score": "0.023909", "ticker_sentiment_score": "0.042639", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Stock Of The Day: Weight-Loss Kingpin Retakes 50-Day Line", "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-bounds-above-50-day-line-weight-loss-drugs-drive-enthusiasm/", "time_published": "20230720T171000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Novo Nordisk Stock Stock Bounds Above 50-Day Line. Weight-Loss Drugs Drive Enthusiasm Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/NVO-SOTD-chart1.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.160127, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.296582", "ticker_sentiment_score": "0.246581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.154758", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MASI", "relevance_score": "0.060694", "ticker_sentiment_score": "-0.35758", "ticker_sentiment_label": "Bearish"}, {"ticker": "ABT", "relevance_score": "0.121037", "ticker_sentiment_score": "0.154758", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.553595", "ticker_sentiment_score": "0.192666", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.121037", "ticker_sentiment_score": "0.154758", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/vir-biotech-slumps-over-3-year-low-flu-prevention-therapy-fails-trial-2023-07-20/", "time_published": "20230720T163748", "authors": ["Reuters"], "summary": "July 20 ( Reuters ) - Vir Biotechnology's ( VIR.O ) shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage trial.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=149", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.118784, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.144275", "ticker_sentiment_score": "0.076742", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.144275", "ticker_sentiment_score": "0.076742", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.144275", "ticker_sentiment_score": "-0.087257", "ticker_sentiment_label": "Neutral"}]}, {"title": "Who is Reshma Kewalramani: Know more about her journey from a trained doctor to first female CEO of large US biotech company | The Financial Express", "url": "https://www.financialexpress.com/lifestyle/who-is-reshma-kewalramani-know-more-about-her-journey-from-a-trained-doctor-to-first-female-ceo-of-large-us-biotech-company/3177748/", "time_published": "20230720T030000", "authors": [], "summary": "Who is Reshma Kewalramani: Know about her journey from a trained doctor to first female CEO of a US-based biotech company The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/Untitled-Project-2-2.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.249298, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.144275", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2124100/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230719T215021", "authors": ["Zacks Investment Research"], "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $358.57, moving -0.11% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default120.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.238027, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.600271", "ticker_sentiment_score": "0.359101", "ticker_sentiment_label": "Bullish"}]}, {"title": "Coinbase Global, Moderna And 2 Other Stocks Insiders Are Selling - Moderna  ( NASDAQ:MRNA ) , Coinbase Glb  ( NASDAQ:COIN ) ", "url": "https://www.benzinga.com/news/23/07/33283526/coinbase-global-moderna-and-2-other-stocks-insiders-are-selling", "time_published": "20230719T122644", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed higher on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/19/coinbase_global_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.150494, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.466325", "ticker_sentiment_score": "0.054598", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.466325", "ticker_sentiment_score": "0.108142", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.381463", "ticker_sentiment_score": "0.256636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNS", "relevance_score": "0.099066", "ticker_sentiment_score": "0.29144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.466325", "ticker_sentiment_score": "0.282736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.099066", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Healthcare Stocks to Buy and Hold for the Next 10 Years", "url": "https://www.fool.com/investing/2023/07/19/3-healthcare-stocks-to-buy-and-hold-for-the-next/", "time_published": "20230719T121500", "authors": ["Prosper Junior Bakiny"], "summary": "It helps to offer products everyone needs.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740156%2Fbob_iger.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.338782, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.308891", "ticker_sentiment_score": "0.358895", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.259451", "ticker_sentiment_score": "0.263973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.308891", "ticker_sentiment_score": "0.270539", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 No-Brainer Stocks to Buy With $400 Right Now", "url": "https://www.fool.com/investing/2023/07/19/3-no-brainer-stocks-to-buy-with-400-right-now/", "time_published": "20230719T092100", "authors": ["Sean Williams"], "summary": "A modest amount of money can go a long way when it's invested in industry-leading businesses.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739936%2Fwallet-count-cash-bills-money-four-hundred-dollars-credit-card-invest-retire-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}], "overall_sentiment_score": 0.242411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.033098", "ticker_sentiment_score": "0.091149", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.099066", "ticker_sentiment_score": "0.130987", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.033098", "ticker_sentiment_score": "0.001925", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.131823", "ticker_sentiment_score": "0.122841", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Group Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/replimune-group-getting-closer-to-key-technical-benchmark-2/", "time_published": "20230719T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Replimune Group ( REPL ) headed into a higher percentile Wednesday, as it got a lift from 69 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.303015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.679474", "ticker_sentiment_score": "0.168002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.157483", "ticker_sentiment_score": "0.179347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "argenx ADR Joins Elite Club Of Stocks With RS Ratings Over 90", "url": "https://www.investors.com/ibd-data-stories/argenx-adr-joins-elite-club-of-stocks-with-rs-ratings-over-90/", "time_published": "20230719T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "argenx ADR ( ARGX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 88 to 91. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.342315, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.297661", "ticker_sentiment_score": "0.116829", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.433523", "ticker_sentiment_score": "0.499681", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.297661", "ticker_sentiment_score": "0.116829", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength", "url": "https://www.investors.com/research/stock-upgrades-aurinia-pharmaceuticals-shows-rising-relative-strength-3/", "time_published": "20230718T145500", "authors": ["Investor's Business Daily", "GLENN LARKIN", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Aurinia Pharmaceuticals ( AUPH ) climbed into a new percentile Tuesday, with a rise from 79 to 82. Last week it actually hit 83, then fell on a couple of down days before reversing higher.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.283563, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.249106", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.249106", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.47452", "ticker_sentiment_score": "0.009246", "ticker_sentiment_label": "Neutral"}]}, {"title": "Halozyme Therapeutics  ( HALO )  Soars 5.4%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2122549/halozyme-therapeutics-halo-soars-54-is-further-upside-left-in-the-stock", "time_published": "20230718T093900", "authors": ["Zacks Investment Research"], "summary": "Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.127394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARGX", "relevance_score": "0.293506", "ticker_sentiment_score": "-0.17113", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRTX", "relevance_score": "0.293506", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.469744", "ticker_sentiment_score": "0.282269", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Upgrades: Aurinia Pharmaceuticals Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-aurinia-pharmaceuticals-shows-rising-relative-strength-3/", "time_published": "20230718T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Aurinia Pharmaceuticals ( AUPH ) climbed into a new percentile Tuesday, with a rise from 79 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.269773, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.33628", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.33628", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.615462", "ticker_sentiment_score": "0.161981", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks With Rising Relative Strength: SpringWorks Therapeutics", "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-springworks-therapeutics/", "time_published": "20230718T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Tuesday, SpringWorks Therapeutics ( SWTX ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 68 to 73. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.323609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.702434", "ticker_sentiment_score": "0.41014", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks To Watch: Mirum Pharmaceuticals Sees Relative Strength Rating Jump To 82", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-mirum-pharmaceuticals-sees-relative-strength-rating-jump-to-82/", "time_published": "20230718T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Mirum Pharmaceuticals ( MIRM ) , which had its Relative Strength ( RS ) Rating upgraded from 78 to 82 Tuesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.297982, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIRM", "relevance_score": "0.451494", "ticker_sentiment_score": "0.35385", "ticker_sentiment_label": "Bullish"}]}, {"title": "Vertex Pharmaceuticals Unusual Options Activity For July 17 - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/markets/options/23/07/33253241/vertex-pharmaceuticals-unusual-options-activity-for-july-17", "time_published": "20230717T163116", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Vertex Pharmaceuticals VRTX. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.184423, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.690822", "ticker_sentiment_score": "0.359856", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.101154", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Monster Stocks to Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/07/17/2-monster-stocks-to-buy-without-any-hesitation/", "time_published": "20230717T093000", "authors": ["Adria Cimino"], "summary": "These players each bring in billions of dollars in earnings every year.", "banner_image": "https://media.ycharts.com/charts/30eeb9e12d66e1fc98d91cfd6687d4cc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.309065, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.065327", "ticker_sentiment_score": "0.124195", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.130217", "ticker_sentiment_score": "0.141193", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.130217", "ticker_sentiment_score": "0.14593", "ticker_sentiment_label": "Neutral"}]}, {"title": "More Investing Advice From 's \"Rule Breaker Investing\"", "url": "https://www.fool.com/retirement/2023/07/15/investing-advice-from-motley-fools-rule-breaker-in/", "time_published": "20230715T123000", "authors": ["Motley Fool Staff"], "summary": "We talk about Royal Caribbean stock, advice for new investors, dividend reinvestment, and more.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739358%2Fa-person-looking-off-thinking.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.253691, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BUD", "relevance_score": "0.003848", "ticker_sentiment_score": "0.126174", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.007697", "ticker_sentiment_score": "0.199808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.030779", "ticker_sentiment_score": "0.059985", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.049995", "ticker_sentiment_score": "0.120544", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.007697", "ticker_sentiment_score": "0.074268", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.011545", "ticker_sentiment_score": "0.16704", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.007697", "ticker_sentiment_score": "0.096375", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.003848", "ticker_sentiment_score": "0.157951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCL", "relevance_score": "0.046154", "ticker_sentiment_score": "0.026968", "ticker_sentiment_label": "Neutral"}, {"ticker": "WRBY", "relevance_score": "0.003848", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EA", "relevance_score": "0.011545", "ticker_sentiment_score": "0.097042", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNBR", "relevance_score": "0.015392", "ticker_sentiment_score": "0.050994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals: Buy at the High?", "url": "https://www.fool.com/investing/2023/07/14/vertex-pharmaceuticals-buy-at-the-high/", "time_published": "20230714T093000", "authors": ["Adria Cimino"], "summary": "Vertex's next blockbuster may be right around the corner.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739520%2Fdividends-cart-full-of-money-on-hundred-dollar-bills.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.101105, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.105836", "ticker_sentiment_score": "-0.080201", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( NASDAQ:VRTX )  Lifted to Strong-Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/07/14/vertex-pharmaceuticals-nasdaqvrtx-lifted-to-strong-buy-at-stocknews-com.html", "time_published": "20230714T053448", "authors": ["Defense World Staff"], "summary": "Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report released on Friday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/vertex-pharmaceuticals-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.897321"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.277319, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.702807", "ticker_sentiment_score": "0.420627", "ticker_sentiment_label": "Bullish"}, {"ticker": "PEP", "relevance_score": "0.046184", "ticker_sentiment_score": "0.100571", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEIC", "relevance_score": "0.092213", "ticker_sentiment_score": "0.216639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNV", "relevance_score": "0.092213", "ticker_sentiment_score": "0.216639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.046184", "ticker_sentiment_score": "0.044181", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex Pharmaceuticals  ( VRTX )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2120936/vertex-pharmaceuticals-vrtx-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230713T215020", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $349.02, marking a +0.86% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default23.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.23347, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.670305", "ticker_sentiment_score": "0.410341", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 No-Brainer Healthcare Stocks to Buy With $100 Right Now", "url": "https://www.fool.com/investing/2023/07/13/2-no-brainer-healthcare-stocks-to-buy-with-100-now/", "time_published": "20230713T133000", "authors": ["David Jagielski"], "summary": "These stocks may not stay this low for long.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}], "overall_sentiment_score": 0.243044, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.068502", "ticker_sentiment_score": "0.124448", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.393977", "ticker_sentiment_score": "0.319161", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Magnificient Growth Stocks to Buy in July", "url": "https://www.fool.com/investing/2023/07/13/2-magnificient-growth-stocks-to-buy-in-july/", "time_published": "20230713T133000", "authors": ["George Budwell"], "summary": "These two growth stocks might be incredibly undervalued right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739596%2Fgrowth.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.299191, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.066784", "ticker_sentiment_score": "0.118275", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.024099", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.198493", "ticker_sentiment_score": "0.281365", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.066784", "ticker_sentiment_score": "0.02115", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Biotech Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/07/13/3-top-biotech-stocks-defying-the-bear-market/", "time_published": "20230713T114500", "authors": ["Sushree Mohanty"], "summary": "Each has the potential to dramatically outperform the market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739109%2Fscientist-in-a-lab.jpeg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.977154"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.177301, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.09186", "ticker_sentiment_score": "0.124205", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.09186", "ticker_sentiment_score": "-0.126079", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.046006", "ticker_sentiment_score": "-0.076503", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.09186", "ticker_sentiment_score": "0.05163", "ticker_sentiment_label": "Neutral"}]}, {"title": "Got $500? 3 Growth Stocks to Buy That Could Double Your Money", "url": "https://www.fool.com/investing/2023/07/13/got-500-3-growth-stocks-to-buy-that-could-double-y/", "time_published": "20230713T095000", "authors": ["Keith Speights"], "summary": "There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.15437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.055492", "ticker_sentiment_score": "0.19694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.110717", "ticker_sentiment_score": "0.060194", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEP", "relevance_score": "0.373911", "ticker_sentiment_score": "0.082434", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.055492", "ticker_sentiment_score": "0.020089", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.165409", "ticker_sentiment_score": "0.090061", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Price Strength", "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-agios-pharmaceuticals-flashes-improved-price-strength/", "time_published": "20230713T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "The Relative Strength ( RS ) Rating for Agios Pharmaceuticals ( AGIO ) entered a new percentile Thursday, as it got a lift from 67 to 79. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.251821, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.705799", "ticker_sentiment_score": "0.274759", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Showing Improved Relative Strength: Arcus Biosciences", "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improved-relative-strength-arcus-biosciences/", "time_published": "20230713T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "On Thursday, Arcus Biosciences ( RCUS ) received an upgrade to its Relative Strength ( RS ) Rating, from 67 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating tracks price action with a 1 ( worst ) to 99 ( ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.322297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.769861", "ticker_sentiment_score": "0.306162", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.158519", "ticker_sentiment_score": "0.144492", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARCT", "relevance_score": "0.310843", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations", "url": "https://www.prnewswire.com/news-releases/cryoport-announces-certain-preliminary-results-for-second-quarter--updates-2023-revenue-expectations-301875999.html", "time_published": "20230712T200500", "authors": ["Cryoport", "Inc."], "summary": "\u2022 Second quarter results were impacted by weaker than expected global demand for capital equipment. clinical trial start delays.", "banner_image": "https://mma.prnewswire.com/media/371732/cryoport_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999767"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.125833, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.031696", "ticker_sentiment_score": "0.096272", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.031696", "ticker_sentiment_score": "0.096272", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYRX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.261604", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Now the Right Time to Embrace Biotech ETFs?", "url": "https://www.zacks.com/stock/news/2120021/is-now-the-right-time-to-embrace-biotech-etfs", "time_published": "20230712T150900", "authors": ["Zacks Investment Research"], "summary": "Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/2266.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.986413"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.182418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.027545", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Things About Vertex Pharmaceuticals That Smart Investors Know", "url": "https://www.fool.com/investing/2023/07/12/3-things-about-vertex-pharmaceuticals-that-smart-i/", "time_published": "20230712T100000", "authors": ["Adria Cimino"], "summary": "Vertex shares have advanced about 20% so far this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.231573, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.209365", "ticker_sentiment_score": "0.170804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.105604", "ticker_sentiment_score": "0.18866", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Healthcare Stocks Defying the Bear Market", "url": "https://www.fool.com/investing/2023/07/11/2-top-healthcare-stocks-defying-the-bear-market/", "time_published": "20230711T100000", "authors": ["Adria Cimino"], "summary": "These stocks are rising in the double digits -- and outperforming the S&P 500.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738884%2Fbuy-sell-stock-market-rolling-dice-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.320313, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.067919", "ticker_sentiment_score": "0.053115", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.135347", "ticker_sentiment_score": "0.139132", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sitting on Cash? These 2 Stocks Are Great Buys", "url": "https://www.fool.com/investing/2023/07/11/sitting-on-cash-these-2-stocks-are-great-buys/", "time_published": "20230711T093000", "authors": ["Adria Cimino"], "summary": "Coca-Cola and Vertex Pharmaceuticals are excellent choices to add to your portfolio for the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738884%2Fbuy-sell-stock-market-rolling-dice-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.335544, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KO", "relevance_score": "0.427726", "ticker_sentiment_score": "0.418982", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.116972", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Flashing Renewed Technical Strength: Immunocore Holdings ADR", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-immunocore-holdings-adr/", "time_published": "20230711T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Immunocore Holdings ADR ( IMCR ) saw a positive improvement to its Relative Strength ( RS ) Rating on Tuesday, with an increase from 88 to 92. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.438115, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.340915", "ticker_sentiment_score": "0.129984", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMCR", "relevance_score": "0.622414", "ticker_sentiment_score": "0.62442", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.174587", "ticker_sentiment_score": "0.263678", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.340915", "ticker_sentiment_score": "0.129984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rocket Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "url": "https://www.investors.com/ibd-data-stories/rocket-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark/", "time_published": "20230711T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When putting together your watch list, look for stocks with an 80 or higher RS Rating. Rocket Pharmaceuticals ( RCKT ) now meets that criteria, with a jump from 71 to 81 Tuesday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.248598, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.331765", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCKT", "relevance_score": "0.479683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.331765", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks To Watch: Viridian Therapeutics Sees Relative Strength Rating Jump To 84", "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-viridian-therapeutics-sees-relative-strength-rating-jump-to-84/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Viridian Therapeutics ( VRDN ) just met that criteria with a new score of 84. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.242859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.331765", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.331765", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRDN", "relevance_score": "0.479683", "ticker_sentiment_score": "0.124483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Upgrades: Sage Therapeutics Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-sage-therapeutics-shows-rising-relative-strength-7/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Sage Therapeutics ( SAGE ) , which had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Tuesday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.435205, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.595343", "ticker_sentiment_score": "0.288112", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.165031", "ticker_sentiment_score": "0.179389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.323078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dynavax Technologies Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/dynavax-technologies-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Tuesday, Dynavax Technologies ( DVAX ) received an upgrade to its Relative Strength ( RS ) Rating, from 78 to 84. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.287156, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.459624", "ticker_sentiment_score": "0.467587", "ticker_sentiment_label": "Bullish"}]}, {"title": "Celldex Therapeutics Shows Rising Price Performance With Jump To 83 RS Rating", "url": "https://www.investors.com/ibd-data-stories/celldex-therapeutics-shows-rising-price-performance-with-jump-to-83-rs-rating/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Celldex Therapeutics ( CLDX ) is one stock that just reached the mark, now earning a score of 83. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.252685, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.316846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.585687", "ticker_sentiment_score": "0.254591", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Upgrades: Agios Pharmaceuticals Shows Rising Relative Strength", "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-agios-pharmaceuticals-shows-rising-relative-strength-4/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Agios Pharmaceuticals ( AGIO ) headed into a new percentile Tuesday, as it got a lift from 66 to 73. X When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.319933, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIO", "relevance_score": "0.570165", "ticker_sentiment_score": "0.307379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Generating Improved Relative Strength: Arrowhead Pharm", "url": "https://www.investors.com/ibd-data-stories/stocks-generating-improved-relative-strength-arrowhead-pharm/", "time_published": "20230711T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Arrowhead Pharm ( ARWR ) had its Relative Strength ( RS ) Rating upgraded from 64 to 79 Tuesday -- a welcome improvement, but still short of the 80 or better score you look for. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.259867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amicus Therapeutics Sees Relative Strength Rating Climb To 73", "url": "https://www.investors.com/ibd-data-stories/amicus-therapeutics-sees-relative-strength-rating-climb-to-73/", "time_published": "20230711T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Tuesday, Amicus Therapeutics ( FOLD ) got an upgrade to its Relative Strength ( RS ) Rating, from 61 to 73. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.370546, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.67628", "ticker_sentiment_score": "0.487964", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.156461", "ticker_sentiment_score": "0.173392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aurinia Pharmaceuticals Stock Shows Rising Relative Strength", "url": "https://www.investors.com/research/stock-upgrades-aurinia-pharmaceuticals-shows-rising-relative-strength-2/", "time_published": "20230711T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily", "GLENN LARKIN"], "summary": "Stock Upgrades: Aurinia Pharmaceuticals Shows Rising Relative Strength Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.32871, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.240489", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.240489", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.459624", "ticker_sentiment_score": "0.228721", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much $1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33175319/heres-how-much-1000-invested-in-vertex-pharmaceuticals-20-years-ago-would-be-worth-today", "time_published": "20230710T213149", "authors": ["Benzinga Insights"], "summary": "Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 9.24% on an annualized basis producing an average annual return of 17.01%. Currently, Vertex Pharmaceuticals has a market capitalization of $88.72 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Want to Get Richer? 2 Unstoppable Stocks to Invest $1,000 In This Week", "url": "https://www.fool.com/investing/2023/07/09/want-to-get-richer-2-unstoppable-stocks-to-invest/", "time_published": "20230709T101300", "authors": ["Rachel Warren"], "summary": "A tech giant and a biotech standout are both proving their mettle in 2023.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738800%2Fsocial-security-cards-3_gettyimages-488815648.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.264736, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.22616", "ticker_sentiment_score": "0.240754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABNB", "relevance_score": "0.269776", "ticker_sentiment_score": "0.135328", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Growth Stocks With 55% to 71% Upside, According to Wall Street", "url": "https://www.fool.com/investing/2023/07/09/3-growth-stocks-with-55-to-71-upside-according-to/", "time_published": "20230709T092100", "authors": ["Cory Renauer"], "summary": "Find out why investment bank analysts are so bullish on these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738661%2Fsmart-investment-bank-analyst-on-wall-street.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.079641, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.047371", "ticker_sentiment_score": "-0.076976", "ticker_sentiment_label": "Neutral"}, {"ticker": "SE", "relevance_score": "0.322474", "ticker_sentiment_score": "0.096394", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUBO", "relevance_score": "0.187827", "ticker_sentiment_score": "0.118382", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGI", "relevance_score": "0.047371", "ticker_sentiment_score": "0.113747", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Stocks You Can Buy Right Now", "url": "https://www.fool.com/investing/2023/07/08/3-no-brainer-stocks-you-can-buy-right-now/", "time_published": "20230708T101400", "authors": ["Keith Speights", "and Prosper Junior Bakiny", "David Jagielski"], "summary": "Going with these stocks is an easy decision.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738685%2Fteaching-kids-how-to-invest-and-save-money.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.17837, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.089712", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.039878", "ticker_sentiment_score": "0.016573", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.34729", "ticker_sentiment_score": "0.098843", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.039878", "ticker_sentiment_score": "0.016573", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.273661", "ticker_sentiment_score": "0.122758", "ticker_sentiment_label": "Neutral"}]}, {"title": "Delta Air Lines, Vertex Pharmaceuticals, And A Major US Bank Nearing A Breakout Level: CNBC's 'Final Trades' - Cooper Companies  ( NYSE:COO ) , Delta Air Lines  ( NYSE:DAL ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33144384/delta-air-lines-vertex-pharmaceuticals-and-a-major-us-bank-nearing-a-breakout-level-cnbc", "time_published": "20230707T132542", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Amy Raskin of Chevy Chase Trust said Vertex Pharmaceuticals Incorporated VRTX, has \"done relatively well this year.\" Morgan Stanley recently reiterated Vertex Pharmaceuticals with an Equal-Weight and raised the price target from $305 to $340.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/stock_traders_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.146584, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.595343", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COO", "relevance_score": "0.595343", "ticker_sentiment_score": "-0.069228", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTS", "relevance_score": "0.165031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.468029", "ticker_sentiment_score": "0.188942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.468029", "ticker_sentiment_score": "0.385155", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.323078", "ticker_sentiment_score": "-0.17409", "ticker_sentiment_label": "Somewhat-Bearish"}]}]}